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• MyoD: Myogenic differentiation 1  
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• Nanog: Nanog Homeobox 
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• NF-κβ: Nuclear Factor Kappa-B DNA Binding Subunit 
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• Oct4: Octamer-binding transcription factor 4 
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• PCA: Principal component analysis 
• PcG: Polycomb group Complexes 
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• PCR: polymerase chain reaction 
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• PLZF-RARα:  Promyelocytic leukemia zinc finger-retinoic acid receptor α 
• Pol-II: RNA polymerase II  
• PRC1/2: Polycomb repressive complex 1/2 
• PRE: Polycomb Response Elements  
• Pro B/pre B: B cell progenitors 
• PTM: Post-translational modification 
• qPCR: quantitative PCR 
• qRT-PCR: quantitative real time-PCR 
• RAG: recombinant activation genes  
• RbAp46/48: Retinoblastoma binding protein 46/48 
• Ring1a/1b: E3 ubiquitin protein ligase 
• RNA-seq: RNA sequencing 
• RT-PCR: Reverse Transcriptase PCR 
• RT: room temperature 
• SAH: S-adenosylhomocystein hydrolase  
• SAM: S-adhenosylmethionine 
• SET: Su (var) 3-9, Enhancer of zeste, Trithorax 
• SHM: Somatic hyper mutation  
• Snail 1: Snail Family Zinc Finger 1  
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• SPL: Spleen 
• ss: single strand 
• Suz12: Suppressor of zest 12  
• T-ALL: T cell acute lymphoblastic leukemia  
• TCR: T cell antigen receptor  
• TF: Transcription factors  
• TFH: T follicular helper cells 
• Tp53: Tumor protein 53 
• UTX: Ubiquitously transcribed tetratricopeptide repeat, X chromosome 
• V: Variable  
• WT: wild type 
• Xist: X chromosome specific transcript 
• YY1: Yin Yang1 
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4 Abstract 
The Polycomb group protein Ezh2 catalyzes the Histone H3 lysine-27 trimethylation 
(H3K27me3) within the Polycomb Repressive Complex 2 (PRC2). PRC2 exerts a critical 
control over the expression of a large set of target genes controlling important biological 
functions, including cell proliferation, differentiation and stem cell self-renewal.  
Aberrant Ezh2 function is commonly observed in several cancer types and is due to 
deregulated enzymatic activity and/or expression of the Polycomb protein. Studies in 
preclinical models have started to reveal the importance of Ezh2 in B cell lymphomagenesis. 
In contrast, little is known about the effects of Ezh2 deregulated function/constitutive 
expression in B cell tumor maintenance and progression. 
The present study addresses this issue taking advantage of a MYC-driven mouse lymphoma 
model, featuring high Ezh2 expression as a result of malignant B cell transformation. 
Conditional, genetic inactivation of Ezh2 methyltransferase activity in aggressive primary 
Burkitt-like mouse B cell lymphomas led to the identification of two classes of tumors, 
differentially responding to the loss of Polycomb function. In type-1 lymphomas, Ezh2 
inactivation impaired clonal tumor growth starting from single lymphoma cells. Instead, 
type-2 lymphomas were largely resistant to the loss of Ezh2 catalytic function, giving rise to 
a substantial number of Ezh2 mutant clones. Transcriptome analyses allowed the 
identification of a molecular signature discriminating type-1 from type-2 lymphomas, 
including genes controlling cell cycle progression, DNA replication and cell survival, which 
were more expressed in type-2 tumors. These results correlated with a more aggressive 
behavior of type-2 lymphomas when transplantated into immunoproficient hosts.  
The growth of rare Ezh2 mutant subclones, established from type-1 lymphomas, was 
impaired by the treatment with an Ezh1/2 small molecule inhibitor, identifying the Ezh2 
paralog, Ezh1, as a determinant of resistance of tumor cells to Ezh2 inactivation. Ezh2 
inhibition led to genome wide loss of H3K27me3, which was comparable between 
 18 
lymphoma types. However, while the loss of H3K27me3 at target genes in type-1 
lymphomas failed to alter their expression, in type-2 lymphomas Ezh2 targets were in most 
cases deregulated following the loss of the histone mark. Based on these results, we propose 
that Ezh2 mutant subclones from type-1 lymphomas select an H3K27me3-independent 
mechanism to ensure correct regulation of Ezh2 target genes, which is needed for tumor 
growth. We also find that residual H3K27me3 is deposited at the promoter of new genes by 
a non-canonical PRC2/Ezh1, in Ezh2 mutant subclones from type-1 lymphomas. This 
activity alters the expression of target genes contributing to tumor growth.  
We finally report the isolation of clonal variants from type-1 lymphomas that acquire 
secondary resistance to pharmacological Ezh1/2 inhibition. The latter tumors (together with 
type-2 lymphomas) will be instrumental to unravel the genetic bases of resistance of MYC-
driven lymphomas to PRC2 inhibition.  
Anti-Ezh2 inhibitors are currently being tested in phase-1 and -2 clinical trials for the 
treatment of both solid and blood cancers including B cell lymphomas. Our studies highlight 
the importance of understanding in more detail the mechanisms of action of Ezh2/PRC2 in 
tumors, in order to identify those that may benefit from anti-Ezh2 therapies. Our results also 
provide evidence for mechanisms of lymphoma resistance to Ezh2 inhibition and suggest 
strategies to circumvent such resistance.  
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5 Introduction 
5.1 Epigenetics 
The complexity of multicellular organisms is achieved through the differentiation of several 
types of cells, with specialized functions. Two principal levels of regulation control the 
appropriate development of different cell subtypes. The first level of regulation, namely the 
genetic regulation, relies on the activity of cell-type specific transcription factors (TFs) that 
establish defined gene expression profiles. TFs act binding to cis-regulatory regions of target 
genes to modulate (promote or repress) their expression, by the recruitment of the 
transcriptional machinery. The capacity of TFs to bind their targets depends on the local 
status of the chromatin. The chromatin consists of genomic DNA and histones (H) 
compacted in basic units, called nucleosomes. Each nucleosome consists of 146 bases of 
DNA wrapped around two copies each of histones H2A, H2B, H3 and H4 (Kornberg, 1974). 
Post-translational modifications (PTMs) of histones target the amino (N)- terminus region, 
thereby causing changes in chromatin compaction. Histone modifications include 
methylation, phosphorylation, acetylation and ubiquitylation. The deposition of PMTs on 
histone tails is mediated by the highly dynamic activity of enzymes with opposing function 
that catalyzes the addition or removal of specific modifications to modulate gene expression 
and/or the access to chromatin of protein complexes controlling chromosome function. The 
latter mechanisms contribute to a second level of gene regulation, defined as epigenetics, 
which is critical to ensure cell identity through subsequent cell divisions (Beck et al., 2010). 
Epigenetic alterations are commonly associated to inherited disorders as well as sporadic 
diseases including cancer (Alberghini et al., 2015). 
 
5.2 Polycomb group proteins  
The histones PTMs are catalyzed by proteins, commonly acting within macromolecular 
complexes. Polycomb group (PcG) complexes are epigenetic modifiers whose activity is 
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thought to promote transcriptional gene silencing. Recent evidences have however 
challenged this model, associating the function of PcG proteins to active transcription 
(Scelfo et al., 2015). Polycomb proteins act within two main structural complexes, the 
Polycomb repressive complex 1 (PRC1) and the Polycomb repressive complex 2 (PRC2) 
(Levine et al., 2002). Polycomb genes were identified in Drosophila melanogaster (Lewis, 
1949) as repressor of homeotic (Hox) genes, which play a critical role in early embryonic 
development (Lewis, 1978). In mammals, PRC2 core components are Embryonic ectoderm 
development (Eed), Suppressor of zest homologue 12 (Suz12) and the catalytic subunit 
Enhancer of zeste homologue 2 (Ezh2) or its close paralog Ezh1. Ezh2 catalyzes di- and tri-
methylation of lysine-27 on histone H3 (H3K27me3). Additional PRC2 components include 
the zinc finger protein AE Binding protein (AEBP) 2 and the Retinoblastoma binding 
protein (RbAp46/48). Chromobox-domain (CBX) containing proteins belonging to PRC1 
recognize H3K27me3, thereby mediating the recruitment of canonical PRC1 on target genes 
(Margueron and Reinberg, 2011). As consequence of this targeting, through the E3 ubiquitin 
protein ligases Ring1a and Ring1b, PRC1 catalyzes the monoubiquitylation of lysine-119 on 
histone H24 (H2AK119ub1). Concerted deposition of H3K27me3 and H2AK119ub1 
histone marks is though to contribute to target gene repression (Morey and Helin, 2010). 
Recently, alternative, non-canonical PRC1 complexes, lacking the CBX proteins have been 
described. It has been proposed that non-canonical PRC1 is recruited onto target genes by 
sequence-specific DNA binding proteins, independent of H3K27me3 recognition (Di Croce 
and Helin, 2013; Gao et al., 2012) (Figure 1).  
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Figure 1: Polycomb group proteins 
Polycomb group (PcG) proteins act within two main multiprotein complexes: PRC1 and 
PRC2. PRC1 through Ring1a/b proteins promotes H2A lysine-119 monoubiquitylation 
(H2AK119ub1). The core subunit of PRC2 consists of the EZH1/2 methyltransferases that 
catalyze Histone H3 lysine-27 trimethylation (H3K27me3). The epigenetic modifications 
introduced by PRC1/2 facilitate chromatin compaction, thereby contributing to 
transcriptional repression of target genes. 
 
While in Drosophila, the binding of PcG occurs through the recognition of specific DNA 
sequences, known as Polycomb Response Elements (PREs) (Schuettengruber and Cavalli, 
2009) (Simon and Kingston, 2009), in mammals the modalities of PCR2 recruitment to its 
target sites is still poorly understood. So far three main mechanisms have been proposed. A 
first mechanism is based on numerous observations in Embryonic Stem (ES) cells showing a 
substantial overlap between genome wide PRC2 binding patterns and CpG islands. 
Although the binding of Polycomb complex to these regions is not direct (Ku et al., 2008), 
recent findings have unveiled that PRC2 bindings partners, Jumonji AT Rich Interactive 
Domain 2 (JARID2) and AEBP2 bound to CpG islands, can facilitate PRC2 recruitment to 
CpG rich regions (Landeira et al., 2010; Li et al., 2010; Pasini et al., 2010; Peng et al., 2009; 
Shen et al., 2009). A second mechanism involves the interaction of PRC2 with non-coding 
RNAs (ncRNAs). The X-chromosome-specific 17-kb ncRNA (Xist) is responsible for 
PRC2-dependent H3K27me3 of the inactive X-chromosome (Plath et al., 2003). In a similar 
fashion, the recently discovered ncRNA ANRIL, transcribed in the antisense orientation 
Di Croce L. and Helin K., Nature Structural & Molecular Biology 2013 
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from the INK4 locus, is able to recruit PRCs to Cyclin-dependent kinase inhibitor 2a 
(Cdkn2a), through the interaction with Cbx7 and Suz12, to promote gene repression (Kotake 
et al., 2011; Yap et al., 2010). Following a similar mechanism, the antisense RNA HOTAIR, 
transcribed from the HOX locus, promotes PRC2 binding in trans to repress genes of the 
HOXD locus (Rinn et al., 2007; Tsai et al., 2010).  
Finally, it has been proposed that PRC2 recruitment to target sites is mediated by the 
interaction with specific TFs, including YY1 (Satijn et al., 2001; Wilkinson et al., 2006), E2 
transcription factor 6 (E2F6) (Attwooll et al., 2005; Trimarchi et al., 2001), Snail Family 
Zinc Finger 1 (Snail 1) (Herranz et al., 2008), Promyelocytic zinc finger (PLZF) and 
Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα) (Boukarabila et 
al., 2009; Villa et al., 2007). 
 
5.3 Polycomb Repressive Complex 2  
Transcriptional repression of PRC2 target genes is achieved through the deposition of 
H3K27me3. H3K27me3 is catalyzed by the methyltransferase member Ezh2 and critically 
relies on PRC2 core components Eed and Suz12 (Cao et al., 2002; Cao and Zhang, 2004; 
Pasini et al., 2004). Ezh2 disposes of the catalytic Su (var) 3-9, Enhancer of zeste, Trithorax 
(SET) domain (Cao et al., 2002; Rea et al., 2000) (Figure 2) to exert processive di- or tri-
methylation (Zee et al., 2010) starting from H3K27me1. Therefore, H3K27me3 is a bona 
fide epigenetic mark. Upon DNA replication, the histone mark gets perpetuated onto newly 
synthetized histones at the target sites in the daughter cells through the recognition of 
partially H3K27 methylated nucleosomes by PRC2 component Eed (Campos et al., 2014; 
Mohn et al., 2008).  
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Figure 2: Schematic representation of Ezh2 protein domains 
Ezh2 is a 85 kDa (746 amino acids) protein containing the H3K27 methyltransferase C-term 
SET domain (purple). Ezh2 binds both Eed (through the WD40 binding domain, white) and 
Suz12 (through central SANT domain, blue). Moreover, Ezh2 binds histone tails via N-term 
SANT domain (blue) and RNA molecules through ncRBD1 domain (yellow). 
 
Recent studies on ES cells have shown that around 80 % of the genome is methylated on 
lysine-27 of histone H3 (Peters et al., 2003). The most representative form of 
H3K27methylation is the H3K27me2 (50 %), whereas H3K27me3 and H3K27me1 
contribute only for 15 % (Peters et al., 2003). The di- and tri-methylated forms of H3K27 
are commonly associated with facultative heterochromatin, which plays a critical role during 
developmental processes. Instead, H3K27me1 is often associated with constitutive 
heterochromatin (Trojer and Reinberg, 2007), although it can be also found within the body 
of actively transcribed genes (Cui et al., 2009). H3K27 mono-methylation can occur 
independently of PRC2 activity, as it is unaffected by the loss of PRC2 core components 
(Pasini et al., 2004; Schoeftner et al., 2006). It has been proposed that H3K27me1 marking 
of actively transcribed genes may depend on H3K27 specific demethylases Ubiquitously 
transcribed tetratricopeptide repeat, X chromosome (UTX) or Jumonji Domain Containing 3 
(JMJD3) function, acting on H3K27me2/3 (Swigut and Wysocka, 2007). H3K27me3 can 
sterically interfere with the binding of chromatin remodeling complexes and/or prevent the 
establishment of activating histone modifications, thereby enforcing transcriptional silencing 
(Beisel et al., 2007; Ezhkova et al., 2009; Shao et al., 1999). Indeed, it has been proposed 
that RNA polymerase II (Pol-II) can directly bind to H3K27me3-rich chromatin regions, 
resulting in a weak transcriptional activity (Stock et al., 2007). Further studies have 
 
WD40 
Modified from Reinberg D. and Margueron R., Nature 2011 
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demonstrated that short transcripts, generated from PcG target genes and associated to a 
paused form of Pol-II, may recruit PRC2 to interfere with Pol-II transcriptional elongation 
(Kanhere et al., 2010).  
 
5.3.1  The Ezh1 and Ezh2 proteins 
In mammals, Ezh2 represents the essential catalytic subunit of PRC2. The Ezh2 close 
paralog Ezh1 can also be recruited into PRC2, as it is able to bind to the core components 
Suz12 and Eed, forming an alternative complex. Ezh1 preferentially binds to H3K27me1, 
but substantially displays weaker methyltransferase activity when compare to Ezh2 
(Margueron et al., 2008; Shen et al., 2008). Whereas Ezh2 knock down results in a strong 
decrease of H3K27me2/3 levels, the absence of Ezh1 function has a minor impact on global 
H3K27 di or tri- methylation (Margueron et al., 2008). Importantly, although the two 
complexes have different chromatin binding properties (Margueron et al., 2008), Ezh1-
containing PRC2 shares targets with canonical PRC2 (Shen et al., 2008). Interestingly, Ezh1 
and Ezh2 have different expression pattern, pointing to alternative PRC2 functions in 
different types of cells. Whereas Ezh1 is predominantly expressed in resting cells, Ezh2 
function is commonly observed in actively proliferative cells (Margueron et al., 2008; Shen 
et al., 2008). Together, these data suggest that while Ezh2 is the major player in the 
regulation of global H3K27me2/3 dynamics in dividing cells, Ezh1 may ensure 
H3K27me2/3 deposition at target sites in non-dividing cells to counteract H3K27 
demethylase activity, to ultimately guarantee stable gene repression.  
Recent findings have shown that Ezh1 can compensate for the loss of Ezh2 function during 
cell differentiation (Ezhkova et al., 2009), somatic cell reprogramming (Fragola et al., 2013) 
and possibly diseases such as cancer (Mochizuki-Kashio et al., 2015). All together, these 
data support a model whereby functional compensation by Ezh1 may represent a common 
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mechanism enabling complex organisms or its components to overcome functional 
inhibition of the canonical PRC2 complex. 
 
5.4 Mechanisms of action of PRC2 
5.4.1 H3K27me3-dependent functions of Ezh2 
5.4.1.1 Pluripotency, cellular commitment and differentiation 
Studies on ES cells, which express high levels of PcG proteins, have highlighted the 
relevance of the Polycomb axis in the regulation of stem cell pluripotency and lineage 
commitment. Data obtained from Polycomb mutant mouse ES cells have indicated that 
inactivation of PcG components is compatible with pluripotency and self-renewal of the 
stem cells, due to sustained expression of pluripotency factors, including Octamer-binding 
transcription factor 4 (Oct4) and Nanog homeobox (Nanog) (Leeb et al., 2010; Pasini et al., 
2007; Walker et al., 2010). However, PcG mutant ES cells (Suz12-/-, Eed-/-, Ezh2-/-) showed 
severe differentiation defects both in vitro and in vivo (Boyer et al., 2006; Pasini et al., 2007; 
Shen et al., 2008). The failure of Polycomb mutant ES cells to undergo proper 
differentiation lies in the property of Polycomb axis to ensure coordinate expression of 
master regulators (including representatives of the HOX, SRY box (Sox), Forkhead box 
(Fox) families of TFs) of alternative lineage specific programs (Boyer et al., 2006; Oguro et 
al., 2010). Indeed, the induction of differentiation of Polycomb mutant ES cells causes 
concomitant activation of multiple lineage programs, ultimately resulting in aberrant 
differentiation (Chamberlain et al., 2008). Polycomb proteins also exert fine regulation of 
self-renewal versus differentiation of stem cells. For example, Ezh2 controls transcriptional 
silencing of the Wnt-β catenin pathway to avoid premature adipogenesis (Wang et al., 
2010). In a similar fashion, in the epidermis Ezh2, on one hand sustains the proliferative 
potential of basal progenitors by repressing the Cdkn2a locus, while, on the other, it 
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represses the function of Activator protein (AP) 1 transcriptional activator to preclude 
premature differentiation (Ezhkova et al., 2009). In undifferentiated myoblasts, Ezh2 
prevents precocious muscle differentiation by repressing Myogenic differentiation 1 
(MyoD) target genes. Upon triggering of muscle differentiation, Ezh2 dissociates from its 
targets, allowing terminal differentiation of myoblasts (Caretti et al., 2004) (Figure 3). 
                                  
Figure 3: Ezh2 regulation in pluripotency and lineage commitment 
H3K27me3-dependent function of Ezh2 regulates embryonic stem cells (ESCs) pluripotency 
through the repression of developmental genes (HOX: homeobox; DLX: distal-less 
homeobox; SIX: six homeobox; FOX: forkhead box; SOX: SRY box; GATA: GATA 
binding protein; TBX: T-box). In addition, Ezh2 controls adult stem cell differentiation 
(MSCs: mesenchymal stem cells; HSCs: hematopoietic stem cells; SMSCs: skeletal muscle 
stem cells), targeting genes involved in lineage commitment (WNT: wingless; HDAC9c: 
histone deacetylase 9c; PIP5K1C: phosphatidylinositol-4-phosphate-5 kinase 1 C; ATF4: 
activating transcription factor 4; NRTK3: neurotrophic tyrosine kinase receptor3; MCK: 
muscle creatine kinase; MHC IIb: myosin heavy chain IIb). 
 
5.4.1.2 Cell cycle regulation and cellular senescence 
Multiple evidences pointed to a critical role exerted by PRC2 in the control of cell cycle 
progression. A major focus of investigation has been the influence exerted by PRC2 on the 
control of the G1-to-S phase transition. The G1-to-S transition is controlled by the 
Chen et al., Am J Transl Res 2012 
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p16Ink4A/Rb1 (retinoblastoma1, pRb)-E2F circuitry. In details, hypo-phosphorylated Rb1 
interacts with members of the E2F superfamily of TFs repressing their activity and thus 
blocking G1-to-S progression. Upon mitogen stimulation, Rb1 phosphorylation unleashes 
E2F factors, which in turn induce transcription of S phase specific genes, allowing cells to 
replicate DNA and complete cell division (Giacinti and Giordano, 2006). Expression of the 
Ezh2 gene is induced by E2F proteins (Bracken et al., 2003) and contributes to promote G1-
to-S transition through the repression of Cyclin-dependent kinase inhibitor p16Ink4A encoded 
by the Cdkn2a locus (van den Heuvel and Dyson, 2008). The negative regulation imposed 
by both PRC1 and PRC2 on CDK inhibitors extends beyond the p16Ink4A and includes genes 
coding for cell cycle inhibitors Cdkn1a/p21/Cip1, Cdkn1b/p27/Kip1 and Cdkn1c/p57/Kip2 
(Fan et al., 2011; Fasano et al., 2007; Guo et al., 2011; Itahana et al., 2003; Yang et al., 
2009). The contribution of Polycomb proteins to the regulation of cell cycle has an intimate 
connection with the role of PRC1/2 in the control of cellular senescence. The latter process 
is an irreversible arrest of the cell in the G0/G1 phase of the cell cycle, which is a tumor 
suppressive mechanisms triggered by excessive telomeric shortening and/or oncogene-
induced DNA damage (Campisi and d'Adda di Fagagna, 2007; Di Micco et al., 2011). 
Senescent cells express low levels of PcG proteins (Jacobs et al., 1999). Studies on mutant 
mice have unveiled an important contribution of PcG in the prevention of cellular 
senescence. Inactivation of both PRC1 and PRC2 components facilitates cellular senescence 
(Guo et al., 2007). In particular, it was shown that PcG proteins inhibit senescence through 
active repression of the Cdkn2a locus (Agherbi et al., 2009; Chen et al., 2009; Miki et al., 
2007). Conversely, transgenic mice overexpressing PcG proteins (Ezh2, Bmi1, Cbx2/8) are 
resistant to age-dependent senescence of tissue and organs (Dietrich et al., 2007; Sasaki et 
al., 2009).  
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5.4.1.3 DNA damage response 
DNA damage response (DDR) is a safeguard mechanism enabling cells to recognize DNA 
lesions and ensure their appropriate repair. The DDR is the result of a multistep activation 
process that involves a substantial number of proteins/enzymes involved in the recognition 
of the damage, in the recruitment to the site of damage of repair factors and in their active 
repair of the DNA lesions, respectively. These processes are highly coordinated and 
intimately connected to the regulation of the cell cycle progression (Sulli et al., 2012). In the 
past years, several evidences have proposed a role for PcG proteins in the control of DDR.  
In particular, PcG proteins are recruited in the early phases of the DDR to the sites of DNA 
damage (Chagraoui et al., 2011; Chou et al., 2010; Facchino et al., 2010; Ginjala et al., 
2011; Ismail et al., 2010) PRC2 promotes H3K27 trimethylation at sites of DNA double 
strand breaks (DSBs), which in turns recruits, through CBX proteins, PRC1. The arrival of 
PRC1 to sites of DNA lesions promotes ubiquitylation of H2A variant X (H2AX), which 
ultimately contributes to the recruitment and retention of DSB repair proteins at sites of 
damage (Ginjala et al., 2011; Ismail et al., 2010). A contribution of Ezh2 in DDR was first 
proposed studying the cellular response to a genotoxic insult (Campbell et al., 2013). Further 
evidences supporting a role of Ezh2 in the protection against genotoxic damage has recently 
come studying the role of the Polycomb protein in the germinal center (GC) B cells (see 
below). In particular, it was shown that Ezh2 exerts a critical role in protecting B cells, 
recruited into an immune response, from the genotoxic activity of an endogenous protein 
called Activation-induced cytidine deaminase (AID) (Caganova et al., 2013). Ezh2 was 
recently reported to influence the response of cells exposed to a genotoxic stress (Wu et al., 
2011). Under these conditions, Ezh2 triggers both a G1/S and G2/M cell cycle arrest, 
regulating transcriptional repression of F-box protein (FBXO) 32, which directs p21 
proteasome-degradation. As consequence, DDR occurred at the sites of lesions to protect 
cells from undergoing apoptosis (Wu et al., 2011). Recent data have also shown that Ezh2 
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recruitment to sites of DNA damage depends on Poly (ADP-ribose) polymerase (PAPR) 
protein, while it is independent on H2AX phosphorylation and PI-3-related kinases ATM 
and DNA-PKcs (Campbell et al., 2013).  
 
5.4.2 H3K27me3-independent functions of Ezh2 
Besides the property to facilitate gene silencing through H3K27me3, recent studies have 
proposed a role for Ezh2 in mediating post-translational modifications of non-histones 
substrates (Nolz et al., 2005). First evidence suggesting a role for Ezh2 to modulate the 
function of cytosolic proteins has come from the Tarakhovsky group (Su et al., 2005). 
Specifically, a cytosolic pool of Suz12/Eed/Ezh2 was proposed to influence actin 
polymerization in T lymphocytes in response to T cell receptor (TCR) cross-linking. PRC2 
components were shown to interact in the cytoplasm of T cells with the Vav1 signaling 
protein. Such interaction may influence the proximal signaling events triggered in T cells in 
response to TCR cross-linking at the immunological synapse (Su et al., 2005). Recent 
evidences by Su and colleagues have provided further proof for the relevance of the 
cytosolic Ezh2/Vav1 interaction (Gunawan et al., 2015). Indeed, Ezh2 was shown to 
methylate the Vav1-binding protein, Talin1, which in turns was critical for its interaction 
with F-actin. The failure to methylate Talin1 was responsible for the impaired migratory 
properties of Ezh2 mutant leukocytes as a result of defects in cell adhesion (Gunawan et al., 
2015). 
 
5.5 Ezh2 and B cell differentiation 
5.5.1 B cell development 
B cell development is a highly regulated process, coordinated by the action of a pool of TFs, 
which ensure specific step-wise maturation of lymphoid cells. B cell lymphopoiesis starts in 
 30 
the bone marrow (BM), where hematopoietic stem cells (HSCs) commit through multiple 
differentiation intermediates to become pro B cells, in response to environmental cues and 
interaction with stromal cells. Pro B cells activate the Recombinant Activation Genes 
(RAG) 1 and 2 proteins to initiate Variable (V), diversity (D) and joining (J) (VDJ) 
rearrangement. This process is completed in pre B cells, giving rise to a vast repertoire of 
variable regions of the immunoglobulin (Ig) Heavy (H) and Light (L) chain polypeptides. 
Expression of an Ig (also called B cell receptor or BCR) on the surface of pre B cells leads 
to their differentiation into immature B cells. In the BM, immature cells are subjected to a 
critical checkpoint that eliminates all cells expressing an auto-reactive BCR. Only immature 
B cells that succeed to pass this checkpoint are allowed to exit the BM to complete their 
maturation in secondary lymphoid organs, such as spleen and lymph nodes (Rajewsky, 
1996). Here, a small fraction of newly generated immature B cells succeeds to further 
differentiate to become one of the three major mature B cell subpopulations represented by 
Follicular (FO), Marginal zone (MZ) and B1 B cells, respectively (Casola, 2007). B1 B cells 
predominantly reside in the body-cavity sierosa. They belong to the innate immune system, 
where they contribute to the production of the so-called natural antibodies reacting against 
common microbial antigens. FO B cells represent the major population of mature B cells. 
They recirculate among primary and secondary lymphoid organs and actively participate in 
both T cell-dependent and -independent immune responses. Finally, MZ B cells are 
restricted to the spleen, where they contribute, together with B1 B cells, to produce 
antibodies in response to blood born pathogens during T cell-independent immune 
responses. Occasionally, MZ B cells may contribute with FO B cells to T cell-dependent 
immune responses (Casola, 2007) (Figure 4). 
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Figure 4: Schematic view of B cell development 
B cell development starts in the BM, where HSCs through intermediate steps become B cell 
progenitors. Upon successful VDJ recombination in B cell progenitors, expression of a 
functional non auto-reactive Ig receptor drives the formation of immature B cells, which 
ultimately egress from the bone marrow to home to secondary lymphoid organs, such as 
spleen and lymph nodes. The three major mature B cell subsets are follicular (FO), marginal 
zone (MZ) and B1 B cells. The principal role of B1 B cells is the production of natural 
antibodies and rapid response to T independent antigens by low-affinity antibodies secreting 
plasma cells. In contrast, FO and MZ B cells, after antigen encounter enter in the germinal 
center (GC), in a T cell-dependent manner. GC B cells undergo many cycles of division, Ig 
gene mutations and selection to finally differentiate into high-affinity Ig expressing memory 
B cells and high-affinity antibodies secreting plasma cells. 
 
Upon recognition of T cell-dependent antigens through the BCR, B cells are recruited into 
the GC reaction. In the dark zone (DZ) of GC, antigen-specific B cells intensively 
proliferate as so-called centroblasts (CB). Following controlled exit from the proliferation 
state, GC B cells migrate to a different region of GC, called light zone (LZ), where as 
centrocytes (CC) they get in close contact with antigen-presenting follicular dendritic cells 
(FDC) and T follicular helper cells (TFH) (Allen et al., 2007; McHeyzer-Williams et al., 
2009; Victora et al., 2010). As CBs, B cells accumulate at high rate mutations within the Ig 
V region genes, through a process catalyze by AID, also called somatic hypermutation 
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(SHM) process. As a result of SHM, GC B cells express BCRs with a large range of 
affinities for cognate antigen (Wagner and Neuberger, 1996). GC B cells that are not 
sustained by BCR-mediated survival signals, resulting by BRC engagement, rapidly undergo 
apoptosis (Liu and Mullbacher, 1989). In fact, GC B cells express high levels of pro-
apoptotic factors (Klein et al., 2003; MacLennan, 1994; Martinez-Valdez et al., 1996), 
whereas they lack the expression of most anti-apoptotic factors (Klein et al., 2003; Liu and 
Mullbacher, 1989; MacLennan, 1994). CBs, carrying mutated BCRs, migrate to the LZ 
becoming CCs. In the LZ, CCs are in close contact with FDCs, which present antigen on 
their surface in the form of immune complexes (Allen et al., 2007; Schwickert et al., 2007). 
As a result of an aggressive competition, only few GC B cells, expressing high-affinity 
BCRs, succeed to bind to the antigen and to receive by the TFH cells the co-stimulatory 
signals necessary for survival and to proceed in further rounds of expansion and Ig SHM 
(McHeyzer-Williams et al., 2009; Schwickert et al., 2007). TFH are also important because 
they release cytokines that instruct the process of Ig class switch recombination (CSR). Ig 
CSR (also called isotype switching) leads to the replacement of the constant region of IgM 
with that of another class including IgG3, IgG1, IgG2a, IgG2b, IgE and IgA (Chaudhuri and 
Alt, 2004). Both Ig SHM and CSR depend on the function of AID, whose expression is 
strongly induced in GC B cells (Muramatsu et al., 1999). Antigen-driven selection of B cells 
ultimately promotes their exit from the GC after completing their differentiation into high-
affinity, long-lived, memory B cells or antibody secreting-plasma cells (PCs) (Rajewsky, 
1996). Whereas PCs represent the endpoint of B cell differentiation, memory B cells provide 
a pool of B cells expressing high-affinity BCRs, which are preferentially recruited into 
secondary immune response after antigen re-encounter. GC-derived PCs are long-lived and, 
after their differentiation, they repopulate the BM representing the source of high-affinity 
antibodies. Memory B cells represent precursors of GC B cells while retaining the capacity 
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to directly differentiate into terminally differentiate PCs (Mond et al., 1995; Rajewsky, 
1996; Tarlinton and Smith, 2000)(Figure 5). 
 
                           
Figure 5: The germinal center reaction 
Upon antigen encounter, activated B cells expressing a fully functional BCR on their 
surface, enters in the GC reaction. In the dark zone (DZ), centroblast (CB) B cells start 
proliferating and undergo somatic hypermutation (SHM) of Ig variable region to diversify 
their immunoglobulin repertoire. After this process CB migrate in the light zone (LZ) of GC 
and differentiate in centrocytes (CC), which, through class-switch recombination (CSR), 
produce high-affinity antibodies of different isotype classes. Upon selection in the LZ, CC 
have three different outcomes: re-enter into the DZ for further rounds of SHM, undergo 
apoptosis due to low affinity maturation or terminally differentiate into both memory B cells 
and high-affinity secreting plasma cells.  
 
5.5.2 Effects of Ezh2 inactivation on B cell development 
Recently, several studies have assigned to the Polycomb protein Ezh2 a critical function in 
the control of B cell lymphopoiesis. Ezh2 expression is modulated during B cell 
differentiation, reaching the highest level in progenitor B cells. In accordance with its 
expression profile, conditional inactivation of Ezh2 catalytic function starting in pro B cells 
Basso K. and Dalla Favera R., Nature Review, 2015 
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causes an early block in B cell development (Su et al., 2003; Su et al., 2005). As result of 
this defect, conditional Ezh2 mutant mice suffer from a severe B cell lymphopenia (Su et al., 
2003) (Caganova and Casola, unpublished results). Mechanistically, Ezh2 mutant progenitor 
B cells suffer from defects in VDJ recombination, possibly resulting from defects in IgH 
locus contraction (Su et al., 2003). 
In accordance with its low expression in resting B cells, conditional inactivation of Ezh2 in 
the latter cells caused no over defects in the three mature B cell subsets (Caganova et al., 
2013). A rise in Ezh2 expression is observed when resting B cells are recruited into the GC 
reaction during a T cell-dependent immune response (Caganova et al., 2013). Specific 
ablation of Ezh2 enzymatic function in GC B cells causes a significant reduction in the 
number of GC B cells. As consequence of this defect, mutant animals fail to generate high-
affinity, long-lived, memory B cells and displaying a substantial reduction in antigen-
specific serum antibodies produced by PCs (Beguelin et al., 2013; Caganova et al., 2013). 
Moreover, conditional Ezh2 inactivation in GC B cells led to strong up-regulation of 
Cdkn2a locus. This evidence suggests that Ezh2 promotes cell cycle progression through the 
silencing of cell cycle regulator p16 and p19, encoded by the Cdkn2a locus. Surprisingly, 
the loss of Cdkn2a is not sufficient to rescue impaired GC responses of Ezh2 mutants, 
demonstrating that the defects of Ezh2 mutant GC B cells are independent of the regulation 
that Ezh2 exerts on Cdkn2a locus (Caganova et al., 2013). Ezh2 is also critical to prevent B 
cell terminal differentiation. Ezh2 deficient GC B cells up-regulate the expression of PCs 
master regulators B lymphocyte induced maturation protein 1 (Blimp1) and Interferon 
regulator factor (Irf) 4. According to these results, in GC B cells Ezh2 directly modulates 
Blimp-1 expression, thus preventing a premature exit from GC compartment to guarantee a 
protective adaptive immune response (Caganova et al., 2013). 
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5.6 EZH2 function in tumorigenesis 
The ability of Polycomb proteins to regulate central aspects of cell biology including stem 
cell pluripotency, lineage specification, cellular differentiation, cell cycle regulation and 
DDR, renders deregulation of this regulatory axis a potential determinant of diseases, 
including cancer. Indeed, expression of PcG proteins, as EZH2, is very often deregulated in 
aggressive forms of human malignant cancers. Experiments using human cell lines and 
mouse tumor models have unveiled important contributions of EZH2 to tumor biology 
(Koppens and van Lohuizen, 2015). In addition, recent advancements in high-throughput 
genome sequencing have identified common genetic alterations affecting several 
components of the Polycomb regulatory axis, including EZH2. The picture that has come 
out from these studies highlights the importance of the cellular context to explain the 
contribution of Polycomb proteins to malignant transformations. For the interest of this 
project, following paragraphs will be focused on the evidences linking aberrant EZH2 
function to cancer initiation, maintenance and/or progression (Table 1).  
 
 
Table 1: EZH2 alterations in cancer 
Table summarizing the main mutations affecting H3K27 methyltransferase EZH2 in several 
types of cancers. 
 
Volkel et al., Am J Transl Res, 2015 
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5.6.1 EZH2 overexpression in solid cancer 
Transcriptome analysis has provided the first evidence indicating recurrent overexpression 
of EZH2 in malignant prostate and breast cancer (Ku et al., 2008; Varambally et al., 2002). 
An increase in EZH2 expression levels often correlates with tumor progression, with high 
EZH2 expression levels commonly observed in metastatic stages and, hence, associated with 
poor prognosis (Collett et al., 2006; Kleer et al., 2003). In breast cancer, an initial increase in 
EZH2 expression is already monitored in precancerous lesions, while its levels substantially 
rise in aggressive metastatic tumors (Collett et al., 2006; Kleer et al., 2003). EZH2 up-
regulation has also been described in bladder, ovarian, kidney and lung cancers (reviewed 
(Yamaguchi and Hung, 2014). Increased EZH2 expression correlates with higher levels of 
H3K27me3 deposition at its target genes (Tan et al., 2007). Silencing by EZH2 of tumor 
suppressor genes, including Cdkn2a and Breast and Ovarian Cancer Susceptibility Protein 1 
(Brca1) is thought to contribute to tumor initiation, maintenance and/or progression (Tan et 
al., 2007; Wilson et al., 2010). In specific circumstances, EZH2 can also act as 
transcriptional activator. In breast cancer, EZH2 interacts with several partners depending 
on estrogen receptor status (ER). In ER-positive breast cancer cells, EZH2 was shown to 
interact with ERα and β-catenin proteins, facilitating their recruitment to promoters of target 
genes, including Axin2, c-Myc and Cyclin D1, which in turn, become activated (Shi et al., 
2007). The interaction between EZH2 and β-catenin was also reported in colon cancer cells, 
where the two factors form a trimeric complex with the DNA repair protein proliferating cell 
nuclear antigen (PCNA)-associated factor to promote β-catenin target gene expression. 
Along the same lines, EZH2 can directly activate Cyclin D gene expression, thereby 
triggering cell proliferation of natural killer/T-cell lymphomas (Yan et al., 2013). 
Importantly, in all instances, positive regulation of gene expression by EZH2 did not rely on 
its catalytic activity (Jung et al., 2013; Kim et al., 2013a; Xu et al., 2012). The repertoire of 
TFs, whose activity is supported by EZH2, is completed by evidences in ER negative breast 
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cancer cells, where EZH2 was shown to facilitate NF-κβ-mediated gene expression (Shi et 
al., 2007). 
EZH2 can influence the biology of cancer cells acting also on non-histones substrates. 
Studies on castration-resistant prostate cancer (CRPC) cells, have underlined the ability of 
EZH2, once phosphorylated by the AKT kinase, to catalyze lysine methylation of the 
androgen receptor (AR) or AR-binding proteins to promote their expression and ultimately 
support their transcriptional activity. Interestingly, in the same experimental setting, it was 
observed that EZH2 cooperated with the AR in activating the expression of target genes, 
further emphasizing the ability of the Polycomb protein to act either as repressor or activator 
of gene transcription, depending on the cellular context and repertoire of interacting partners 
(Xu et al., 2012). The ability of EZH2 to mediate methylation of non-histone proteins has 
been also confirmed in glioblastoma (Kim et al., 2013a). In the stem cell-like fraction of the 
latter tumors, serine-21 phosphorylation of EZH2 by AKT can trigger the binding to the 
transcription factor STAT3, followed by lysine methylation of the latter. EZH2 methylation 
of STAT3 potentiates the transactivation activity of the TF, thereby contributing to tumor 
maintenance (Kim et al., 2013a). Finally, EZH2-mediated lysine methylation of the tumor 
suppressor retinoic acid-related orphan nuclear receptor α (RORα) was shown to contribute 
to its degradation by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex, identifying a 
novel mechanism through which EZH2 is able to modulate the half-life of interacting 
partners (Lee et al., 2012). 
 
5.6.2 EZH2 inactivating mutations in myeloid disorders 
Whereas a large body of evidences supports a role for EZH2 in promoting tumorigenesis, 
recent data obtained through whole genome/exome sequencing projects have unveiled 
possible tumor suppressor function for the Polycomb protein. Indeed, somatic inactivating 
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mutations in the EZH2 gene were commonly identified in myelodisplastic syndromes, 
myeloproliferative neoplasms (MSD/MPS) and acute myeloid leukemia (AML). A first 
study identified 49 mutations in a total of 614 patients affected by MSD/MPS, chronic 
myelomonoctyic leukemia and atypical chronic myeloid leukemia. EZH2 mutations often 
targeted both alleles, consistent with a tumor suppressor role for the PcG protein (Ernst et 
al., 2010). A second study performed in 126 patients identified a series of frame-shift, 
missense and nonsense mutations, in most of the case targeting codons encoding for the 
methyltransferase SET domain of EZH2 (Nikoloski et al., 2010). Furthermore, in patients 
displaying heterozygous 7q36.1 deletions, encompassing the EZH2 locus, the EZH2 protein 
was expressed at very low levels. Importantly, patients with homozygous inactivating EZH2 
mutations had a poorer prognosis, compared to those retaining one functional copy of the 
Polycomb gene. More recently, a third study on 469 patients with myeloid malignancies 
identifies EZH2 mutations in 8 % of patients. Decreased EZH2 levels resulted from 
mutations in splicing factor genes, including U2 Small Nuclear RNA Auxiliary Factor 1 
(U2AF1) and Serine/Arginine-Rich Splicing Factor 2 (SRSF2) or from EZH2 loss of 
heterozygosity (LOH). As consequence of EZH2 haploinsufficiency/loss, tumor-relevant 
target genes, including HOXA9 could not be further repressed, possibly contributing to 
leukemogenesis (Khan et al., 2013). Loss of function (l.o.f) mutations in core PRC2 
components have also been reported in T cell acute lymphoblastic leukemia (T-ALL) with a 
frequency of 18 % for EZH2 and 7 % for SUZ12 (Ntziachristos et al., 2012). Studies in T-
ALL mouse models, in particular those driven by increased Notch1 signaling, confirm the 
pro-tumorigenic effect of Ezh2 inactivating mutations. Furthermore, Ezh2 inactivation 
rendered T-ALL cells more tumorigenic than control cells, after transplantion into Non 
obese diabetic/severe combined immunodeficiency (NOD-SCID) mice (Simon et al., 2012). 
Recent studies in mouse tumor models have provided unexpected hints on the activation of 
Ezh2 as tumor suppressor in myeloid malignancies (Lund et al., 2014). Specifically, 
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inactivation of Ezh2 in HSCs causes the development of myeloid tumors, including MDS 
and MPN. Combination of transcriptome and genome wide H3K27me3 distribution data 
allowed the identification of Ezh2 targets that become up-regulated in Polycomb mutant 
HSCs. Interestingly, the latter set of genes acquired de novo H3K27 trimethylation in MDS 
tumor cells as result of the action of Ezh1 (Mochizuki-Kashio et al., 2015). Hence, 
occurrence of myeloid malignancies is the result of deregulated Ezh1, whose function is 
unleashed by the concomitant absence of its paralog Ezh2. 
 
5.6.3  Histone mutations alter EZH2 function in pediatric gliomas 
Data obtained from whole genome/exome studies of high-grade pediatric gliomas have 
unveiled a novel mechanism contributing to the deregulation of Polycomb function in tumor 
cells. Specifically, it was shown that 70-80 % of high-grade pediatric gliomas, including 
glioblastoma multiforms (GBM) and diffuse intrinsic pontine gliomas (DIPG) carry a 
heterozygous mutation causing the substitution of lysine-27 with methionine in the gene 
coding for the histone variant H3.3 (Schwartzentruber et al., 2012). The occurrence of this 
mutation is associated with poor clinical outcome. The mechanism of action of this 
mutation, affecting a small proportion of histone proteins in the tumor, is yet poorly 
understood. It has been proposed that nucleosomes containing H3.3K27M stably recruit 
PRC2, thereby inhibiting genome wide H3K27me3 deposition (Venneti et al., 2013). The 
exception is represented by genetic loci within chromatin domains containing H3.3, which 
still appear heavily H3K27 trimethylated. The silencing of the latter genes has been 
proposed to contribute to tumorigenesis (Lewis et al., 2013). Together, these evidences 
support a scenario whereby in tumor cells mutations in H3.3 hijack the function of PRC2 
onto a selected subset of Polycomb target genes to ensure their stable repression, which is 
required for tumor growth. This condition unleashes the remaining set of Polycomb targets 
from epigenetic silencing, possibly contributing as well to sustain the malignant phenotype.  
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5.7  EZH2 activating mutations in B cell lymphomas 
5.7.1 Non Hodgkin Lymphomas 
B cell lymphomas represent the 95 % of all yearly-diagnosed lymphoma worldwide. 
Malignant B cell transformation results from alterations in the complex mechanisms 
regulating B cell development, identity and function. B cell Non Hodgkin lymphomas 
(NHL) originate in most of the cases from mature B cells. The most common forms of NHL 
are represented by Follicular lymphomas (FL), Diffuse large B cell lymphomas (DLBCL) 
and Burkitt lymphomas (BL) (reviewed in (Shaffer et al., 2012)). Tumor B cells of the three 
NHL subtypes outlined above display somatic mutation within their Ig V genes, pointing to 
a possible GC origin (Kuppers et al., 1999; Stevenson et al., 2001). GC B cell 
transformation results from the acquisition of reciprocal chromosomal translocations 
juxtaposing Ig loci to several proto-oncogenes, including MYC (in BL), BCL6 (in DLBCL) 
and BCL2 (in FL). The effect of such translocation is the deregulated constitutive action of 
genes, which promote cell proliferation and/or protect tumor cell precursors from 
undergoing programmed cell death (Basso and Dalla-Favera, 2015; Klein and Dalla-Favera, 
2008). Chromosomal translocation represents the byproduct of Ig CSR triggered in GC B 
cells by the action of AID (Dorsett et al., 2007; Pasqualucci et al., 2008). Aberrant AID 
function is also responsible for the acquisition of somatic mutations within non-Ig genes, 
which contribute to lymphomagenesis (Basso and Dalla-Favera, 2015; Dorsett et al., 2007; 
Pasqualucci et al., 2008) (Figure 6).  
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Figure 6: B cell NHL are commonly derived from GC reaction 
Schematic representation of the principal NHLs, which originate from the GC reaction. 
Genetic alternations consist in most of the cases in chromosomal translocation between Ig 
genes with different oncogenes including MYC in BL, BCL2 in FL and BCL6 in DLBCL, 
leading to their constitutive expression. 
 
5.7.2  EZH2 gain-of-function mutations in DLBCL and FL  
Expression of PcG proteins, including EZH2, is commonly observed in NHL (Basso and 
Dalla-Favera, 2015). In particular, tumors of GC origin, including BL, DLBCL and FL 
express high levels of EZH2 and other components of both PRC1 and PRC2 (Dukers et al., 
2004; van Kemenade et al., 2001). Beside augmented expression, whole genome/exome 
sequencing of DLBCL and FL have revealed the frequent occurrence of EZH2 gain-of-
function (g.o.f.) mutations (Lohr et al., 2012; Morin et al., 2010) (Figure 7). As a 
consequence of such mutations, which preferentially target specific residues of the catalytic 
SET domain, H3K27 trimethylation is substantially increased in malignant B cells (Morin et 
al., 2011; Yap et al., 2011). In DLBCL and FL, EZH2 g.o.f. mutations occur always in 
heterozygous fashion, consistent with their function. Moreover, in vitro biochemical studies 
Basso K. and Dalla Favera R., Nature Review, 2015 
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have suggested that mutant forms of EZH2 loose the ability to perform H3K27 mono-
methylation, becoming therefore dependent on the wild type Polycomb protein to generate 
H3K27me1, required for the subsequent methylation reactions (McCabe et al., 2012a; Yap 
et al., 2011; Sneeringer et al., 2010). Whole exome sequencing of cases of indolent FL have 
revealed the presence of EZH2 g.o.f. mutations starting from the earliest stages of the 
tumorigenic process (Bodor et al., 2013; Pasqualucci et al., 2014). This result highlights the 
possible tumor driver function associated with mutant EZH2. Moreover, in DLBCL, EZH2 
g.o.f. mutations are commonly associated with the occurrence of IgH/BCL2 translocations, 
pointing to a possible cooperation between the two proto-oncogenes in driving the 
tumorigenic process events (Okosun et al., 2014; Pasqualucci et al., 2014; Sungalee et al., 
2014). In support to these data, bone marrow reconstitution studies in the mouse model have 
confirmed cooperation between mutant EZH2 and BCL2 in promoting aggressive B cell 
lymphoproliferative disorders (Beguelin et al., 2013). Similar results were observed 
combining the expression of mutant EZH2 with constitutive activation of the MYC proto-
oncogene in the EµMYC lymphoma model (Berg et al., 2014). The combination of studies 
performed in vivo on Ezh2 conditional knockout and knock-in (for mutant EZH2) mouse 
strains, respectively, has pointed to the mechanisms through which deregulated activity of 
the Polycomb proteins participates to the transformation of GC B cells. First, Ezh2 stably 
represses through H3K27me3 of the promoter region, the expression of tumor suppressor 
Blimp1 (Beguelin et al., 2013; Caganova et al., 2013). Second, EZH2 is required to sustain 
the function of Bcl6 proto-oncogene, which is commonly deregulated in GC derived B cell 
malignancies (Beguelin et al., 2013). Third, Ezh2 protect B cells from genotoxic damage 
introduced by AID. In doing so, EZH2 g.o.f. mutations may allow the accumulation, in GC 
B cells, of exceeding levels of somatic mutations outside the Ig V genes (Caganova et al., 
2013). Finally, by repressing critical tumor suppressor genes, including Cdkn2a and p21, 
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Ezh2 may facilitate cell proliferation and protect B cells and their tumor derivatives from 
undergoing senescence (Caganova et al., 2013). 
 
 
Figure 7: EZH2 activating mutations are selected in GC-derived DLBCL and FL 
Identification by Sanger sequencing of mutations (Y641 and A677) in the catalytic (SET) 
domain of EZH2 gene in wild type control sample, Pfeiffer DLBCL cell line and in a 
primary DLBCL patient sample (sample ID CD564308), harboring EZH2 heterozygous C-
to-G missense (red asterisks) mutations. 
 
5.8 EZH2 overexpression and BL 
5.8.1 Burkitt lymphoma 
BL is an aggressive form of B-NHL, firstly identifies by Dr Burkitt in malarial areas of 
subequatorial Africa and described as a sarcoma of the jaws of African children (Burkitt, 
1958). Together with the endemic form of the disease present in Africa, BL appears as a 
sporadic disease in the Western world (Burkitt, 1962). Sporadic BL commonly develop in 
the gut associated lymphoid tissues where it rapidly disseminates to the bone marrow and 
other organs. The molecular hallmark of BL is represented by the t(8;14) chromosomal 
 
 
McCabe et al., PNAS, 2012  
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translocation that juxtaposes the c-­‐‑MYC proto-oncogene to IgH cis regulatory region locus, 
leading to constitutive MYC expression in B lymphoid cells. In 20 % of the cases, MYC 
translocation involves the Igκ or Igλ loci on chromosome 2 and 22, respectively (Dalla-
Favera et al., 1982; Hecht and Aster, 2000; Taub et al., 1982). BL tumor cells express 
somatically mutated Ig V genes and often display ongoing Ig SHM (Chapman et al., 1996; 
Klein et al., 1995). Recent studies have attempted to define the cell of origin of BL. MYC 
expression is transiently observed in GC B cells upon T-B cell interaction in the light-zone. 
The burst in proliferation triggered by MYC in response to CD40/CD40L interaction is 
followed by the re-entry of B cells in dark zone of the GC. At this point MYC expression is 
extinguished through the action of repressors, such as BCL6 (Dominguez-Sola et al., 2012). 
Upon acquisition of a t(8;14) translocation, the negative regulation of MYC expression in 
CB is lost leading to constitutive expression of the proto-oncogene in these cells. The 
accumulation of additional genetic events, such as the loss of tumor suppressor Tumor 
protein (TP) 53 gene or CDKN2A (Evan et al., 1992; Meyer et al., 2006; Schmitz et al., 
2012), or deregulated expression of pro-survival factors such as BCL2 (Blum et al., 2004), 
allow BL precursors to overcome programmed cell death and ultimately acquire a malignant 
phenotype. BL cells retain a CB transcriptional program, which sustains intense 
proliferation of tumor cells fuelled by MYC deregulation (Calado et al., 2012; Dominguez-
Sola et al., 2012; Victora et al., 2012). Besides recurrent inactivation of tumor suppressor 
TP53 and CDKN2A, and within the transactivation domain of MYC itself, BL cells display 
several recurrent mutations interfering with the biology of GC B cells (Schmitz et al., 2012). 
Mutations in the TCF3 (E2A)/ID3 transcriptional network are thought to potentiate the 
expression of genes important for BCR function, pointing to a contribution of the antigen 
receptor to tumor growth. Moreover, BL cells display frequent mutations in the gene coding 
for the Foxo1 transcription factor that has been shown to play an important role in the GC B 
cell biology (Chang, 2011). At the histological level, BL have a peculiar “starry sky” 
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appearance and are characterized by dense clusters of CD10/CD20/IgM-positive cells 
(Campo et al., 2011; Xie et al., 2015). The high proliferative rate of BL renders this cancer 
particularly sensitive to cytostatic drugs including cyclophosphamide, vincristine, 
prednisolone and doxorubicin (CHOP), which are given at doses that are proportional to the 
stage of the disease. The addition of rituximab (anti-­‐‑CD20) (or improved variants of anti-­‐‑
CD20 antibodies, such as Veltuzumab or Ofatumumab) to primary therapy (R-CHOP) has 
been assessed with an overall cure rate of roughly 90 % (Foon et al., 2012). Current 
therapeutic treatment, based on intensive chemotherapy, has pronounced hematological 
toxic effects and mucositis, as well as high risk of severe infections. Moreover, relapse of 
BL, even though uncommon, occurs on average 6 months after the end of the treatment, and 
has a very poor prognosis, probably because of the selection of particularly aggressive 
chemo resistant clones (Molyneux et al., 2012). 
 
5.8.2 Models of Burkitt lymphoma  
To better understand BL pathogenesis and develop safer/loss toxic therapeutic regimens, 
several transgenic mouse models recapitulating major aspects of human BL were developed 
over the past 20 years (Schmitz et al., 2014). The first described MYC-driven B cell 
lymphoma mouse model was the EµMYC model. In these transgenic mice, the c-MYC gene 
was placed under the control of IgH intronic enhancer (Eµ).  EµMYC mice develop 
lymphomas with a latency of 4th to 6th months (Adams et al., 1985). However, given the 
premature expression of the c-MYC transgene starting in B cell progenitors, the majority of 
tumors developing in EµMYC animals are of pro B/pre B origin. An alternative MYC 
driven-lymphoma model, called λ-­‐‑MYC, takes advantage of the Ig Light chain regulatory 
sequences to postpone constitutive MYC expression to IgM-expressing B cells (Kovalchuk 
et al., 2000). Indeed, in λ-MYC mice the majority of lymphoma develops from 
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immature/mature BCR-expressing B cells (Kovalchuk et al., 2000). Tumors in λ-MYC mice 
resemble human BL in terms of surface phenotype (IgM+; CD19+; B220+; CD43+; BAFF-
R+; CD5-; CD23-), most common genetic alterations (frequent loss of TP53 and CDKN2A) 
and histological appearance. The main difference with BL consists in the pre-GC origin of 
λ-­‐‑MYC B cell lymphomas, as confirmed by the lack of somatic mutations accumulated in 
clonal Ig V gene rearrangements. A third BL mouse model, targeting deregulated MYC 
expression to GC B cells in combination with constitutive activation of the PI3K pathway, 
has recently been described (Sander et al., 2012). In these transgenic animals the combined 
action of MYC deregulation and chronic PI3K activation has led to the development of bona 
fide GC B cells-derived BL (Sander et al., 2012). The relevance of this murine tumor model 
for the study of BL biology is further support by the isolation of recurrent genetic mutations 
that are shared with human BL (Schmitz et al., 2012), including Tcf3, Id3 and Cyclin D3.  
 
5.8.3 EZH2 overexpression in BL 
Regardless of the mutational status, the EZH2 gene is commonly highly expressed in most 
forms of aggressive B-NHLs (Dukers et al., 2004; van Kemenade et al., 2001). In particular, 
in Burkitt lymphoma EZH2 protein levels are substantially incremented when compared to 
their normal B cell counterparts (Sander et al., 2008). Previous data have linked EZH2 gene 
expression to the activation of the E2F1 TF. Since MYC-driven lymphomas display 
substantial E2F1 transcriptional activity, it is possible that high EZH2 levels reflect 
sustained function of the E2F1/MYC transcriptional network in tumor B cells. A direct 
influence of MYC on EZH2 gene has also been suggested. Indeed, several studies have 
proposed the existence of a positive feedback loop centered on the MYC/EZH2 axis, which 
is mediated by the action of specific microRNAs (miRNAs) species. In BL cell lines, 
constitutive high MYC activity results in the deregulation of several miRNAs, including 
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miR-26a (Zhang et al., 2012). Ectopic expression of miR-26a reduces EZH2 protein levels, 
interfering with tumor cell proliferation. These data have proposed a model whereby 
deregulated c-MYC action sustains EZH2 expression through the repression of miR26a 
(Sander et al., 2008). Conversely, EZH2 together with Histone deacethylase (HDAC) 3 was 
shown to inhibit miR494, that is capable of down-regulating c-MYC expression (Zhang et 
al., 2012) (Figure 8). 
 
 
Figure 8: MYC-EZH2 positive feedback loop 
Schematic model displaying the mechanism by which MYC activates EZH2 via repressing 
EZH2-targeting miR-26a, in c-MYC driven lymphomas. As results, EZH2 induces silencing 
of miR-494, that suppresses MYC expression, leading to a constitutive expression of both 
MYC and EZH2 and consequent repression of miR-29. 
 
The strong increase in EZH2 levels observed in BL cells is compatible with the hypothesis 
that the Polycomb proteins exert pro-oncogenic functions in malignant MYC-transformed 
GC B cells. However, recent data have challenged this model (Lee et al., 2013). Using the 
EµMYC lymphoma model, it was shown that haploinsufficiency of Ezh2/Suz12, starting 
from HSCs and achieved through gene targeting or RNA interference technology, 
accelerates progenitor B cell tumorigenesis (Lee et al., 2013). The shorter latency in tumor 
appearance was associated to an expansion of the progenitor B cell compartment as a result 
Zhang et al., Cancer Cell, 2012 
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of the interference imposed by PRC2 haploinsufficiency on early B cell development (Lee et 
al., 2013). The substantial interference with early hematopoiesis caused by the deregulation 
of PRC2 function in all hematopoietic lineage precursors, combined with a preferential 
occurrence of progenitor B cell tumors, poses some doubts on the values of these results to 
understand the function of EZH2 in GC-derived BL. In support of this, works describing the 
combined effect of in vivo EµMYC and a constitutive active form of EZH2 restricted to B 
cells, have revealed potent cooperation between the two transgenes in promoting B cell 
tumorigenesis (Berg et al., 2014). All together these results indicate that cellular context 
plays a crucial role in the regulation by EZH2 on c-MYC driven tumorigenesis. Moreover, 
whereas many studies have attempted to define the role of deregulated EZH2 in the 
development of MYC-driven tumors, there are currently no evidences showing the actual 
requirement for EZH2 in established MYC lymphomas. 
 
5.9  EZH2 as target anti-cancer therapy 
5.9.1 Development of anti-EZH2 inhibitors 
The recurrent identification of EZH2 g.o.f. mutations in B-NHL as well as the common 
increase in EZH2 expression in advanced stages of both solid and hematopoietic 
malignancies, has identified Polycomb protein as possible target of anti-cancer therapies. 
The first described EZH2 inhibitor is 3-deazaneplanocin A (DZNep) (Tan et al., 2007). It 
acts to suppress S-adenosylmethionine (SAM)-dependent cellular methylations through the 
inhibition of the S-adenosylhomocystein hydrolase (SAH) (Miranda et al., 2009; Richon et 
al., 2011). DZNep is a global inhibitor of histone methylation, which has shown potent anti-
tumor activity in breast, colon cancer and melanoma cancers (Fan et al., 2011; Puppe et al., 
2009; Tan et al., 2007).  
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Later generations of SAM inhibitors showed more restricted specificity towards EZH2. The 
latter class of inhibitors competitively binds to the SAM pocket within the catalytic SET 
domain of EZH2. The first two described inhibitors were EPZ005687 (Knutson et al., 2012) 
and GSK126 (McCabe et al., 2012b). Both drugs showed high specificity for their target 
EZH2. Moreover, studies in preclinical DLBCL models indicated that the inhibitors acted on 
both the (WT) type and the constitutively active mutant form of EZH2 (Knutson et al., 2012; 
McCabe et al., 2012b; Qi et al., 2012). EPZ005687 targets selectively EZH2, while largely 
sparing the activity of its close paralog EZH1. A derivative of GSK126, GSK343, was 
developed soon after to increase Ezh2 specificity. UNC1999 represents the first described 
orally bioavailable small molecule inhibitor that is able to inhibit both EZH1 and EZH2 
methyltansferase activities (Konze et al., 2013). UNC1999 inhibition results in a global loss 
of H3K27me3, followed by growth impairment of DLBCL cell lines displaying EZH2 g.o.f. 
mutations (Konze et al., 2013). Recently, a novel approach was employed to inhibit PRC2 
function (Kim et al., 2013b).  Specifically, the Orkin laboratory developed a 27-mer 
hydrocarbon-stapled (SAH-EZH2), that is able to compete with EZH2 binding to the core 
PRC2 component EED. SAH-EZH2 mimics the α-helical EED binding domain of EZH2. 
Exposure of DLBCL cells to SAH-EZH2 leads to growth interference resulting from 
impaired H3K27 methyltransferase activity. Importantly, SAH-EZH2 will inhibit PRC2 
regardless of whether EZH1 or EZH2 constitute the catalytic subunit of the complex (Konze 
et al., 2013) (Figure 9). 
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Figure 9: Principal EZH2 inhibitors 
Schematic model displaying three models of action of EZH2 inhibitors targeting the SET 
catalytic domain of the methyltransferase: SAM competitive inhibitors, DZNep and SAH.  
 
5.9.2  Comparison between EZH2 and EZH1/2 inhibitors  
The studies describing the efficacy of anti-Ezh2 inhibitors in DLBCL lines have underlined 
a heterogeneous response to the drug. Even lymphomas showing EZH2 g.o.f. mutations 
display in some instance resistance to EZH2 inhibitors (McCabe et al., 2012b). In this 
context, targeting the methyltransferase activity of both EZH1 and EZH2 may represent a 
better strategy to inhibit PRC2 function in tumor cells. In support of this, in vivo studies on 
MLL-AF9 driven leukemias have recognized a possible redundancy between Ezh2 and Ezh1 
in supporting tumor growth and progression (Neff et al., 2012). Importantly, recent in vivo 
studies on the similar MLL-AF9 driven leukemias have described a potent anti-tumor 
activity for the EZH1/2 UNC1999, which was not achieved with the EZH2 selective 
inhibitor GSK126 (Xu et al., 2015a). An alternative to SAM competitors interfering with 
Tan et al., Acta Pharmacologica Sinica, 2014  
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both EZH1 and EZH2 is represented by the SAH-EZH2 peptide, which has shown potent 
anti-lymphoma activity in pre-clinical models (Kim et al., 2013b).  
It remains to be seen whether combined EZH1/2 inhibition may exert stronger adverse 
effects as compared to EZH2 selective inhibitors, as EZH1 is the predominant EZH protein 
expressed in cell cycle arrested differentiated somatic cells. 
 
5.9.3  Resistance to anti-EZH2 therapies 
The successful results achieved by the use of anti-EZH2 inhibitors in preclinical models 
have led to the rapid translation of the findings into the clinical settings. So far, two clinical 
trials based on EZH2 inhibitors are currently ongoing. The first trial involves the use of 
EZH2 inhibitor EPZ-6438 (also known as E7438) by Epizyme. It is a phase-1 study for 
advanced solid tumors and a phase-2 for the treatment of DLBCL and FL 
(http://clinicaltrials.gov/ct2/show/NCT01897571). The second trial is based on the use of 
GSK2816126, from GlaxoSmithKline (GSK). It is presently in phase-1 and is directed to 
patients with relapsed or refractory DLBCL and transformed FL, solid cancers and multiple 
myeloma (http://clinicaltrials.gov/ct2/show/NCT02082977).  
The effectiveness of anti-EZH2 inhibitors is counterbalanced by emerging reports describing 
forms of acquired resistance of tumor cells to H3K27 methyltransferase inhibition.  
Recently, the EZH2 specific inhibitor EI1 from GSK (Qi et al., 2012) has been used to 
develop a model of acquired resistance using the DLBCL line Karpas, which was shown to 
be highly sensitive to EZH2 inhibition (Gibaja et al., 2015; Qi et al., 2012). Chronic 
exposure of lymphoma cells to EI1 led to the selection of clonal variants resistant to the 
drug. Sequencing of the EZH2 gene in such cells revealed the presence of two de novo 
missense mutations lysing outside (Tyr111) and within (Tyr661) the catalytic SET domain, 
respectively (Gibaja et al., 2015). In addition, whereas the Tyr111 mutation mapped to the 
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WT allele, replacement of Tyr661 occurred on the EZH2Y641 allele (Gibaja et al., 2015). 
These data predict that EZH2 inhibitors may select tumor clonal variants resistant to the 
treatment in patients enrolled in anti-EZH2 therapeutic protocols. A comprehensive 
understanding of the mechanisms of resistance to anti-EZH2 therapies hence represents a 
pressing medical need. 
 
5.10 Aim of the study 
Aggressive forms of both solid and hematopoietic malignancies display, especially in late 
stages of the disease, incremented levels of EZH2 expression. Whether tumor cells benefit 
from increased EZH2 expression in order to sustain their growth and/or to select clonal 
variants with increased malignancy is yet unknown. Data on DLBCL and FL, showing 
EZH2 g.o.f. mutations, indicate that inhibition of the Polycomb protein in the tumor cells 
has a negative impact on tumor growth. 
The scope of this research project has been to elucidate the role of Ezh2 in an aggressive 
form of NHL driven by MYC deregulation, in which expression of Polycomb protein is 
substantially increased. To achieve this goal, we developed a MYC-driven B cell lymphoma 
model in which Ezh2 catalytic activity can be inactivated in a time-controlled fashion using 
the Cre/loxP technology. Using this approach, we succeeded to inhibit the catalytic function 
of Ezh2 in established, highly aggressive, primary B cell lymphomas. Using a combination 
of both in vitro studies and in vivo analyses based on reconstitution of immunoproficient 
animals with lymphomas undergoing acute Ezh2 inactivation, we determined the effects of 
inhibition of Ezh2 methyltransferase on tumor growth and established its consequence on 
the transcriptional program of tumor cells. Another major focus of this study has been to 
define possible mechanisms of resistance of MYC lymphomas to genetic and/or 
pharmacological inhibition of Ezh2 catalytic function. Through such investigations, this 
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study aims to provide novel insights into the regulation by EZH2 of tumor cell biology and 
establish molecular signatures that may allow to select patients with BL (and possibly other 
cancer types) that could most benefit from anti-EZH treatments and/or to reveal early stages 
of disease relapse. 
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6  Materials and methods 
6.1 Mice 
6.1.1 Mouse strains 
λ-MYC; Ezh2fl/fl mice were obtained crossing λ-MYC and Ezh2fl/fl transgenic mice 
described in (Kovalchuk et al., 2000) and (Su et al., 2003), respectively. C57BL/6J and 
C57BL/6J x BALB/c F1 (CB6F1) mice were purchased from Charles River laboratories or 
Jackson Laboratories. Mice were housed and bred in the animal facility located at the 
IFOM-IEO Campus in Milan.  
 
6.1.2 Mice monitoring  
Mouse experimentations were performed under the protocol number approved by the Italian 
Ministry of Health and the IFOM IACUC Committee. According to published data, λ-MYC 
mice spontaneously develop neoplastic lesions of lymphoid origin starting from the 4th 
month of age. During the study, transgenic mice were monitored for tumor formation once 
every month between the 8th and 16th week of age and at least once every week from then 
onwards. Suffering mice were sacrificed when they showed a consistent loss of weight 
(15%), hair ruffling and reduced motility, always associated with enlarged lymph nodes and 
splenomegaly, according to guidelines for animal welfare (Workman et al., 2010). 
 
6.2 Molecular biology techniques 
6.2.1 Genomic DNA extraction from tail biopsy 
Tail biopsies of λ-MYC; Ezh2 compound mutants were incubated in 400 µL of lysis buffer 
(100 mM Tris-HCl pH 8.5; 5 mM EDTA; 200 mM NaCl; 0.2 % SDS) with Proteinase K 
(PK) (100 µg/mL) at 56 °C, shaking at 850 revolutions per minutes overnight in 
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Thermomixer compact (Eppendorf). Lysed material was transferred into a new 1.5 mL tube 
and 1 mL of isopropanol was added, mixed through inversion and centrifuged at maximum 
speed for 1 minute in a tabletop centrifuge. The DNA was pelleted by centrifugation, air-
dried and dissolved in 300 µL of Milli-Q (MQ) water (Q-POD Element, Merck Millipore) 
by incubation at 50 °C for 20 minutes. 
 
6.2.2 Genotyping strategy 
Genomic DNA extracted from tail biopsies of all mouse offspring was analyzed by 
polymerase chain reaction (PCR). Primers described in table 2 and PCR reagents in table 3 
were used to perform the PCR reaction. PCR conditions are summarized in table 4. PCRs 
were performed in automatic thermocycler GeneAmp PCR System 9700 (Life 
Technologies). 
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Table 2: Genotyping primers, annealing temperature (TA) and amplicons 
Primers 
TA 
Product 
Name Sequence Amplicon Size 
Human c-MYC 
Human c-MYC Fw 5’-GAGGCAGGCTCCTGGCAAAAGGTA-­‐‑3’ 
58 °C Tg 400 bp 
Human c-MYC Rv 5’-­‐‑GAAATGAGCTTTTGCTCCTCTGCTTG-­‐‑3’ 
Ezh2 SET 
Ezh2 flox Fw 5’-TTATTCATAGAGCCACCTGG-3’ 
60 °C 
Flox 450 bp 
Ezh2 flox Rv 5’-CTGCTCTGAATGGCAACTCC-3’ WT 400 bp 
Ezh2 ΔSET 
Ezh2 ΔSET Fw 5’-ACTTCACTGCCAGCCAGTCT-3’ 
60 °C Δ 500 bp 
Ezh2 ΔSET Rv 5’-ACACACCCGACTGGCTTTAC-3’ 
Cdkn2a 
Ink4a/Arf Fw 5’-­‐‑TTAACAGCGGAGCTTCGTACA-­‐‑3’ 
60 °C Tg 150 bp 
Ink4a/Arf Rv 5’-­‐‑CTGCACCGTAGTTGAGCAGAA-­‐‑3’ 
VkJk 
Vκ Fw1 5’-GCGAAGCTTCCCTGATCGCTTCACAGG-­‐‑3’ 
55 °C 
VκJκ1 
800 bp 
Vκ Fw2 5’-GCGAAGCTTCCCWGCTCGCTTCAGTGG-­‐‑3’ VκJκ2 
550 bp 
Vκ Fw3 5’-GCGAAGCTTCCCAKMCAGGTTCAGTGG-­‐‑3’ VκJκ3 
250 bp 
Jκ5 Rv 5’-­‐‑CTCAGAGCTCTAGGCCCCTCTTTGAT-­‐‑3’ VκJκ5 100b p 
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Table 3: Master mix used for genotyping 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Genotyping PCR conditions 
PCR Cycle 
Temperature (°C) Time (minutes) 
94 2:30 
95 0:30 
TA                        35x 0:30 
72 0:30 
72 5:00 
4 Hold 
 
 
PCR master mix µL 
5X Flexi Buffer 5 
MgCl2 2.5mM 2 
dNTPs 2.5mM 2 
Primer Fw (50µM) 0.2 
Primer Rv (50µM) 0.2 
Go Taq Flexi 0.2 
DNA 1-2 
H2O Up to 25  
 58 
6.2.3 Agarose gel electrophoresis and DNA gel extraction 
Size of DNA fragments, amplified by PCR, was defined by electrophoresis agarose (0.7 %- 
2.5 %) (GellyPhorLE, EuroClone) gel separation in 1 X TAE (Sambrook and Russell, 2001) 
and 1 X Gel RedTM nucleic acid gel stain (BIOTIUM).  As reference marker for agarose gel 1 
kilo bases (kb) or 100 base pair (bp) DNA ladder (Promega) were used. The size of 
amplicons was visualized using UV trans illuminator (EuroClone). 
 
6.3 DNA and RNA extraction 
Simultaneous purification of total RNA and genomic DNA from 1 to 5x106 cells was 
performed using All Prep DNA/RNA mini kit (Qiagen) following the manufacturer’s 
protocol. Purified DNA and RNA were quantified by a microvolume UV spectrophotometer 
(NanoDrop ND-100).  
 
6.3.1 cDNA synthesis 
Total RNA was extracted from 1 to 5x106 cells, using RNeasy mini kit (Qiagen), following 
the manufacturer’s instructions. Possible DNA contamination was removed through a 
DNAse (Qiagen) digestion step, before RNA elution in RNase-free water, which was 
included in the RNA extraction kit. Total RNA was quantified by a microvolume UV 
spectrophotometer (NanoDrop ND-100). Complementary DNA (cDNA) was obtained by 
reverse transcription (RT) with the Reverse Transcriptase SuperScript II kit (Life 
Technologies). RNA (500 ng to 1 µg) was mixed with 50 to 250 ng of Random Primers 
(Life Technologies) and incubate 5 minutes at 65 °C in the automatic thermocycler 
GeneAmp PCR System 9700 (Life Technologies). Following this incubation step and a 
quick chill on ice, a master mix composed of 5 X First Strand (FS) buffer, 0.1 M 
Dithiothreitol (DTT), 10 mM dNTPs mix, 40 U/µL RNase OUT and 200 U/µL Super Script 
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II (Life Technologies), included in the kit, was added. Subsequent incubation steps of 2 
minutes at 25 °C, 50 minutes at 50 °C and heat inactivation of the enzymatic reaction for 15 
minutes at 72 °C were performed in the automatic thermocycler GeneAmp PCR System 
9700 (Life Technologies).  
 
6.3.2 Quantitative PCR and quantitative real-time PCR  
Ezh2 deletion efficiency (DE) was defined measuring gene copy number by quantitative 
PCR (qPCR). For gene expression analysis, quantitative Real Time PCR (qRT-PCR) was 
performed. 500 nM primers mix and 10 µL of LightCycler 480 SYBR Green I Master 
containing Hot-­‐‑start polymerase (Roche) were added to DNA (25 ng) or cDNA (25 ng) in a 
final volume of 20 µL per reaction in 96-­‐‑well plates (Roche). Reaction conditions included 
serial steps at 95 °C for 10 minutes, 45 cycles of 95 °C for 10 seconds, 60 °C for 10 seconds 
and 72 °C for 10 seconds, followed by a final elongation step for 10 minutes. Accumulation 
of fluorescent products was monitored using the LightCycler® 480 software, version 1.5 
provided along with the LightCycler® 480 Real-­‐‑Time PCR System (Roche). Specificity of 
the PCR reaction was controlled through the assessment of the melting  temperature profiles 
of the final products (dissociation curve). Ezh2 gene copy number analysis was performed 
using primers annealing within the Ezh2 SET domain loxP flanked segment to quantify the 
amount of remaining Ezh2 SET locus (table 5). To normalize for DNA input, a segment of 
the Gapdh gene was amplified (table 5).   
Ezh2 DE was calculated as: 
DE (%) = 100% - retained SET domain (%) for Ezh2fl/fl  
DE (%) = 50% / retained SET domain (%) x 100 for Ezh2fl/Δ 
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Gene expression levels were normalized to the Ribosomal protein large p0 (Rplp0) 
housekeeping gene expression levels (table 5) (Akamine et al., 2007; Laborda, 1991). 
Transcript fold enrichment was calculated by ΔΔct method (Livak and Schmittgen, 2001). 
 
Table 5: Primer list for qPCR and qRT-PCR 
Primers Sequence Target 
Gapdh4d Fw 5’-AGCGCTGACCTTGAGGTCTCCTTG-3’ DNA 
Gapdh4d Rv 5’-GTTGCCTACGCAGGTCTTGCTGAC-3’ DNA 
Ezh2 ΔSET Rv 5’-CAGCAGTGAGCAGGAAGACA-3’ DNA 
Ezh2 ΔSET Rv 5’-AGATTTTGTGGTGGATGCAA-3’ DNA 
 
Rplp0 Fw 5’-­‐‑TTCATTGTGGGAGCAGAC-­‐‑3’ RNA 
Rplp0 Rv 5’-­‐‑CAGCAGTTTCTCCAGAGC-3’ RNA 
Ezh1 Fw 5’-GGAGCAAAGGAGTACGCCAT-3’ RNA 
Ezh1 Rv 5’-TTCTGTTTCGTGGGGGTCTG-3’ RNA 
p16/Ink4A Fw 5’-GAACTCTTTCGGTCGTACC-3’ RNA 
p16/Ink4A Rv 5’-CCAGCGTGTCCAGGAAG-3’ RNA 
p21/Cdkn1a Fw 5’-CCACAGCGATATCCAGACATTC-3’ RNA 
p21/Cdkn1a Rv 5’-CGGAACAGGTCGGACATCA-3’ RNA 
 
 
6.4 Cell culture techniques 
6.4.1 Preparation of cell suspension from lymphoid organs 
Lymphoma cells were obtained from spleen, bone marrow and lymph nodes (mesenteric and 
axillary) of 8-12 weeks to 2-10 months-old diseased experimental  mice. Spleen and lymph 
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nodes samples were smashed between frosted slide glasses and subsequently filtered 
through 70 µm nylon meshes (Becton Dickinson, USA). Femurs were flushed using a 
syringe filled with 10 mL of B cell medium containing Dulbecco’s Modified Eagle Medium 
(DMEM) (Lonza) supplemented with 10 % heat-inactivated fetal bovine serum (FBS) 
(Sigma-Aldrich), 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 50 µM β-
mercaptoethanol (Life Technologies) and 5 mM L-glutamine (Microtech) to obtain bone 
marrow cells. Erythrocytes lysis from spleen and bone marrow preparations was achieved 
incubating cell suspensions in 1 mL of a 9:1 (v/v) solution of 0.15 M NH4Cl and 0.17 M 
Tris-HCl pH 7.65 for 3 minutes on ice. Red blood cell lysis reaction was inactivated adding 
10 volumes of B cell medium. Cells were centrifuged at 290 g at 4 °C and resuspended in B 
cell medium before counting. Cell density was adjusted to 2x105 cells/mL and medium was 
refreshed every 48 hours. 
 
6.4.2 B cell purification 
Primary B cells were isolated from spleen of C57 BL6/J mice by magnetic activating cell 
sorting (MACS) purification. Spleens were processed as described in section 6.4.1 and 
single cell suspensions were magnetically labeled using anti-CD19 conjugated MicroBeads, 
according to the manufacturer’s protocol (Miltenyi Biotec, Germany). Subsequently, cell 
suspensions were purified using LS column (Miltenyi Biotec, Germany), loading the cells 
under the magnetic field of a MACS separator (Miltenyi et al., 1990). Magnetically labeled 
CD19+ B cells were retained in the column, whereas the CD19- fraction was removed 
through washing steps with MACS buffer (1X PBS, 0.5% BSA, 2mM EDTA). Columns 
were then removed from the magnetic support and CD19+ cells were eluted as selected B 
cell fraction. Purified B cells were used as control for further experiments.  
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6.4.3 Establishment of cell lines from λ−MYC lymphomas 
Primary lymphomas were cultivated in 25 mm2 or 75 mm2 cell culture flasks at 37 °C in a 
humidified cell culture incubator (Galaxy S RSBiotech, Scientific Laboratories) with 5 % 
CO2. On average two weeks after initial seeding over 50 % of primary lymphomas gave rise 
to tumor cell lines adapted to grow under in vitro experimental conditions. 
 
6.4.4 TAT-Cre transduction of primary lymphoma cells  
Primary lymphoma cells were washed twice in serum-free media (Hyclone, USA) at a 
density of 107 cells/ml and incubated for 45 minutes at 37 °C with 37.5 µg/mL (final 
concentration) of recombinant TAT-Cre. Transduction was inactivated adding 10 volumes 
of B cell medium to the samples. Cells were centrifuged at 290 g, resuspended in B cell 
medium and cultured at a density of 2x105 cells/mL. Deletion efficiency of Ezh2 was 
measured 48 hours later by qPCR on genomic DNA purified from transduced cells. 
 
6.4.5 Isolation of Ezh2 mutant cells by limiting dilution  
48 hours following TAT-Cre transduction, tumor cells were plated by limiting dilution at 
final cell density of 1.5 cells/mL in 96 well plates in a final volume of 100 µL. Cells were 
incubated at 37 °C, 5 % CO2. After one week, additional 100 µL of fresh B cell medium was 
added to the 96 well plates. Plates were monitored for clone formation during the following 
two to three weeks until colonies derived from single cells were visible. Ezh2 genotype was 
defined by PCR analysis on genomic DNA extracted from each colony. 
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6.4.6 Growth curve analysis and lymphoma treatment with small molecule inhibitors 
Cell growth analysis was performed plating lymphoma cells at cell density of 2x105 
cells/mL in triplicates at 37 °C, 5 % CO2. Cells were counted and medium was refreshed 
every two days. Growth curve experiments were also performed to test the effect of 
Ezh1/Ezh2 dual inhibitor UNC1999 (Konze et al., 2013) treatment on established 
lymphomas. Cells were treated every two days with UNC1999 at a final concentration of 
2.5, 1.25 or 0.6 µM in B cell medium. Drug vehicle, DMSO, was used as treatment control. 
Parallel experiments were performed using the Mdm2 inhibitor nutlin (Tovar et al., 2006). 
Cells were treated every two days with increasing doses (2.5, 5 or 10 µM) of nutlin in B cell 
medium or with DMSO, used as vehicle for the drug. 
 
6.4.7 Lymphomas transplantation  
Lymphoma cells derived from λ-MYC; Ezh2 mutant or control mice, once established as 
cell suspension, were transplanted via tail vein injection in immunoproficient syngenic mice. 
Before transplantation into recipient animals, lymphoma cells were washed twice in 1 X 
PBS, resuspended at 5x107 cells/mL and 100 µL of cell suspension was injected into the tail 
vein of 16-20-weeks old immunoproficient CB6F1 or C57BL/6J mice. Animals were 
monitored for tumor formation performing abdominal palpation to reveal splenomegaly and 
increased size of superficial lymph nodes. Recipient mice developed tumors after 15-26 
days on average. Tumors were isolated and stabilized in culture as described previously.  
 
6.5 Imaging techniques 
6.5.1 Immunostaining for flow cytometry 
For flow cytometric analysis aliquots of 106 cells were stained for 20 minutes at 4 °C in the 
dark in 50 µL FACS buffer (PBS 1 %, BSA 0.01 %) containing the appropriate mixture of 
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fluorescently labeled antibodies (Abs) (table 6). Stained cells, resuspendend in FACS buffer, 
were acquired on a FACSCalibur (BD Pharmingen, USA). Dead cells were excluded from 
the analysis by propidium iodide (PI) labeling or based on forward and side scatter 
parameters. Data were analyzed using the FlowJo software (Tree Star, USA). 
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Table 6: List of antibodies used for flow cytometry 
Antibody and antigen (clone) Source Dilution Factor 
Anti mouse IgM (R33.24.12) Home-made 1/400 
Anti mouse IgM (R331.12) Home-made 1/400 
Monoclonal Rabbit anti-mouse H3K27me3 (C36B11) Home made 1/1000 
Monoclonal Rat-anti mouse CD138 (281-2) eBiosciences 1/200 
Monoclonal Rat-anti mouse CD19 (eBio1D3) eBiosciences 1/400 
Monoclonal Rat-­‐‑anti mouse CD21/CD35 (eBioD89) eBiosciences 1/1000 
Monoclonal Rat-­‐‑anti mouse CD23 (B3B4) eBioscience 1/100 
Monoclonal Rat-­‐‑anti mouse CD25 (PC61.5) eBiosciences 1/200 
Monoclonal Rat-­‐‑anti mouse CD38 (90) eBiosciences 1/600 
Monoclonal Rat-­‐‑anti mouse CD43 (eBioR2/60) eBiosciences 1/400 
Monoclonal Rat-anti mouse IgD eBiosciences 1/3000 
Monoclonal Rat-anti mouse/human CD45R (B220) (RA3-­‐‑6B2) eBiosciences 1/400 
Monoclonal Rat-­‐‑anti mouse BP-1 (6C3) eBiosciences 1/100 
Monoclonal Rat-anti mouse CD24 (HSA) (30-F1) eBiosciences 1/1000 
Monoclonal Rat-anti mouse CD117 (c-Kit) (2B8) eBiosciences 1/200 
Monoclonal Rat-anti mouse CD93 (AA4.1) eBiosciences 1/400 
Monoclonal Rat-anti mouse MHC II (M5/114.15.2) eBiosciences 1/200 
Monoclonal Rat-anti mouse CXCR4 (2B11) eBiosciences 1/200 
Monoclonal mouse-­‐‑anti BrdU (PBR-­‐‑1) BD 1/5 
Monoclonal Rat-anti mouse CD268 (BAFF-R) (7H22-E16)  BD 1/400 
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6.5.2 Intracellular immunostaining for flow cytometry 
Intracellular staining for H3K27me3 was performed on 106 cells. Cells were permeabilized 
and fixed in U-bottom 96 well plates for 20 minutes at room temperature (RT), shaking, 
with 100 µL of Cytofix/CytopermTM solution (BD Bioscience). Fixed cells were washed 
with 100 µL of 1 X Perm/WashTM buffer (P/W) (BD Bioscience). After centrifugation at 4 
°C, 340 g for 3 minutes, cells were refixed with 100 µL of Cytofix/CytopermTM solution 
(BD Bioscience) for 20 minutes at RT, shaking. Cells were then incubated with the primary 
Ab (Alexa647-labeled monoclonal rabbit anti-mouse H3K27me3 C36B11, Cell Signaling, 
working dilution 1/1000 in 1 X P/W) for 1 hour at RT, shaking. Cells were then washed 
twice with 100 µL 1 X P/W buffer and resuspended in FACS buffer. Samples were acquired 
and analyzed using FACSCalibur (BD Pharmingen, USA) and FlowJo software (Tree Star, 
USA), respectively.  
 
6.5.3 Cell cycle analysis  
106 B cell lymphomas (mouse λ-MYC and human Ramos) were pulsed with 33 µM of BrdU 
(Sigma Aldrich) for 10 minutes at 37 °C, 5 % CO2. After two rounds of washing with cold 1 
X PBS, cells were transferred in U-bottom 96 well plates. Cells were fixed in 
Cytofix/CytopermTM buffer (BD Bioscience) for 20 minutes, washed with 1 X P/W Buffer 
and re-fixed in BD Cytofix/CytopermTM Plus buffer (BD Bioscience) for 10 minutes, at RT, 
light protected. Cells were washed with 1 X P/W and incubated 5 minutes with BD 
Cytofix/CytopermTM buffer, at RT, protected from light, and washed again with 1 X P/W. 
Fixed cells were treated with 300 µg/mL DNAse for at least 1 hour at 37 °C, washed with 1 
X P/W, and stained with FITC-labeled anti-­‐‑BrdU   Ab (BD Bioscience), for 30 minutes at 
RT. Stained cells were washed two times, resuspended in 1 ml of cold 1 X PBS containing 
PI (50 µg/mL, Sigma) and RNase (250µg/mL) and incubated overnight at 4 °C. Samples 
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were acquired by FACSCalibur (BD Pharmingen, USA) and analyzed using FlowJo 
software (Tree Star, USA). PI staining coupled with immunoflorescent BrdU staining 
allowed to characterize cells according of their distribution into the different phases of the 
cell cycle, namely the G0/G1, S and G2/M phases.  
 
6.6 Biochemical techniques 
6.6.1 Immunoblot analysis  
Cells were harvested by centrifugation for 5 minutes at 290 g and washed with cold 1 X 
PBS. Protein extraction was performed on whole cell extracts with RIPA buffer (10 mM 
Tris-HCl, pH 8.0; 1 % Triton-X-100, 0.1 % SDS; 0.1 % Sodium Deoxycholate, 150 mM 
NaCl; 1 mM EDTA; 1 mM DTT; 1 mM PMSF and protease inhibitor cocktail Set III 
(EDTA-free, Calbiochem,) and incubate 1 hour on ice. Sonication consisted of 3 cycles, 15-
20 seconds each (BioruptorTM Next Gen, Diagenode). Lysates were centrifuged at maximum 
speed for 1 minute in a tabletop centrifuge to remove cell debris. Proteins were quantified 
with DCTM protein assay (BioRad Laboratories) using a bovine serum albumin (BSA) 
standard curve as reference. Absorbance at 595 nm was measured using Wallac VICTOR3 
1420 Multilaber Counter (Perkin Elmer). 20-50 µg of proteins in Laemmli loading buffer 
(62.5 mM Tris-HCl, pH 6.8; 2 % SDS; 0.001 % Bromophenol Blue and 10 % glycerol) and 
10 µL of NOVEX Sharp Pre Stained protein standard (Life Technologies) were run onto 7-
10 % polyacrylamide gels. Gels were run in an XCell SurelockTM Mini-cell apparatus (Life 
Technologies) in NuPAGE MOPS SDS running buffer (ThermoFisher Scientific) and 
transferred to nytrocellulose membranes (iBLOT gel transfer stack, Life Technologies) by 
iBLOT dry blotting system (Life Technologies) in 6 to 10 minutes. After transfer, 
nitrocellulose membranes were stained with Ponceau S staining solution  (0.1 % Ponceau S 
and 5 % acetic acid) to verify equal loading and appropriate transfer. Membranes were 
briefly washed in water and blocked for 1 hour at RT in blocking solution 5 % BSA or 5 % 
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milk in 1 X TBS-T (20 mM Tris-HCl, pH 7.4; 500 mM NaCl, 0.1 % Tween). Membranes 
were incubated with primary antibodies (table 7), diluted in blocking solution for 1-2 hours 
at RT or overnight at 4 °C. After 5 washes of 5 minutes each in TBS-T, membranes were 
incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary 
antibody (table 7), diluted in blocking solution for 1 hour at RT. Membranes were washed 5 
times for 5 minutes each in 1 X TBS-T and the bound secondary antibody was revealed with 
SuperSignalTM West Pico Chemiluminescent Substrate (ThermoFisher Scientific) or 
SuperSignalTM West Dura Extended Duration Substrate (ThermoFisher Scientific). 
Membrane stripping was performed with RestoreTM PLUS western blot stripping buffer 
(ThermoFisher Scientific). Immunoblot images were acquired using the ChemiDoc system 
(Bio-rad). Protein levels quantification was performed using the ImageJ software tool. 
 
Table 7: List of antibodies used for immunoblot protein detection 
Primary Abs Clone Dilution Factor Source 
Mouse α−Ezh2 AE25-13 1/100 (milk) Home-made 
Rabbit α–H3K27me3 C36B11 1/10000 (BSA) Cell Signaling 
Rabbit α –H3 tot 07-690 1/25000 (milk) Millipore 
Mouse α−Vinculin h-VIN-1 1/20000 (milk) Sigma Aldrich 
Secondary Abs 
Goat α−mouse Ig 170-6516 1/2000 BioRad 
Gaot α−rabbit Ig 170-6515 1/2000 BioRad 
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6.6.2 Chromatin immunoprecipitation  
6.6.2.1 Cell fixation  
H3K27me3 Chromatin Immunoprecipitation (ChIP) was performed from λ−MYC; Ezh2 
proficient or mutant lymphoma cells. Cells were washed twice with cold 1 X PBS and fixed 
(10 mL/107 cells) with freshly prepared 1 % formaldehyde in 1 X PBS for 10 minutes at RT, 
on rotation. Fixation was stopped by adding glycine to a final concentration of 0.125 M (1 
mL of 1.37 M/107 cells) for 5 minutes at RT, on rotation. Cells were centrifuged at 290 g at 
4 °C for 10 minutes, washed with cold 1 X PBS and transferred to 1.5 mL tubes. After 
centrifugation at 4 °C, 3300 g for 5 minutes, cells were resuspended in 1 mL SDS buffer 
(0.5 % SDS; 50 mM Tris-HCl pH 8.1; 100 mM NaCl; 5 mM EDTA pH 8; 0.02 % NaN3), 1 
mM PMSF and protease inhibitor cocktail Set III (EDTA-free, Calbiochem,). Fixed cells 
were stored for least one overnight at -80 °C. 
 
6.6.2.2 Sonication  
Before sonication step, cells were gradually defrosted in a water bath, centrifuged at 15 °C, 
1500 g for 10 minutes and resuspended in Immunoprecipitation (IP) buffer (1mL IP 
buffer/2x107 cells) composed by two volumes of SDS buffer and one volume of 1X Triton 
buffer (5 % Triton-X100; 100 mM Tris-HCl pH 8.6; 100 mM NaCl; 5 mM EDTA pH 8; 
0,02 % NaN3), 1 mM PMSF and protease inhibitor cocktail Set III (EDTA-free, 
Calbiochem,). Cells were resuspended in IP buffer at a density of 2x106/mL. To share the 
DNA, a maximum of 130 µL of cell suspension was transferred to microTUBE (Covaris) for 
sonication, which was performed in the S220 Focused ultra-sonicator (Covaris). To obtain 
200 bp fragments, machine parameters were set to a duty factor of 10 %, peak incidence 
power (W) of 175 and 200 cycles per busts, according to manufacturer’s guidelines. Each 
sonication round was performed for 180 seconds. Sonicated material was centrifuged at 
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maximum speed (16100 g) at 4 °C for 10 minutes and transferred to a new 1.5 mL tube to 
remove cellular debris. An aliquot (10 µL) of sonicated chromatin was decrosslinked to 
serve as sonication control. Final 1 % SDS, 0.1 M NaHCO3 and water up to 100 µL was 
added to the aliquot of sonicated materials and incubated for 1 hour at 30 °C, shaking. After 
1 hour, 0.2 M NaCl and 0.025 µg/µL RNase A were added to the mix and incubated 
overnight at 65 °C. The following day, final 10 mM EDTA; 40 mM Tris-HCl pH 6.5; PK 
0.5 µg/µL were added to the same mix and incubated for 1 hour at 45 °C. DNA purification 
was performed by adding 600 mL PB buffer (Qiagen) to the decrosslinked material. The 
mix was subsequently loaded onto Qiagen column provided by Qiagen Gel extraction Kit 
and DNA purification was performed according to the manufacturer’ protocol.  DNA was 
eluted in 20 µL of MQ water and quantified using Qubit double strand (ds) DNA high 
sensitivity (HS) assay (range: 0.2-100 ng) (ThermoFisher Scientific) with Qubit 2.0 
Fluorometric quantitation (Life Technologies). Quality of DNA shearing was controlled 
using High sensitivity DNA assay (concentration range: 100-10000 pg/mL) (ThermoFisher 
Scientific) with Bioanalyzer 2100 (Agilent Technologies). Bioanalyzer profiles provide 
information on size distribution of DNA peaks (between 150-200 bp), as a result of an 
appropriate sonication. 
 
6.6.2.3 Immunoprecipitation  
After sonication control, protein quantification was performed using Biorad DCTM protein 
assay, according to guidelines of DC protein assay instruction manual. BSA dissolved in IP 
buffer was used as standard protein reference, starting from a BSA concentration of 2 
µg/µL, through a 7-points two-folds dilutions standard curve. Following protein 
quantification, 40 µg of chromatin were used for immunoprecipitation and the final reaction 
volume was adjusted to 1 mL with IP buffer. An aliquot of 10 µL (1 %) of chromatin before 
immunoprecipitation (Input) was used as baseline for further analyses. 10 µg of primary Ab 
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(monoclonal rabbit anti-H3K27me3, C36B11, Cell Signaling) were added to 40 µg of 
chromatin and immunoprecipitation was carried out overnight at 4 °C, on rotation. The 
following day, an aliquot of 20 µL protein G dynabeads/sample (Life Technologies) was 
equilibrated with 1mL of IP buffer, transferred to tubes containing chromatin and Ab and 
incubated for 3 hours at 4 °C on rotation. Following incubation, tubes containing beads-Ab-
chromatin were fitted onto an ice-cold magnet (Life Technologies) to wash off excess beads. 
Beads washing included 3 steps with 1 mL ice-cold 150 mM Wash Buffer (1 % Triton-X 
100; 150 mM NaCl; 20 mM Tris-HCl pH 8; 0.1 % SDS; 2 mM EDTA pH 8), 1 step with 1 
mL ice-cold 500 mM Wash Buffer (1 % Triton-X100; 500 mM NaCl; 20 mM Tris-HCl pH 
8; 0.1 % SDS; 2 mM EDTA pH 8) and a final step with 1 mL 1 X Tris-EDTA (TE) Buffer. 
 
6.6.2.4 Decrosslinking 
Final 1 % SDS, 0.1 M NaHCO3 and water up to 100 µL were added to the beads and to 
Input samples and incubated for 1 hour at 30 °C. After 1 hour, immunoprecipitated samples 
were fitted onto the magnet at RT to remove the beads. Eluted DNA was then transferred to 
a new 1.5 mL tube. Following a 1 hour incubation, 0.2 M final NaCl and 0.025 µg/µL final 
RNase A were added to the mix and incubated overnight at 65 °C. The following day, final 
10 mM EDTA; 40 mM Tris-HCl pH 6.5; PK 0.5 µg/µL were added to the same mix and 
incubated for 1 hour at 45 °C. DNA purification was performed by adding 600 mL PB 
buffer (Qiagen) to the decrosslinked material. The mix was subsequently transferred onto 
Qiagen column provided by Qiagen Gel extraction Kit and DNA purification was performed 
according to the manufacturer’ protocol. DNA was eluted in 25 µL of MQ water and 
quantified at Qubit Fluorometric quantitation (ThermoFisher Scientific). 10 ng of input and 
immunoprecipitated materials were used for sequencing analyses. 
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6.7 Next generation sequencing techniques 
6.7.1 ChIP-sequencing 
To evaluate genome wide distribution of H3K27me3 in λ-MYC; Ezh2 control or mutant 
lymphoma cells, 10 ng of sonicated chromatin before (input) and after immunoprecipitation 
with H3K27me3 Ab (C36B11, Cell Signaling) were used for construction of libraries using 
a High Throughput (HT) ChIP-sequencing (ChIP-seq) protocol optimized by Italian Institute 
of Technology (IIT) Genomic Unit, in Milan. DNA concentration of ChIP-seq libraries was 
quantified with Qubit HS ds DNA assay (ThermoFisher Scientific). Bioanalyzer 2100 
(Agilent Technologies) run was performed to assess the size distribution of ChIP-seq 
libraries and possible contaminations by adapter dimers. Sequencing reactions were 
performed on HiSeq2000 instrument (Illumina), in collaboration with Italian Institute of 
Technology (IIT) Genomic Unit, in Milan. 
 
6.7.2 RNA-sequencing 
To perform transcriptome analysis of λ-MYC; Ezh2 control and mutant lymphomas, total 
RNA purified from tumor cells was quantified by a microvolume UV spectrophotometer 
(NanoDrop ND-100). RNA quality was controlled using RNA 6000 Nano kit (Agilent 
Technologies) with Bioanalyzer 2100 (Agilent Technologies). Profiles generated by the 
instrument provide information on RNA integrity and generate ribosomal ratio of 18S and 
28S ribosomal subunits, to exclude nucleic acid degradation.  500 ng/sample of total RNA 
was used for library construction. First, total RNA was processed using Dynabeads mRNA 
direct micro kit (ThermoFisher Scientific) to isolate intact polyadenylated (polyA) mRNAs. 
Purified polyAmRNAs were then used to prepare cDNA libraries for strand-specific RNA 
sequencing on an Ion ProtonTM instrument with Ion Total RNA Seq kit v2 (ThermoFisher 
 73 
Scientific).  Construction of libraries and sequencing reactions were performed with an Ion 
ProtonTM instrument, in collaboration with IFOM Genomic Unit, in Milan. 
 
6.8 Bioinformatic analysis 
6.8.1 Bioinformatic analysis of ChIP-sequencing data 
After filtering for artifacts with FASTX Toolkit 0.0.13.2, reads with a minimum median 
base quality score greater than 20 were aligned, -end-to-end, to the mm9 genome using 
Bowtie 2 version 2.2.1 (Langmead and Salzberg, 2012). ChIP-seq provided an average of 30 
millions of uniquely mapped reads for each profiled sample (both Input and H3K27me3-
immunoprecipitated samples). To identify genomic regions enriched for H3K27me3 (Peaks) 
in Immunoprecipitated samples relative to the Input samples was used Macs14 (version 
1.4.2) (Zhang et al., 2008) with default parameters (p<10-5). Peaks calling was assigned to 
genes by assessing for each RefSeq transcript whether a peak laid within a +/−5 Kb region 
around the transcription start site (TSS). Read density heat maps in a window of +/− 5 Kb 
around the transcriptional start site (TSS) were generated with ngs.plot.r function of the 
ngs.plot software (Shen et al., 2014). 
Venn diagrams displaying overlaps among different list of genes were produced using 
BioVenn tool (http://www.cmbi.ru.nl/cdd/biovenn/). 
 
6.8.2 Bioinformatic analysis of RNA-sequencing data 
Quality control of raw reads was performed using the FASTX Toolkit 0.0.13.2 software, to 
remove the adapters and low quality sequences. Reads with a minimum median base quality 
score greater than 15 were aligned to the mouse mm9 transcriptome using TopHat version 
2.0.11 (Trapnell et al., 2009). The aligned reads were used as input for Cufflinks version 
2.1.1, to estimate the relative abundances of transcripts in each sample.  
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The Cuffmerge script of Cufflinks merged together the Cufflinks assemblies. Running the 
Cuffdiff program of Cufflinks eventually assessed differential gene expression between 
groups. Only genes with a Fold discovery rate (FDR) q value < 0.05 were defined as 
differentially expressed genes (DEGs). To select genes more homogeneous expressed in 
each groups, R analysis was performed to identify genes satisfying the following conditions: 
a) minimum value of first group was grater than maximum value of second group: b) 
maximum value of first group was less than minimum value of the second group.  
Unsupervised hierarchical clustering and heat maps for the expression values 
were generated in R using the heatmap.2 function of the gplots 
library. ChIP-enrichment analyses and pathways analyses were performed using the EnrichR 
software tool. Gene lists provided by EnichR were ranked based on the combined score (log 
of the p-value computed with the Fisher exact test multiplied by the z-score of the deviation 
from the expected rank (http://amp.pharm.mssm.edu/Enrichr/) 
 
6.8.2.1 B cell subsets signature 
To evaluate whether DEGs identified in the comparison between Ezh2 dependent or 
independent λ-MYC lymphomas relied on a B cell specific signature, microarray raw data 
of murine B cell subsets were retrieved from Gene Expression Omnibus (GEO, Query 
DataSets for GSE15907). Data analysis was performed using R software version 3.1.3. Data 
were normalized using robust multichip analysis (RMA) algorithm. To identify DEGs 
among the B cell subsets, the makeContrasts function of the limma package of Bioconductor 
(www.bioconductor.org) was applied. Expression of B cell specific subsets genes was 
evaluated in the transcriptome profiles obtained from 6 independent λ-MYC; Ezh2fl/fl 
lymphomas.  
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6.9 Statistical analysis  
6.9.1 Student’s t test 
Statistical analysis of normally distributed values (Gaussian) was performed by two-­‐‑tailed 
unpaired Student’s t-­‐‑test. Differences were considered significant at p-­‐‑value<0.05. 
 
6.9.2 2-Way-Anova test 
Statistical analysis to compare two independent variables in grouped samples was performed 
using 2-­‐‑way-ANOVA test. Differences were considered significant at p-­‐‑value<0.05. 
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7 Results 
7.1 Conditional inactivation of Ezh2 in a mouse model of MYC-driven B cell 
lymphoma 
7.1.1 Malignant transformation is associated with Ezh2 up-regulation  
Previous reports have described high levels of EZH2 expression in human BL cell lines and 
primary tumors (Dukers et al., 2004; Sander et al., 2008; van Kemenade et al., 2001). In 
order to study the function of Ezh2 in the maintenance of MYC-driven lymphomas, we 
employed the λ-MYC transgenic mouse model (Kovalchuk et al., 2000). λ-MYC transgenic 
mice express a mutant/stabilized form of the human c-MYC proto-oncogene (c-MYC), 
originally isolated from a BL cell line (Battey et al., 1983). The transgene is placed under 
the control of its endogenous promoter. Robust cell-type (B cells) specific expression of 
the λ-MYC transgene is achieved juxtaposing the c-MYC mini-gene to Ig-lambda (Igλ) 
light chain cis regulatory sequences, mimicking the t(8;22)(q24;q11) translocation present in 
a fraction of BL (Figure 10). λ-MYC transgenic mice spontaneously develop aggressive B 
cell lymphomas that resemble human BL in terms of surface phenotype of the malignant B 
cells, mode of dissemination of the disease (BM and secondary lymphoid organs) and 
histological appearance (Kovalchuk et al., 2000). 
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Figure 10: The λ-MYC transgene 
Cartoon depicting the structure of the λ-MYC transgene. The MYC gene was cloned from a 
BL line and placed under the control of its own promoter and mouse Igλ light chain 
regulatory sequences. 
 
We measured the expression of the Ezh2 protein in B cell lymphomas of λ-MYC animals at 
different stages of tumorigenesis. Robust expression of transgenic MYC was detected in λ-
MYC B cells of young (8-to-10 weeks old) transgenic mice, before the appearance of overt 
signs of disease (Figure 11). The levels of Ezh2 substantially rose in λ-MYC B cells isolated 
from diseased animals, when signs of systemic dissemination of lymphoid cells suggested 
the occurrence of malignant transformation (Figure 11). The significant rise of Ezh2 
expression, observed in the transition from the pre-tumoral to the tumoral stage, supports the 
hypothesis that Ezh2 contributes to the transformation process and/or to sustain the growth 
of the malignant B cells.  
 
 
Figure 11: Ezh2 expression in λ-MYC B cells increases from the pre-tumoral to 
tumoral stage 
Immunoblotting analysis of Ezh2 levels in splenic WT C57BL/6J B cells and in pre-tumoral 
(pre-T) and tumoral B cells isolated from two (Tumor 1 and Tumor 2) representative λ-
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MYC transgenic mice. Bar graph displays Ezh2 protein levels after normalization of protein 
input measuring vinculin expression. 
 
7.1.2 Development of a mouse model to study Ezh2 function in MYC-driven lymphomas 
The strong induction of Ezh2 expression in aggressive full-blown λ-MYC lymphomas 
renders this transgenic model particularly suitable to study the role of Ezh2 in lymphoma 
maintenance. To achieve this goal,  λ-MYC transgenic mice were crossed to animals 
carrying a conditional knockout allele for the Ezh2 gene (Ezh2fl) (Su et al., 2003). In 
conditional Ezh2fl/fl mice, the exons coding for the catalytic SET domain are flanked by loxP 
sites, allowing inactivation of the methyltransferase activity of the Polycomb protein 
through Cre-mediated recombination (Su et al., 2003) (Figure 12).  
 
 
Figure 12: The Ezh2 conditional allele 
Cartoon depicting the structure of the Ezh2 conditional knockout allele (Ezh2fl), in which the 
exons coding for the catalytic SET domain are flanked by two loxP sites. 
 
These animals developed aggressive B cell lymphomas resembling the λ-MYC tumors 
previously described by Kovalchuk and colleagues (Kovalchuk et al., 2000). The only 
exception consisted in the longer tumor latency observed in λ-MYC; Ezh2fl/fl compound 
mutants, which may result from the different genetic background of the animals (the mice 
employed for our studies were on the pure C57BL/6J genetic background).  
Tumors arising in λ-MYC; Ezh2fl/fl animals were preferentially located in the bone marrow 
and peripheral lymph nodes. The spleen of diseased animals was often enlarged due to the 
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conspicuous infiltration of the organ by malignant B cells. So far, we were able to 
established lymphomas cells from a restricted, but yet consistent number (6) of λ-MYC; 
Ezh2fl/fl compound mutant mice. Lymphoma B cells, taken from enlarged lymphoid organs 
of diseased mice, could be successfully transplanted into immunoproficient syngenic hosts, 
confirming their malignant nature (Table 8). In vitro culture of λ-MYC; Ezh2fl/fl primary 
lymphomas gave rise, in most cases, to primary cell lines that rapidly adapted to in vitro 
growth conditions. Tumor cell lines were established from either primary lymphomas or 
after one passage of malignant B cells into syngenic immunoproficient animals (Table 8).  
 
Tumor ID Tumor 
latency 
(Month) 
Degree of tumor infiltration 
(% of tumor B cells) 
Serial 
passages 
(#) 
Organ 
of origin 
SPL BM MLN ALN 
#73664 10 22 10 31 27 1 MLN 
#95379 6 35 52 59 61 1 MLN 
#123617 10 10 18 5 60 1 ALN 
#160887 2.5 50 63 / / - BM 
#126803 10 23 13 5 80 1 ALN 
#142291 9 15 13 / 44 - BM 
 
Table 8: Summary of λ-MYC; Ezh2fl/fl lymphomas used for the study 
The table summarizes data relative to 6 different primary λ-MYC; Ezh2fl/fl lymphomas that 
have been used throughout the study. Mouse identification (ID) and survival time are 
reported in the first two columns, respectively. In addition, the table displays the degree of 
tumor infiltration represented by the percentage of tumor B cells, assessed by flow 
cytometry in the indicated lymphoid organs (SP: spleen, BM: bone marrow, MLN: 
mesenteric lymph nodes and ALN: axillary lymph nodes). The number of serial passages 
(Serial TP) prior to the establishment of primary cell lines is indicated. Organ of origin 
refers to the lymphoid organ from which primary cultures were successfully established. 
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To assess the clonal status of λ-MYC; Ezh2fl/fl lymphoproliferative disorders, we performed 
immunoglobulin Igκ V gene rearrangement analysis on primary lymphoma cell lines 
established from 6 λ-MYC; Ezh2fl/fl primary tumors, using a genomic PCR approach. 
Specifically, a mixture of degenerate primers annealing to most Vκ genes was used in 
combination with an oligonucleotide annealing downstream of the Jκ5 gene segment, to 
amplify VκJκ rearrangements from ex vivo isolated tumor B cells. Purified splenic WT B 
cells representing a polyclonal population of B cells were used as comparison. Whereas 
PCR amplification from the latter cells gave rise to 4 distinct PCR products representing 
polyclonal VκJκ rearrangements, that respectively consist of Jκ1, Jκ2, Jκ4 and Jκ5 gene 
segments (Jκ3 is a pseudogene and hence not involved in IgL chain V gene rearrangements), 
genomic DNA amplified from λ-MYC B cells gave rise in most cases to a single PCR band, 
indicative of a monoclonal IgL chain V gene rearrangement (Figure 13). Although the 
presence of genomic DNA in all samples was assessed by the amplification of Gapdh gene 
(data not shown), tumor #95379 resulted negative for Vκ gene rearrangements. This result, 
combined with the lack of surface Ig expression in the malignant B cells of this lymphoma 
(Figure 14) suggests a pro B cell origin of this particular tumor.  
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Figure 13: Clonal assessment of λ-MYC; Ezh2fl/fl B cell lymphomas 
Genomic PCR analysis to assess the status of VκJκ gene IgL gene rearrangements in splenic 
WT C57BL/6J B cells and 6 independent primary λ-MYC lymphomas. The four PCR bands 
amplified in the control sample identify VκJκ rearrangements using Jκ1, Jκ2, Jκ3 and Jκ5 
segments, respectively. The 1 Kb ladder was used as reference to determine the size of PCR 
products. 
 
 
Figure 14: Surface IgM expression levels in  λ-MYC; Ezh2fl/fl tumors 
Histograms display average expression of surface IgM in 6 primary λ-MYC; Ezh2fl/fl B cell 
lymphomas (grey filled bar), assessed in a representative flow cytometric analysis. Splenic 
CD19+; IgM+ C57BL/6J B cells were used as comparison (black filled bar). 
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7.1.3 λ-MYC; Ezh2fl/fl mice develop IgM+ B cell lymphomas  
To investigate the cell of origin of λ-MYC; Ezh2fl/fl lymphomas, we performed a 
comprehensive immunophenotypic analysis on the 6 primary tumors (Figure 15A, B). All 
lymphomas expressed the pan B cell markers B220 and CD19. As previously shown, except 
for tumor #95379, all lymphomas expressed surface Ig receptor/BCR in the form of IgM 
(Figure 14). This result indicates that malignant transformation of λ-MYC; Ezh2fl/fl B cells 
occurred in most cases in an immature/mature B cell that had completed Ig V gene 
rearrangements. Further immunophenotypic characterization of lymphomas revealed the 
recurrent expression of markers highly expressed in progenitor B cells (c-Kit, CD43, AA4.1 
and in one instance CD25) (Figure 15B), whereas markers of mature B cell identity (CD21, 
CD23, CD38 and IgD) were largely missing on the surface of malignant B cells (Figure 
15B). Tumor cells expressed low levels of histocompatibility class-II molecules (MHC-II), 
suggesting that tumor cells may select a way to evade the immune system. Finally, all λ-
MYC; Ezh2fl/fl lymphomas expressed normal/high levels of the BAFF-R, pointing to a 
possible dependence of the tumors on the pro-survival factor BAFF/BlyS (Kayagaki et al., 
2002) (Figure 15B). All together these results are compatible with a scenario whereby in λ-
MYC; Ezh2fl/fl mice deregulated action of MYC transforms a newly generated IgM-
expressing B cell, leading to substantial reprogramming of its cell identity. 
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Figure 15: Immunophenotypic characterization of primary λ-MYC; Ezh2fl/fl B cells 
Histogram representation of the average expression level of the indicated markers on the 
surface of 6 primary λ-MYC; Ezh2fl/fl B cell lymphomas (grey filled bar), assessed by flow 
cytometric analysis. As comparison, we used the indicated B cell subsets of C57BL/6J 
control mice (black filled bar). The control B cell population expressing the highest levels of 
the indicated markers was chosen for the comparisons (bone marrow B cell progenitors: A) 
(splenic mature B cells: B). For IgD, BAFF-R and MHC class II determination the total 
population of CD19+ splenic B cells was chosen as they predominantly consist of resting 
mature B cells (B). 
 
7.1.4 Molecular heterogeneity of λ-MYC; Ezh2fl/fl lymphomas  
In an attempt to define a common cell identity of λ-MYC; Ezh2fl/fl lymphomas using a 
molecular approach, the 6 tumors were subjected to whole transcriptome analysis by RNA-
sequencing. To understand whether tumors developed from a specific subset of B cells, we 
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established a dedicated “B cell subset (BCS)” transcriptional signature, which included 
around 70 genes whose expression is mostly (if not only) associated to a specific stage of B 
cell development. The BCS signature consists of genes differentially expressed between 
progenitor, immature/transitional, FO, MZ and GC B cells, respectively (Figure 16). 
Applying the BCS signature to whole transcriptome data of λ-MYC; Ezh2fl/fl tumors, we 
failed to recognize patterns of gene expression associated to specific B cell subsets (Figure 
17). This result, which is in accordance with the immunophenotypic data, highlights: i) the 
substantial loss of stage-specific B cell identity resulting from malignant transformation and 
ii) the strong molecular heterogeneity of λ-MYC tumors, which are possibly fuelled by 
genomic instability imposed on tumor cells by deregulated activity of the MYC oncogene 
(Kuzyk and Mai, 2014). 
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Figure 16: Expression of stage-specific B cell markers in λ-MYC; Ezh2fl/fl lymphomas 
Color-coded heat map displaying the expression pattern in the 6 representative λ-MYC; 
Ezh2fl/fl lymphomas of genes selected for their restricted expression in one of the indicated B 
cell subpopulations (pre B/pro B: B cell progenitors; T1/ T2: immature/transitional B cells; 
FO: Follicular B cells; MZ: Marginal zone B cells; GC: germinal center B cells). The stage-
specific B cell signature revealed differentially expressed genes from microarray 
trascriptome data of murine B cell populations obtained from the IMMGEN consortium,  
through the Gene Expression Omnibus (GEO) database. 
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Figure 17: Expression of B cell stage-specific genes in WT B cell subsets 
Heat map representation of stage-specific B cell signature in the indicated B cell 
subpopulations (pre B/pro B: B cell progenitors; T1/ T2: transitional B cells; FO: Follicular 
B cells; MZ: Marginal zone B cells; GC: germinal center B cells) of C57BL/6J control mice. 
 
7.1.5 Acute Ezh2 inactivation in λ-MYC lymphomas unveils two classes of tumors 
The substantial molecular heterogeneity featured by λ-MYC; Ezh2fl/fl lymphomas 
represented an opportunity to establish a putative function of Ezh2 to the epigenetic 
dysregulation that may contribute to the observed variability in tumor phenotype.  
To study the role of Ezh2 function in MYC-driven lymphomas, we established primary 
lymphoma cell lines from the 6 independent λ-MYC; Ezh2fl/fl animals, which were 
subsequently subjected to in vitro TAT-Cre transduction. This procedure is based on the 
transient (45 minutes) incubation in vitro of target cell suspensions with cell permeable 
recombinant TAT-Cre protein (Peitz et al., 2002). This methodology allows efficient 
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delivery of the Cre proteins into target cells, avoiding toxic effects associated with long-term 
Cre expression (Peitz et al., 2002). 
Following TAT-Cre transduction, lymphoma B cells were plated at limiting dilution in order 
to isolate individual subclones (Figure 18). Using this procedure we isolated an average of 
25 clones for each transduced tumor. To assess the Ezh2 status in individual subclones, we 
subjected them to genomic PCR genotyping using a strategy that enables the selective 
amplification of the WT, un-recombined, Ezh2 allele.  
 
 
Figure 18: Conditional inactivation of Ezh2 gene in primary lymphomas and 
identification of Ezh2 defective clones 
Lymphomas developing in λ-MYC; Ezh2fl/fl compound mutant mice were isolated ex vivo 
and subjected to TAT-Cre transduction (Cre). Transduced cells were cultured at limiting 
dilution to isolate individual clones, which were ultimately subjected to Ezh2 genotyping by 
PCR. 
 
Genotyping of 12-40 clones obtained from each λ-MYC; Ezh2fl/fl lymphoma revealed a 
surprising result. For three tumors (classified as type-1), the frequency of subclones 
displaying bi-allelic loss of the SET coding exons was substantially under-represented when 
confronted with the number of Ezh2 proficient clones (Ezh2fl/fl or Ezh2fl/∆) (Figure 19). From 
the remaining three lymphomas (classified as type-2), TAT-Cre transduction gave rise to a 
majority of Ezh2 mutant subclones characterized by bi-allelic Ezh2 inactivation (Ezh2∆/∆) 
(Figure 19). The substantial difference in the recovery rate of Ezh2 mutant clones between 
type-1 and type-2 λ−MYC lymphomas was not dependent on different TAT-Cre 
transduction efficiency. Indeed, quantification of the Ezh2fl allele soon after (48 hours) 
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transduction revealed comparable rates (50-80 %) of Cre-mediated recombination between 
the lymphomas of the two types (Figure 20). These results suggest the existence of two 
classes of MYC-driven lymphomas that differ in the capacity to overcome anoikis and, 
hence, outgrow starting from a single tumor cell. Specifically, whereas type-1 λ-MYC 
lymphomas appear strictly dependent on Ezh2 methyltransferase activity for single cell 
tumor outgrowth, type-2 tumors have selected alternative molecular pathway(s) that enable 
single lymphoma cells to grow undisturbed, despite inactivation of Ezh2. 
A hint indicating the rapid counter-selection of Ezh2 mutant cells in type-1 lymphomas 
came from the quantification of Ezh2 functional alleles in the pool of lymphoma cells 
transduced 6 days earlier with TAT-Cre. Indeed, genomic qPCR data indicated that while at 
48 hours the average Ezh2 gene copy number in the pool of tumor B cells was substantially 
reduced (indicative of Cre-mediated recombination), it reached levels close to control 
tumors at 6 days after transduction (Figure 20). This result supports a scenario whereby 
Ezh2 proficient tumor cells escaping Cre-mediated inactivation rapidly take over their 
Polycomb mutant counterparts during in vitro expansion. Instead, in type-2 lymphomas we 
failed to observe major differences in the average Ezh2 gene copy number assessed in tumor 
cells at 2- and 6-days after TAT-Cre transduction, respectively (Figure 20). This result 
suggests that Ezh2 mutant lymphoma B cells can effectively expand in the presence of their 
Ezh2 proficient counterparts, pointing to a dispensable role for the Polycomb protein for in 
vitro tumor growth.  
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Figure 19: Effects of Ezh2 inactivation on cloning efficiency of lymphoma cells defines 
two types of λ-MYC; Ezh2fl/fl lymphomas 
Pie chart representation of the distribution of the indicated Ezh2 genotypes among tumor 
clones established after TAT-Cre transduction of 6 independent primary λ-MYC; Ezh2fl/fl 
lymphomas. Numbers indicated frequency of clones with the relative Ezh2 genotype.  
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Figure 20: Effect of acute Ezh2 inactivation on short-term in vitro culture of λ-MYC; 
Ezh2fl/fl lymphomas 
Representative qPCR quantification of WT Ezh2 gene copy number in malignant B cells of 
the 6 independent λ-MYC; Ezh2fl/fl lymphomas at the indicated time points (48 hours and 6 
days) after TAT-Cre transduction. Ezh2 gene copy in tumor B cells was assessed after 
normalization for genomic input through the measurement of Gapdh copy number. Data are 
represented as Ezh2 gene copy number relative to that of λ-MYC; Ezh2fl/fl lymphomas prior 
to TAT-Cre transduction (first column of each histogram plot). Columns indicate mean 
values of triplicates ± standard deviation (SD).  
 
Despite the rapid counter-selection of Ezh2 mutant cells after TAT-Cre transduction of type-
1 λ-MYC lymphomas, we succeeded to isolate a restricted number of subclones carrying 
two inactive copies of the Ezh2 gene (Figure 19). This result indicates that a small subset of 
lymphoma cells succeeded to activate compensatory mechanisms to circumvent the loss of 
Ezh2 methyltransferase activity. To investigate whether the mechanism accounting for the 
resistance to Ezh2 inactivation resulted in restoration of H3K27me3, we measured global 
H3K27me3 levels in representative Ezh2∆/∆ subclones derived from type-1 λ-MYC 
lymphomas. Quantification of western blotting data revealed that type-1 lymphomas, 
acquiring resistance to Ezh2 inactivation, lost over 90 % of the initial H3K27me3 levels. 
Hence, compensation for Ezh2 inactivation in type-1 lymphomas does not require recovery 
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of global H3K27 trimethylation. Quantification of H3K27me3 levels was extended to a 
subclone of type-2 lymphoma. Global loss (>90 %) of H3K27me3 levels was observed in 
Ezh2 mutant cells, confirming the results obtained in Ezh2 defective λ-MYC type-1 
lymphomas (Figure 21). All together these results indicate that global loss of H3K27 
trimethylation is compatible with the growth of MYC-transformed B cells.   
 
 
Figure 21: H3K27me3 levels in Ezh2 defective B cell lymphomas 
Immunoblot analysis of Ezh2 and H3K27me3 levels in representative Ezh2 proficient 
(Ezh2fl/fl) and catalytic-dead (Ezh2∆/∆) tumor clones established after TAT-Cre transduction 
of Ezh2-dependent (type-1; #123617) and -independent (type-2; #126803) λ-MYC 
lymphomas. Histone H3 levels were assed to control protein input. Upon Cre-mediated 
deletion of SET coding exons, lymphoma cells express a truncated form of Ezh2 (Ezh2∆SET). 
Numbers below plots indicate normalized H3K27me3 levels in the indicated tumor samples. 
 
7.1.6 Comparison of the in vitro growth properties of type-1 and -2 λ-MYC lymphomas   
The different requirement for Ezh2 methyltransferase activity featured by type-1 and type-2 
λ-MYC lymphomas prompted us to test whether such differences could depend on the 
growth properties of tumor cells belonging to the two categories of tumors. To test this 
hypothesis, we compared the in vitro growth behavior of representative cases of type-1 and 
type-2 lymphomas. Tumor cells were counted over a 14 days time interval, diluting the cells 
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every second day in fresh culture medium. Growth curve analyses revealed a very similar in 
vitro growth behavior between type-1 and type-2 lymphomas (Figure 22). These results 
were confirmed by cell cycle distribution analysis of lymphoma cells belonging to the two 
categories of λ-MYC tumors (Figure 23). All together these results indicate that in vitro 
growth analyses based on bulk cultures of type-1 and type-2 lymphomas do not allow to 
distinguish MYC-driven lymphomas that differ in the requirement for Ezh2 
methyltransferase activity. 
 
 
Figure 22: In vitro growth curves of Ezh2-dependent or independent lymphomas 
Growth curve analysis of representative Ezh2-dependent (type-1, black line; #73664) and -
independent (type-2, grey line; #160887) lymphomas cultured in vitro for 14 days. Tumor 
cells were counted every second day. Each time point represents the average count of 3 
technical replicates ± Standard error (SE). 
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Figure 23: Cell cycle distribution analysis of Ezh2-dependent and -independent λ-
MYC lymphomas 
Representative flow cytometric analysis at day 6 of the cell cycle distribution of Ezh2-
dependent (type-1; #73664) or -independent (type-2; #160887) tumors. Numbers indicate 
frequency of cells in boxed gates. Bar graph summarizes cell cycle distribution analyses 
obtained from 3 technical replicates (±SE) of representative Ezh2-dependent (type-1, black 
bar; #73664) and -independent lymphomas (type-2, grey bar; #160887). 
 
7.1.7 Identification of a transcriptional signature clustering type-1 from type-2 lymphomas  
We hypothesized that the different requirement of type-1 and type-2 lymphomas for Ezh2 
could reflect distinct transcriptional networks active in the two categories of tumors. For this 
purpose, we searched for genes that were differentially expressed between type-1 (n= 3) and 
type-2 (n= 3) lymphomas. Comparison of RNA sequencing data allowed the identification 
of 351 differentially expressed genes (DEGs). Of these, 163 were down-regulated and 188 
were up-regulated in type-2 lymphomas as compared to type-1 tumors (Figure 24).  
 
 94 
  
Figure 24: Differentially expressed genes in type-1 versus type-2 λ-MYC lymphomas  
Pie chart representation of genes (nr.) that are respectively up- and down-regulated (FDR q 
value ≤ 0.05) in a consistent fashion (3 out of 3 tumors) in Ezh2-independent (type-2: 
#126803, #160887, #142291) lymhomas in comparison to Ezh2-dependent (type-1: #73664, 
#95379, #123617) λ-MYC lymphomas. 
 
We performed a further filtering of the list of DEGs to ultimately select a subset of them (n= 
166) with the best consistency when comparing three lymphomas of the first type to the 
same number of the second type (Figure 25). Among the core signature of 166 genes, 119 
were up-regulated and 47 were down-regulated in type-2 lymphomas.  
To assess whether DEGs belonged to specific functional categories, we performed gene 
ontology analysis on the core signature of 166 genes differing between type-1 and type-2 
lymphomas (Figure 26). Interestingly, type-2 lymphomas expressed higher levels of cell 
cycle genes, as Cyclin-D2 (Ccnd2) and genes encoding for critical components of the DNA 
replication machinery, including Minichromosome maintenance complex component 2 and 
4 (Mcm2, Mcm4) and DNA Primase 2 (Prim2). Furthermore, type 2 tumors significantly 
expressed higher levels of the pro-survival factor B cell lymphoma 2 (Bcl2) (Figure 27). 
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Figure 25: Expression pattern in type-1 and type-2 λ-MYC; Ezh2fl/fl lymphomas 
Heat map representation of genes (n= 166) differentially expressed between Ezh2-dependent 
(type-1: #73664, #123617, #95379) and -independent (type-2: #142291, #126803, #160887) 
λ-MYC; Ezh2fl/fl lymphomas, selected according to fold change >2 and FDR qvalue< 0.05.  
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Figure 26: Functional categories of genes differentially expressed between type-1 and 
type-2 λ-MYC lymphomas  
Wiki-pathway of top-8-enriched categories of genes up- (green bars) and down-regulated 
(blue bars) in Ezh2-independent lymphomas (n= 3) compared to their -dependent 
counterparts (n= 3), respectively. Analysis was performed using EnrichR software tool 
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Figure 27: Minisignature of differentially expressed genes in type-1 and type-2 λ-MYC 
lymphomas 
Heat map representation of expression levels of selected genes differentially expressed 
between type-1 and type-2 λ-MYC lymphomas (Fold change > 2; FDR q value <0.05). 
 
7.1.8 Can Cdkn2a and/or Tp53 status discriminate type-1 from type-2 lymphomas?   
Inactivation of tumor suppressor Cdkn2a represents a recurrent genetic lesion cooperating 
with deregulated MYC expression, in promoting B cell lymphomas (Schmitt et al., 1999). 
The Cdkn2a locus encodes for the cyclin-dependent kinase inhibitor p16INK4a and for 
p19ARF, which triggers p53-dependent apoptosis by preventing its interaction with Murine 
double mutant 2 (Mdm2). Cdkn2a inactivation observed in tumor cells facilitates at the same 
time cell cycle progression and protection from p53-dependent apoptosis. Given the critical 
role exerted by the Polycomb axis in the negative regulation of the Cdkn2a locus (Bracken 
et al., 2007), we determined the functional status of Cdkn2a in type-1 and type-2 λ-MYC 
lymphomas, respectively. Genomic PCR using oligonucleotides annealing to the Cdkn2a 
locus revealed consistent retention of the locus in all tested λ-MYC type-1 lymphomas (n= 
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3). Instead, 1 of 3 type-2 lymphomas (#160887) showed bi-allelic loss of the Cdkn2a locus 
(Figure 28). The presence of genomic DNA in all samples was assessed by the amplification 
of Gapdh gene (data not shown). Moreover, transcriptome data identified an additional type-
2 λ-MYC tumor (#142291), which displayed transcriptional silencing of the Cdkn2a locus 
(Figure 29). Hence despite the limited number of tumors so far analyzed, we observed a 
clear distinction between type-1 lymphomas that retained the tumor suppressor and 
Polycomb target locus Cdkn2a and type-2 lymphomas, which inactivated/silenced the tumor 
suppressor in 2 out of 3 cases. 
 
 
Figure 28: Cdkn2a gene status in λ-MYC; Ezh2fl/fl B cell lymphomas 
Genomic PCR genotyping of the Cdkn2a locus in type-1 (n= 3) and type-2 (n= 3) λ-MYC; 
Ezh2fl/fl B cell lymphomas. The 100 bp ladder was used as reference to determine the size of 
PCR products.  
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Figure 29: Cdkn2a mRNA levels in λ-MYC; Ezh2fl/fl B cell lymphomas 
Quantification of Cdkn2a transcripts in the indicated lymphomas classified based on Ezh2 
dependence (type-1: Ezh2-dependent and type-2: Ezh2 independent), as assessed by RNA-
sequencing. Transcript levels are represented as fragments per kilobase of transcript per 
million mapped reads (FPKM) values. 
 
Together with Cdkn2a, Tp53 is the other most common tumor suppressor gene lost in MYC-
driven lymphomas (Evan et al., 1992; Meyer et al., 2006; Schmitz et al., 2012). Therefore, 
we tested the functional integrity of the Tp53 locus by treating λ-MYC lymphomas with the 
Mdm2 inhibitor nutlin (Tovar et al., 2006). Specifically, lymphoma cells were exposed to 
increasing doses of nutlin in vitro and cell viability assessed by PI staining. Three out of 
three type-1 lymphomas displayed nutlin resistance, indicating the acquisition of 
inactivating Tp53 mutations. Instead, two out of three type-2 lymphomas were sensitive to 
nutlin treatment (Figure 30). In accordance with the established mutual exclusivity between 
Tp53 and Cdkn2a inactivation in tumor cells, type-2 lymphomas lacking functional Cdkn2a 
(two out of three cases) retained a functional Tp53 locus. These results will be further 
validated performing a genomic PCR analysis to discriminate the identity of p53 mutations 
in different lymphomas. 
All together these results identify a possibly link between the persistence of a functional 
Cdkn2a locus in lymphoma cells and their dependence on Ezh2 to give rise to a tumor 
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starting from a single cell. Instead, tumors that have lost Cdkn2a during malignant 
transformation display limited dependence on Ezh2, when grown at low density. 
Combining the data on the Cdkn2a and Tp53 locus, it appears that all tested λ-MYC 
lymphomas display inactivation of the Tp53-driven apoptosis, regardless of their 
dependence on Ezh2 catalytic activity. 
 
 
Figure 30: Differential sensitivity of λ-MYC; Ezh2fl/fl B cell lymphomas to the Mdm2 
inhibitor nutlin 
Flow cytometric assessment of cell viability revealed by PI staining in type-1 (#73664, 
#123617, #95379) and type-2 (#160887, #126803 and #142291)  λ-MYC; Ezh2fl/fl 
lymphomas, at 24 hours (24h) (black) and 48 hours (48h) (grey bar), after treatment with 
increasing doses (2.5, 5 and 10 µM) of the Mdm2 inhibitor nutlin, respectively. Vehicle-
treated (DMSO) tumor cells were used as reference. 
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7.2 Characterization of Ezh2 mutant lymphomas 
7.2.1 Immunophenotypic characterization of Ezh2 mutant lymphomas  
The establishment of Ezh2 mutant clones from both type-1 and type-2 lymphomas 
underscores the property of MYC lymphoma cells to overcome the inactivation of a main 
epigenetic determinant regulating cell identity, proliferation, survival and differentiation.  
In the attempt to establish whether Ezh2 mutant cells underwent major epigenetic 
reprogramming, we performed a comprehensive flow cytometric analysis to unveil possible 
changes in their surface phenotype. For this analysis, we performed a side-by-side 
comparison between representative Ezh2 proficient and defective subclones. 
Ezh2 mutant clones retained the pan B cell marker B220 and expressed levels of the other B 
cell markers to an extent similar to that of Ezh2 proficient tumor cells. An exception is 
represented by the chemokine receptor (Cxcr) 4, which was expressed at substantially higher 
levels in most Ezh2 mutant subclones when compared to their proficient counterparts 
(Figure 31). All together these results indicate that Ezh2 defective MYC-driven lymphomas 
retain a remarkably stable immunophenotype, despite suffering from a massive loss in 
H3K27me3 levels.  
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Figure 31: Comparison of the immunophenotype of Ezh2 proficient and defective λ-
MYC lymphoma clones 
Scatter plot chart showing expression levels (mean fluorescence intensity) of the indicated 
surface markers in λ-MYC; Ezh2 proficient (Ezh2fl/fl or Ezh2fl/∆)  (black filled dot, n= 5) and 
mutant (Ezh2∆/∆)  (grey filled dot, n= 6) clones established from a type-1 λ-MYC lymphoma  
(#73664). Each dot represents one independent measurement. 
 
7.2.2 Effects of Ezh2 inactivation on λ-MYC lymphomas growth in vitro 
To assess the effects of functional Ezh2 inhibition on the proliferative potential of λ-MYC 
lymphomas, we performed in vitro growth curve analysis comparing Ezh2 proficient 
subclones to their mutant counterparts, both established from the same primary lymphoma. 
For these studies, we chose to focus on subclones established from type-1 lymphomas, as 
they could help revealing the mechanisms through which MYC tumors overcome the loss of 
Ezh2. Monitoring the in vitro growth property of independent Ezh2 mutant subclones 
revealed a comparable behavior to that of Ezh2 proficient tumors (Figure 32). In accordance 
with this result, cell cycle distribution analyses failed to detect obvious differences between 
Ezh2 proficient and defective tumors (Figure 33). Together, these findings suggest that the 
rare Ezh2 mutant subclones, generated from type-1 lymphomas, may select compensatory 
mechanisms that ensure normal growth of tumor cells in vitro.  
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Figure 32: Ezh2 inactivation is compatible with lymphoma growth in vitro 
Growth curve of representative Ezh2 proficient (Ezh2fl/∆, black line, n= 3) and mutant 
(Ezh2∆/∆, grey line, n= 3) tumor clones established in vitro, from a representative type-1 
(#73664) λ-MYC primary tumor. Tumor cells were counted every second day. Cells were 
cultured for the indicated time points. Each symbol represents the average value of 3 
measurements (±SE). 
 
 
Figure 33: Ezh2 inactivation does not affect cell cycle progression in λ-MYC 
lymphomas 
Flow cytometric analysis cell cycle distribution of representative Ezh2 proficient (Ezh2fl/∆) 
and mutant (Ezh2∆/∆) clones. Numbers within dot plots indicate frequency of boxed cells. 
Bar graph shows a summary of the flow cytometric data obtained from independent (n=3 per 
genotype) Ezh2 proficient (Ezh2fl/∆, black bar) and mutant (Ezh2∆/∆, grey bar) clones (±SE), 
established from a representative type-1 (#73664) λ-MYC lymphoma. 
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7.2.3 Ezh2 mutant lymphomas can expand in vivo 
To verify whether inactivation of Ezh2 influenced the ability of λ-MYC lymphomas to 
grown in vivo, we performed transplantation studies. Specifically, representative Ezh2 
proficient and mutant subclones, established from both type-1 and type-2 lymphomas, were 
injected intravenously into immunoproficient syngenic animals. Recipient animals were 
monitored over time for the development of secondary tumors. Tumor cells, efficiently 
engrafted in recipient animals, leading to the rapid worsening of the general health status of 
the animals. The expansion of tumor cells in vivo was not affected by Ezh2 status (Figure 
34). Importantly, mice receiving Ezh2 mutant tumors derived from type-2 lymphomas 
became sick substantially faster than those transplanted with type-1 lymphomas (15 vs. 26 
days post-transplantation; Figure 34). 
 
 
Figure 34: Ezh2 mutant lymphomas expand in vivo upon transplantation into 
immunoproficient syngenic recipients 
Kaplan-Meier plots representing survival of animals (n= 3) receiving Ezh2 proficient 
(Ezh2fl/fl, red line) and mutant (Ezh2∆/∆, grey line) clones isolated from type-1 (#73664) and 
Ezh2 proficient (Ezh2fl/fl, black line) and mutant (Ezh2∆/∆, green line) clones from type-2 
(#160887) λ-MYC lymphomas, respectively.  
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To confirm the identity of the injected tumors, we quantified Ezh2 gene copy number on 
tumor cells retrieved from diseased animals. The analysis confirmed that mice injected with 
Ezh2 mutant subclones suffered from aggressive lymphomas, entirely consisting of 
Polycomb mutant cells (Figure 35). All together these results reveal that Ezh2 mutant 
lymphomas derived from both type-1 and type-2 lymphomas give rise to aggressive 
secondary tumors when injected into immunoproficient animals. Moreover, the faster tumor 
progression observed for type-2 lymphomas (regardless of Ezh2 genotype) provides the first 
functional indication of the existence of two different types of λ-MYC lymphomas. 
 
 
Figure 35: Assessment of Ezh2 gene status in λ-MYC lymphomas retrieved after 
transplantation 
qPCR quantification of Ezh2 gene copy number in lymphoma cells prior to transplantation 
(T= 0) or retrieved from recipient animals 15-26 days (15d/26d) after transfer.  Lymphoma 
clones with the indicated genotype and established from both representative type-1 (#73664) 
and type-2 (#160887) λ-MYC lymphomas were analyzed. Hash mark (#) refers to each 
recipient mouse transplanted with Ezh2 proficient or deficient clones. Ezh2 gene copy 
number in tumor samples was determined after normalizing samples for DNA input assessed 
through the quantification of an unrelated gene (Gapdh). Data are represented relative to 
Ezh2 gene copy number in λ-MYC; Ezh2fl/fl primary lymphoma cells prior to 
transplantation.  
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7.2.4 Ezh2 mutant lymphomas retain residual H3K27me3 and express the Ezh1 paralog  
The ability of Ezh2 defective clones to grow in a comparable fashion to their proficient 
counterparts both in vitro and in vivo indicated the existence of possible compensatory 
mechanisms sustaining the malignant phenotype of Polycomb mutant tumor B cells. 
Western blotting assessment of H3K27me3 levels in Ezh2 mutant subclones, derived from 
both type-1 and type-2 lymphomas, indicated that residual amounts (between 5 and 10 %) of 
H3K27me3 were consistently detected in Polycomb mutant lymphoma cells (Figure 21). 
This result raised the hypothesis that a different methyltransferase could at least partially 
substitute for Ezh2 inactivation in lymphoma B cells. In search for the latter enzyme, we 
focused our attention on the Ezh2 paralog, Ezh1. Ezh1 displays a substantially weaker 
H3K27 methytransferase activity than Ezh2 (Margueron et al., 2008; Shen et al., 2008), 
which has been shown to replace that of Ezh2 in various in vivo settings (Ezhkova et al., 
2011; Fragola et al., 2013; Hidalgo et al., 2012). We quantified by qRT-PCR the transcript 
levels of Ezh1 in both Ezh2 proficient and defective lymphomas. Ezh1 transcript could be 
successfully detected in λ-MYC lymphomas (Figure 36), compared to protein levels that 
were not analyzed due to the lack of an optimal antibody. Moreover, the loss of Ezh2 was 
associated to a modest, yet consistent, increase in Ezh1 transcript levels, pointing to a 
possible compensatory response of the lymphoma B cells (Figure 36). These data indicate 
that, upon inactivation of the main catalytic subunit of PRC2, MYC-driven B cell 
lymphomas retain residual H3K27me3 levels, possibly contributed by the Ezh2 paralog, 
Ezh1. 
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Figure 36: λ-MYC lymphomas express the Ezh1 gene irrespective of Ezh2 status  
Quantification by qRT-PCR of Ezh1 transcripts in representative Ezh2 proficient (n= 3, 
Ezh2fl/fl) and defective (n= 3, Ezh2∆/∆) clones, established from a type-1 (#73664) λ-MYC 
lymphoma. Ezh1 mRNA levels were normalized to those of the housekeeping Rplp-0 gene. 
 
7.2.5 Ezh2 mutant type-1 lymphomas are sensitive to combined Ezh1/2 inactivation  
To assess whether Ezh1 could compensate for the loss of Ezh2 in type-1 λ-MYC 
lymphomas, we took advantage of the recently described Ezh1/2 double inhibitor, UNC1999 
(Konze et al., 2013). First, we measured the short-term in vitro effects of UNC1999 on the 
viability of 3 Ezh2 proficient type-1 λ-MYC lymphomas. We observed a dose-dependent 
reduction in tumor cell number for all three lymphomas, yet to a different extent (Figure 37). 
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Figure 37: Response of λ-MYC; Ezh2fl/fl to the Ezh1/2 inhibitor UNC1999 
Histograms showing proportion of viable (PI-) lymphoma cells belonging to type-1 (n=3) λ-
MYC; Ezh2fl/fl tumors 48 hours after exposure to either vehicle (DMSO) or to indicated 
doses of UNC1999. 
 
Next, we tested whether UNC1999 could still interfere with in vitro growth of tumor 
subclones that had undergone Ezh2 inactivation.  In the latter tumors, we hypothesized that 
Ezh1 replaced Ezh2 function to sustain tumor expansion. Growth curve analysis performed 
over a period of 10 days of treatment with UNC1999 revealed a significant in vitro growth 
retardation of Ezh2 mutant subclones that received the UNC1999 treatment (Figure 38).  
This result supports the model whereby acute loss of Ezh2 function in type-1 lymphomas 
selects in rare cells a compensatory mechanism centered on the methyltransferase activity of 
Ezh1.  
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Figure 38: Ezh1/2 dual inhibition affects type-1 lymphomas growth in vitro 
In vitro growth curves of representative Ezh2 proficient (Ezh2fl/∆, grey line) and deficient 
(Ezh2∆/∆, blue line) lymphoma subclones exposed either to vehicle (DMSO) or UNC1999 
(2.5 µM) for 10 days. Clones were established from a representative type-1 (#73664) λ-
MYC lymphoma. Tumor cells were counted every second day and each symbol represents 
the average cell count of 3 replicates (±SE). Statistical significance was calculating using 
Student’s t test (***p<0.001). 
 
To further validate this hypothesis, we measured H3K27me3 levels in Ezh2 proficient and 
mutant clones before and after UNC1999 treatment. The comparison by intracellular FACS 
analysis of H3K27me3 levels between Ezh2 proficient and deficient tumor subclones 
revealed a major loss of the histone mark in the latter lymphoma cells, in accordance with 
our own previous observations (Figure 21). Importantly, the treatment of a representative 
type-1 λ-MYC lymphoma with UNC1999 caused a reduction of H3K27me3 levels that 
appeared stronger than the one observed in tumor cells loosing Ezh2 (Figure 39). The data 
were to a large extent confirmed by western blotting quantification of residual H3K27me3 
levels in Ezh2 proficient and defective subclones exposed for 2-6 days to UNC1999 (Figure 
40).  
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Figure 39: UNC1999 induces global loss of H3K27me3 in λ-MYC lymphomas 
Intracellular flow cytometric determinantion of H3K27me3 levels in Ezh2 proficient λ-
MYC lymphomas treated for 6 days with 2.5 µM of UNC1999 (black filled line) or DMSO 
(grey filled line), respectively. Ezh2 mutant cells (Ezh2∆/∆) (blue line) were included as 
negative control. Clones were established from type-1 (#73664) λ-MYC lymphomas.  
 
 
Figure 40: Quantification of H3K27me3 levels in UNC1999-treated lymphomas by 
immunoblotting analysis  
Quantification by western blotting of global H3K27me3 levels in Ezh2 proficient (Ezh2fl/∆) 
and mutant (Ezh2∆/∆) lymphoma clones prior to, or at the indicated days of UNC1999 
treatment (2.5 µM). Numbers indicate H3K27me3 levels after normalization for total H3 
protein, used as input, and relative to vehicle-treated Ezh2 proficient cells. The lack of full-
length Ezh2 protein confirms the identity of Ezh2 mutant cells.  
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Next, we assessed whether UNC1999 treatment could directly influence the expression of 
Ezh1. Quantification by qRT-PCR of Ezh1 transcript in Ezh2 proficient and mutant 
subclones failed to detect significant changes of Ezh1 expression in response to UNC1999 
treatment (Figure 41).  
To establish the mechanisms through which combined Ezh1/2 inhibition interfered with the 
growth of both Ezh2 proficient and mutant type-1 lymphomas, we performed cell cycle 
distribution analysis. UNC1999 treatment did not cause major defects in cell cycle 
progression (Figure 42). Instead, we observed a significant increase in the fraction of sub-
G1 apoptotic cells following combined Ezh1/2 inhibition (Figure 42). This result was true 
for both Ezh2 proficient and defective lymphoma B cells (Figure 42). Hence, in λ-MYC 
type-1 lymphomas PRC2 inhibition triggers a potent cytotoxic response. Moreover, our data 
suggest that inactivation of “canonical” PRC2 function, through the loss of Ezh2 
methyltransferase activity, can be compensated by an alternative PRC2 complex consisting 
of Ezh1 as catalytic subunit. 
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Figure 41: Expression of Ezh1 in B cell lymphomas in response to UNC1999 treatment 
qRT-PCR quantification of Ezh1 transcripts in representative Ezh2 proficient (Ezh2fl/∆, black 
filled bar, n= 2) and defective (Ezh2∆/∆; grey filled bar, n= 2) lymphoma clones established 
from a representative type-1 tumor (#73664), cultured in vehicle-containing medium or in 
the presence of UNC1999 (2.5 µM). Ezh1 levels were normalized to the housekeeping Rplp-
0 gene and represented as relative to those in Ezh2 proficient, vehicle-treated lymphoma 
cells. 
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Figure 42: Ezh1/2 inhibition increases the death rate of λ-MYC lymphomas in vitro 
Cell cycle distribution analysis of Ezh2 proficient (Ezh2fl/∆) and mutant (Ezh2∆/∆) clones 
established from a representative type-1 (#73664) lymphoma, after 6 days of treatment with 
UNC1999 (2.5 µM; grey bar). Vehicle-treated (DMSO; black bar) cells were used as 
comparison. Numbers within dot plots indicate frequency of boxed cells. Summary of cell 
cycle distribution data is shown below. UNC1999 leads to a significant (* p< 0,05, 2-Way-
Anova statistical test) increase in the fraction of sub-G1 dead cells. 
 
7.2.6 Is repression/silencing of Polycomb targets p21 and p16INK4a associated with the 
acquisition of an Ezh2-independent phenotype in MYC lymphoma cells? 
In an attempt to understand the mechanisms allowing the establishment of the rare Ezh2 
mutant subclones derived from type-1 lymphomas, we hypothesized that tumor cells 
selected Ezh1 expression to ensure stable repression of tumor suppressors and Polycomb 
targets Cdkn1a/p21waf1 and p16INK4a. To this end, we measured the effect of UNC1999 
treatment on p21 and p16 expression in both Ezh2 proficient and defective subclones, 
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established from type-1 lymphomas. Transcript levels of both p21 and p16 were 
substantially elevated in Ezh2 mutant subclones, whereas their expression was repressed in 
Ezh2 proficient tumors (Figure 43). Moreover, treatment of lymphomas with UNC1999 led 
to a paradoxical reduction in p16 and p21 transcript levels in Ezh2 mutant tumor cells 
(Figure 43). These results exclude that the compensatory effect provided by Ezh1 in Ezh2 
mutant subclones is exerted via repression of tumor suppressors p16Ink4a and p21waf1. 
 
 
Figure 43: Expression of CDK inhibitors in λ-MYC lymphomas treated with UNC1999 
Quantification by qRT-PCR of Cdkn1a/p21waf1 and p16INK4A transcripts in representative 
Ezh2 proficient (Ezh2fl/∆; black bar, n= 2) and deficient (Ezh2∆/∆; grey bar, n= 2) clones, 
established from a type-1 (#73664) λ-MYC lymphoma, upon treatment with UNC1999 (2.5 
µM). Lymphoma B cells treated with vehicle (DMSO) were used as control. Gene transcript 
levels were normalized to the housekeeping Rplp-0 gene and represented as relative to those 
of vehicle-treated Ezh2 proficient lymphoma cells. 
 
To further investigate a possible contribution of Cdkn2a silencing to the acquired resistance 
of type-1 lymphomas to Ezh2 inhibition, we subjected Ezh2 proficient and mutant 
subclones, established from a Cdkn2a proficient type-1 lymphoma, to Cdkn2a genotyping. 
Interestingly, whereas all Ezh2 proficient subclones retained the Cdkn2a locus, 1 out of 3 
Ezh2 mutant clones underwent bi-allelic loss of the Cdkn2a locus (Figure 44). Moreover, 
growth curve analysis revealed that the Ezh2 mutant subclone acquiring loss of the Cdkn2a 
locus displayed a substantially higher proliferative potential when compared to its Cdkn2a 
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proficient counterparts and to Ezh2 proficient lymphoma cells (Figure 45).  Hence, loss of 
Cdkn2a may represent one mechanism through which lymphoma cells circumvent acute 
inactivation of Ezh2, to ensure continuous tumor growth. 
 
  
Figure 44: Status of the Cdkn2a locus in Ezh2 proficient and  mutant lymphoma clones 
Genomic PCR analysis to assess the status of the Cdkn2a locus in representative Ezh2 
proficient (Ezh2fl/fl) and mutant (Ezh2∆/∆) clones established from type-1 (#73664) primary 
λ-MYC lymphomas that were used as control (Ctrl). Note that one of the two Ezh2 mutant 
clones has lost the Cdkn2a locus during clonal outgrowth starting from a single tumor cell.  
 
 
Figure 45: Loss of Cdkn2a contributes to increase proliferation of Ezh2 mutant 
lymphomas 
Comparison of in vitro growth curves of Ezh2 mutant (Ezh2∆/∆ grey line) lymphoma clones 
differing in the status of the Cdkn2a locus (Ezh2∆/∆ vs. Ezh2∆/∆; Cdkn2a-/-), established from 
type-1 λ-MYC lymphoma (#73664). A representative Ezh2 proficient lymphoma clone was 
included in the analysis. Cells were counted at the indicated time points. Each symbol 
represents the average count of 3 replicates (±SE). Statistical significance was calculating 
using Student’s t test (***p<0.001). 
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7.2.7 λ-MYC type-2 lymphomas are resistant to combined Ezh1/2 inhibition 
The high recovery rate of Ezh2 mutant subclones after TAT-Cre transduction of type-2 
lymphomas suggested a dispensable role for the Polycomb protein in clonal growth starting 
from single cells. The resistance of type-2 lymphomas to Ezh2 loss could depend on 
efficient compensation provided by Ezh1. To test this hypothesis, we exposed type-2 
lymphomas to increasing doses of UNC1999. Short-term in vitro cultures revealed a 
surprising resistance of type-2 lymphomas to combined Ezh1/2 inhibition (Figure 46). To 
determine the effect of UNC1999 on the methyltransferase activities of Ezh1 and Ezh2 in 
type-2 λ-MYC lymphoma cells, we quantified H3K27me3 levels by immunoblotting 
analysis. Global H3K27me3 levels decreased in a dose-dependent manner in tumor B cells 
of three independent lymphomas, reaching levels that ranged between 5- and 10 % of those 
present in untreated cells (Figure 47). These results indicate that type-2 λ-MYC lymphomas 
evolved selecting molecular networks that render tumor cells largely resistant to acute PRC2 
inactivation. 
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Figure 46: Type-2 λ-MYC lymphomas are resistant to pharmacological Ezh1/2 
inhibition 
Histograms representation of the percentage of viable (PI-) lymphoma cells belonging to 
type-2 λ-MYC tumors (n= 3) after 48 hours treatment with the indicated doses of UNC1999. 
Vehicle-treated (DMSO) cells were used as control. 
 
 
Figure 47: Reduction in global H3K27me3 levels in UNC1999-treated type-2 λ-MYC 
lymphomas 
Immunoblotting determination of H3K27me3 levels in a representative type-2 λ-MYC; 
Ezh2fl/fl primary tumor (#160887), treated for 48 hours with the indicated doses of 
UNC1999. Numbers indicate H3K27me3 levels after normalization for protein input 
(assessed through histone H3 measurement) and are represented as relative to vehicle-
treated (DMSO) lymphoma cells. 
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7.2.8 Ezh2 is required for optimal lymphoma fitness  
The isolation of Ezh2 mutant subclones from both type-1 and type-2 lymphomas, combined 
with the ability of Polycomb mutant tumor B cells to grow both in vitro and in vivo, 
indicates that MYC-transformed B cells can circumvent the loss of the main catalytic 
subunit of the PRC2. We wondered whether the putative compensatory mechanisms set in 
place by Ezh2 mutant lymphoma B cells allowed the latter cells to compete in vivo with 
Ezh2 proficient tumors. To this end we performed two types of experiments. First, type-1 
and type-2 lymphomas were TAT-Cre transduced to generate Ezh2 mutant tumor cells 
(Figure 48). The latter cells were then transplantated as a mixture into immunoproficient 
hosts. Quantification by genomic qPCR of Ezh2 gene copy number in tumor cells retrieved 
from the bone marrow of diseased animals revealed a normal set of Ezh2 alleles (Figure 48). 
This result was confirmed assessing H3K27me3 levels in the mixture of transduced cells 
prior to injection and after their retrieval from the bone marrow of diseased animals, 
respectively (Figure 49). Whereas tumor B cells displaying low H3K27me3 levels (likely 
representing Ezh2 mutant cells) were clearly detected at 48 hours after TAT-Cre 
transduction, they become undetectable in the bulk of the tumor retrieved from the bone 
marrow of transplanted mice (Figure 49).  
 
 
Figure 48: In vivo effects of acute inactivation of Ezh2 on primary λ-MYC lymphomas  
Genomic qPCR quantification of Ezh2 gene copy number in representative type-1 (#73664) 
and type-2 (#160887) λ-MYC lymphomas prior to (Ezh2fl/fl) and 48 hours after TAT-Cre 
transduction (48h Cre). The mixture of transduced cells was transplanted into mice and Ezh2 
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gene copy number assessed in the pool of tumor B cells retrieved from the bone marrow 
(BM) of two recipients (#1 and #2). Data on Ezh2 gene copy number were normalized for 
DNA input and represented as relative to those in Ezh2 proficient lymphoma cells (Ezh2fl/fl).  
 
 
Figure 49: Lymphomas acutely loosing Ezh2 activity are counter-selected in vivo 
Quantification of H3K27me3 levels by intracellular FACS analysis in type-1 (#73664) and 
type-2 (#160887) λ-MYC lymphomas prior to (grey filled line) and 48 hours (48h) after 
TAT-Cre transduction (black thin line). H3K27me3 levels are also shown in lymphomas 
retrieved from the bone marrow of mice transplanted with the mixture of TAT-Cre 
transduced cells (ex vivo lymphoma). An Ezh2 mutant lymphoma clone was included in the 
analysis as negative control for H3K27me3 (blu thin line). 
 
A second approach to study the competitive potential of Ezh2 mutant lymphoma cells is 
based on the transplantation of 1:1 mixtures of Ezh2 proficient and mutant lymphoma 
subclones. This strategy avoids imbalances in the proportion of Ezh2 proficient and 
defective tumor cells at the onset of the competition assay. Quantification of Ezh2 gene copy 
number in tumor cells retrieved from the bone marrow of diseased transplanted animals 
indicated the existence of two functional copies of Ezh2 in most lymphoma B cells (Figure 
50). To validate the Ezh2 genotyping result, we compared H3K27me3 levels in 1:1 mixtures 
of Ezh2 proficient (Ezh2fl/∆) and mutant (Ezh2∆/∆) lymphoma cells prior to, and after, 
transplantation into recipient animals. Western blotting analysis confirmed the counter-
selection of Ezh2 mutant lymphoma cells in the bone marrow of diseased animals at the 
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expense of Ezh2 proficient tumor cells expressing normal levels of H3K27me3 (Figure 51). 
Similar results were obtained measuring H3K27me3 at the single cell level by intracellular 
FACS analysis of tumor-enriched bone marrow cells (Figure 52).  
All together these results reveal that acute loss of Ezh2 impairs in vivo fitness of malignant 
B cells of both type-1 and type-2 lymphomas. Moreover, whereas Ezh2 mutant subclones 
can be successfully established from both type-1 and type-2 lymphomas, their capacity to 
grow in vivo is severely compromised by the presence of Ezh2 proficient tumors. Hence, 
compensatory mechanisms, set in place in tumor B cells in response to Ezh2 inactivation, 
can only partially bypass functional inactivation of the Polycomb protein, even in type-2 
lymphomas. 
 
 
Figure 50: Ezh2 inactivation impairs the capacity of λ-MYC lymphoma cells to 
compete in vivo with Ezh2 proficient lymphomas  
Genomic qPCR quantification of Ezh2 gene copy number in pools of lymphoma cells 
retrieved from the bone marrow (BM) of two animals transplanted with 1:1 mixtures of 
Ezh2 proficient (Ezh2fl/fl or Ezh2fl/∆) and defective (Ezh2∆/∆) lymphoma cells. Ezh2 proficient 
and mutant clones alone or within a 1:1 mixture prior to transplantation (1:1 T=0) were used 
as controls. In vivo competition assays were performed using representative clones 
established from type-1 λ-MYC lymphomas (#73664 and #123617). Ezh2 gene copy 
number data were normalized for DNA input and represented as relative to those of Ezh2 
proficient clones used for the competition assays. 
 
 121 
 
Figure 51: Ezh2 mutant lymphoma cells are counter-selected in vivo by Ezh2 proficient 
tumors 
Immunoblot analysis to assess H3K27me3 and Ezh2 levels in pools of lymphoma B cells 
retrieved ex vivo from the bone marrow (BM) of two animals (#1 and #2) injected 26 days 
earlier with 1:1 mixtures of Ezh2 proficient and deficient lymphomas. Levels of H3K27me3 
and Ezh2 in the starting Ezh2 proficient (Ezh2fl/∆) and mutant (Ezh2∆/∆) lymphoma cells are 
also indicated. Numbers indicate normalized H3K27me3 levels, represented as relative to 
those in Ezh2 proficient (Ezh2fl/∆) lymphoma cells. Note that tumor cells retrieved from the 
BM of transplanted mice displayed a ratio between Ezh2 full length and its ∆SET mutant 
counterpart that is higher than the one measured in the 1:1 tumor mixture prior to 
transplantation (1:1 T=0).  
 
 
Figure 52: Flow cytometric determination of H3K27me3 levels in tumor B cells 
retrieved after transplantation of 1:1 Ezh2 proficient/defective tumor mixtures  
Determination of H3K27me3 levels by intracellular FACS analysis, in representative Ezh2 
proficient (Ezh2fl/fl; gray filled line), and deficient (Ezh2∆/∆) (blue line) lymphoma clones, 
1:1 Ezh2 proficient/defective tumor mixtures (black line) prior (T=0) to transplantation and 
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in the pool of lymphoma cells isolated ex vivo from the bone marrow (BM) of a transplanted 
animal. Numbers indicate frequency of H3K27me3-positive and negative cells in 1:1 tumor 
mixtures prior to transplantation.  
 
 
7.3 Analysis of the H3K27me3 epigenome in λ-MYC lymphomas  
7.3.1 Genome wide distribution of H3K27me3 in λ-MYC lymphomas 
To understand the contribution of H3K27me3 to the maintenance of the transformed B cell 
phenotype, we performed ChIP using an antibody against H3K27me3, coupled to ultra deep 
sequencing of the immunoprecipitated genomic material (ChIP-sequencing or ChIP-seq). 
This analysis was performed on two λ-MYC tumors representative of type-1 and type-2 
lymphomas, respectively. Bioinformatic analysis of the sequencing data was performed 
using the MACS algorithm to identify genomic intervals overlapping transcriptional start 
sites (+/- 5 Kb) that were significantly (p< 10-5) enriched for H3K27me3 deposition. The 
analysis identified 1814 H3K27me3 targets in type-1 lymphomas, whereas type-2 
lymphoma displayed around 1000 target genes (Figure 53). The intersection of the lists of 
H3K27me3-marked genes identified in the two types of lymphomas revealed a good number 
of shared targets, with yet a substantial proportion of genes that were marked by H3K27me3 
in a tumor-specific fashion (Figure 53). We confronted the list of H3K27me3 marked genes 
to databases containing a comprehensive list of ChIP-seq datasets, using the Enrichr open 
source software. The analysis revealed that genes marked by H3K27me3 in λ-MYC 
lymphomas were significantly enriched for components of both PRC1 (Rnf2) and PRC2 
(Ezh2, Suz12, Jarid2) and were shared with H3K27me3 targets in mouse embryonic stem 
cells. A further support for the assignment of H3K27me3-marked genes in λ-MYC 
lymphomas to the group of bona fide Polycomb targets came from the observation, that such 
genes are commonly deregulated in Polycomb mutant (Eed and Rnf2 knockout) ES cells 
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(Figure 54). Gene ontology analysis applied to H3K27me3 targets in λ-MYC lymphomas 
revealed enrichment for functional categories including Wnt signaling and ES cells 
pluripotency (Figure 55). 
 
 
Figure 53: Ezh2 proficient clones established from type-1 and type-2 λ-MYC 
lymphomas share a consistent number of H3K27me3 target genes 
Venn diagram representing H3K27me3-marked genes identified by MACS algorithm (p< 
10-5) in Ezh2 proficient (Ezh2fl/fl) clones from representative type-1 (#73664: black) and 
type-2 (#126803: light grey) λ-MYC lymphomas, respectively. 
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Figure 54: Features of H3K27me3 target genes in Ezh2 proficient lymphomas 
List of genes marked by H3K27me3 in Ezh2 proficient (Ezh2fl/fl) clones (#73664 for type-1 
and #126803 for type-2) were confronted with previously published ChIP-seq dataset using 
EnrichR software tool. Bar-representation of the top-8 ChIP-seq datasets for chromatin 
bound proteins (A) and histone marks (B) revealed by ChIP enrichment analysis (ChEA and 
Epigenomics, EnrichR). Top-8 transcriptome datasets (deposited in GEO) enriched in genes 
marked by H3K27me3 in Ezh2 proficient (Ezh2fl/fl) lymphomas, as reveled though EnichR 
(LHF-TF, EnichR) tool (C) established from type-1 (#73664) and type-2 (#126803) λ-MYC 
lymphomas. 
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Figure 55: Functional categories of H3K27me3 target genes in Ezh2 proficient 
lymphomas 
Wiki-pathway of top-8-enriched categories for H3K27me3 target genes identifies in Ezh2 
proficient (Ezh2fl/fl) type-1 (#73664) and type-2 (#126803) independent λ-MYC lymphomas. 
Analysis was performed using EnrichR software tool.  
 
7.3.2 Effects of Ezh2 inactivation on the H3K27me3 epigenome of λ-MYC lymphomas 
To assess the effects of Ezh2 inactivation on the H3K27me3 genome wide distribution, we 
extended ChIP-seq to Ezh2 mutant subclones isolated from type-1 and type-2 lymphomas, 
respectively. Bioinformatic analysis of H3K27me3 ChIP-seq data revealed a 95-to-98 % 
reduction in the number of H3K27me3 targets in lymphoma B cells of both types as a 
consequence of Ezh2 inactivation (Figure 56). In support of this result, distribution of 
H3K27me3 reads around the TSS of target genes in Polycomb proficient tumor cells was 
lost in the Ezh2 mutant lymphomas (Figure 57). This result indicates that sustained growth 
of λ-MYC lymphoma is compatible with a close-to-complete loss of H3K27 methylation 
genome wide.  
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Figure 56: Significant loss of H3K27me3 target genes in Ezh2 mutant lymphomas 
Venn diagram representing numbers of genes marked by H3K27me3 in Ezh2 proficient 
(Ezh2fl/fl: black) and defective (Ezh2∆/∆: light grey) subclones established from type-1 
(#73664) and type-2 (#126803) independent λ-MYC lymphomas, respectively. H3K27me3 
enriched targets were identified by MACS algorithm (p<10-5).  
 
 
Figure 57: Distribution of H3K27me3 around the TSS of target genes in 
Ezh2 proficient and mutant lymphomas  
Heat map representation of H3K27me3 distribution in a ±5 Kb genomic interval centered 
around the TSS of target genes identified by the MACS algorithm to be enriched for the 
histone mark in Ezh2 proficient (Ezh2fl/fl) and mutant (Ezh2∆/∆) subclones, established from 
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type-1 (#73664) and -2 (#126803) λ-MYC lymphomas. Reads were clustered according to 
the H3K27me3 levels. 
 
7.3.3 Effect of the loss of H3K27 methylation on target gene expression in Ezh2 mutant 
lymphomas 
To assess whether the loss of H3K27me3 around the TSS of target genes affected their 
expression, we performed RNA sequencing comparing Ezh2 proficient to mutant clones 
isolated from representative cases of type-1 and type-2 lymphomas. A pairwise comparison 
of Ezh2 proficient and mutant clones derived from the same primary tumor revealed a strong 
correlation (Pearson correlation coefficient R= 0.979) (Figure 58) in the expression levels of 
H3K27me3 targets for type-1 established subclones. Remarkably, instead, the degree of 
similarity in the expression of H3K27me3-marked genes between Ezh2 proficient and 
defective clones derived from type-2 lymphomas was substantially weaker, with most genes 
becoming up-regulated in Ezh2 mutant cells (R= 0.439) (Figure 58). This result suggests 
that establishment of Ezh2 mutant lymphomas from type-1 lymphomas requires the 
activation of compensatory (repressive) mechanisms in order to retain the correct regulation 
of H3K27me3 targets. Instead, Ezh2 mutant clones derived from type-2 lymphomas appear 
much less dependent on the correct regulation of H3K27me3 target genes in order to sustain 
tumor growth. This result is in accordance with our previous evidences indicating primary 
resistance of type-2 lymphomas to pharmacological PRC2 inactivation.  
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Figure 58: Expression of H3K27me3-marked genes in Ezh2 proficient and mutant 
subclones  
Scatter plot representation of transcript levels of H3K27me3-marked genes between Ezh2 
proficient and mutant subclones isolated from representative type-1 (#73664) and type-2 
(#126803) λ-MYC lymphomas. Each dot represents transcript levels of one H3K27me3-
marked genes in pairwise samples as assessed by RNA-sequencing. For both types of 
lymphomas, Pearson’s coefficient (R) was calculated. 
 
7.3.4  Where is H3K27me3 retained in Ezh2 mutant lymphomas? 
The sensitivity of Ezh2 mutant subclones derived from type-1 lymphomas to the Ezh1/2 
inhibitor UNC1999, coupled to the evidence that residual global H3K27me3 levels are 
detected in Polycomb mutant tumor cells, suggests the existence, in these cells, of a non-
canonical PRC2 composed of Ezh1 that may be required to sustain tumor growth.  
In order to have a more comprehensive outlook at targets that retained H3K27me3 in Ezh2 
mutant subclones, we extended ChIP-seq data to a second Polycomb mutant subclone. 
Interestingly, in the latter tumor, the number of target genes that retained the H3K27me3 
mark was substantially higher than in the first analyzed clone (432 vs. 56), pointing to 
remarkable epigenetic variability linked to the establishment/selection of Ezh2 mutant 
clones. Analysis of the distribution of residual H3K27me3 at target sites in Ezh2 mutant 
clones revealed an enrichment for the histone mark proximal to the TSS, in agreement with 
the mode of action of canonical PRC2 (Figure 59A). Surprisingly, the same set of genes was 
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devoid of H3K27me3 enrichment in Ezh2 proficient tumors (Figure 59A), suggesting the 
recruitment of a non-canonical Ezh1/PRC2 to novel genomic regions in Ezh2 mutant 
lymphoma B cells. The evidence that genes displaying H3K27me3 enrichment in Ezh2 
mutant lymphomas were not recognized as bona fide Polycomb targets supports this 
hypothesis (Figure 59B). Indeed, we found that genes marked by H3K27me3 in Ezh2 
mutant lymphomas were significantly enriched for targets of H3K4 methylation, which is 
associated to active gene transcription (Figure 59B). Finally, we tested whether genes 
marked by H3K27me3 in Ezh2 mutant lymphomas had undergone changes in gene 
expression when compared with Ezh2 proficient tumors. The pairwise comparison revealed 
a substantial modulation in gene expression due to de novo H3K27 trimethylation in Ezh2 
mutant lymphomas (R= 0.56; Figure 60).  
All together these results support a scenario whereby Ezh2 inactivation in type-1 λ-MYC 
lymphoma B cells unleashes the activity of a non-canonical PRC2 complex composed of 
Ezh1, which gets recruited to novel transcriptionally active genes, where it likely controls 
their expression.  
 
 
Figure 59: Distribution of residual H3K27me3 in Ezh2 mutant lymphomas  
Heat map representation of H3K27me3 distribution in a ±5 Kb genomic interval centered 
around the TSS of genes identified by the MACS algorithm to be enriched for the histone 
mark in Ezh2 defective tumor B cells established from type-1 (#123617) λ-MYC 
lymphomas. Ezh2 proficient (Ezh2fl/fl) and mutant (Ezh2∆/∆) lymphoma subclones were 
compared. Reads were clustered according to the level of H3K27me3 (A). Bar 
representation of top-8 ChIP-seq datasets for histone marks enriched for H3K27me3 target 
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genes identified in Ezh2 mutant clone from type-1 (#123617) λ-MYC lymphomas, revealed 
by histones enrichment analysis (Epigenomics, EnrichR) (B).  
 
 
Figure 60: H3K27me3 modulates expression of target genes in Ezh2 mutant type-1 
lymphomas  
Scatter plot representation of transcript levels of genes marked by H3K27me3 in Ezh2 
mutant lymphoma cells. Pairwise comparison between Ezh2 proficient and defective 
subclones from type-1 (#123617) λ-MYC lymphomas is represented. Each dot represents 
transcript levels of one of H3K27me3-marked genes, assessed by RNA-sequencing. 
Pearson’s coefficient (R) is shown for each comparison.  
 
7.4  Acquired resistance to PRC2 inactivation in MYC-driven lymphomas 
7.4.1 Generation of λ-MYC lymphomas acquiring resistance to UNC1999 treatment 
Small molecule inhibitors targeting Ezh2 are currently in several clinical trials for the 
treatment of both solid and blood cancers, including high-grade lymphomas. Our studies 
based on the λ-MYC lymphoma model unveiled strategies selected by tumor cells to 
circumvent the need for Ezh2. One possible compensatory mechanism is centered on the 
activity of Ezh1. Indeed, type-1 lymphomas that succeeded to bypass the requirement for 
Ezh2 remained sensitive to the Ezh1/2 double inhibitor, UNC1999. Based on our results, 
UNC1999 may represent a better option than Ezh2 inhibitors in anti-cancer treatments. 
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In this context, we asked whether tumors could also acquire secondary resistance to 
pharmacological inhibition of Ezh1/2. To address this, we subjected both type-1 and type-2 
lymphomas to a prolonged in vitro treatment with low doses of UNC1999. Under these 
experimental conditions, lymphomas continued to grow in vitro, although at a lower pace 
when confronted to vehicle-treated tumors (Figure 61). 
To monitor the action of UNC1999, we determined H3K27me3 levels by intracellular FACS 
analysis over time. We observed two distinct behaviors. Type-2 lymphomas displayed from 
the first days of treatment a substantial loss in H3K27me3 levels, which remained the same 
throughout the treatment period. Instead, type-1 lymphomas displayed an initial phase when 
most lymphoma cells suffered from a significant loss in H3K27me3 levels. Strikingly, 
starting from day 10 of treatment, we identified a distinct subset of tumor cells that had 
restored H3K27me3 activity. The fraction of H3K27me3+ tumor cells steadily grew over 
time, becoming the dominant population by day 20 of the treatment (Figure 62). H3K27me3 
Western blotting analysis was employed to confirm the differential response of type-1 and -
2 lymphoma cells to chronic UNC1999 treatment (Figure 63). 
All together these results reveal that type-1 lymphomas under chronic treatment with a 
PRC2 inhibitor select a resistance mechanism that ensures restoration of H3K27me3 
activity. In striking contrast, type-2 lymphomas lack any selection pressure to re-establish 
H3K27me3 in order to sustain tumor growth in the presence of UNC1999. 
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Figure 61: Growth curve of λ-MYC; Ezh2fl/fl lymphomas chronically exposed to low 
doses of UNC1999 
In vitro growth curves of representative type-1 (#73664) and type-2 (#160887) λ-MYC; 
Ezh2fl/fl lymphomas treated for the indicated days with either vehicle (DMSO, black line) or 
low doses (0.6 µM and 1.25 µM) UNC1999. Each symbol represents the average of 3 
measurements (±SE). Statistical significance was calculating using 2-Way-Anova statistical 
test (***p<0.001). 
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Figure 62: Type-1 λ-MYC; Ezh2fl/fl lymphomas restore H3K27 trimethylation after 
chronic exposure to low doses of UNC1999  
Quantification of H3K27me3 levels by intracellular FACS analysis in representative type-1 
(#73664) and type-2 (#160887) λ-MYC; Ezh2fl/fl lymphomas exposed for the indicated days 
to UNC1999 (1.25 µM) (black thin line). Vehicle-treated (DMSO) lymphoma cells were 
used as positive control (grey filled line). 
 
 
Figure 63: Western blot quantification of H3K27me3 levels in lymphomas chronically 
exposed to low doses of UNC1999 
Immunoblotting determination of global H3K27me3 levels in representative type-1 
(#73664) and type-2 (#160887) λ-MYC; Ezh2fl/fl lymphomas treated for the indicated days 
and doses with either UNC1999 or vehicle (DMSO). Histone H3 was used as loading 
control. Numbers indicate normalized H3K27me3 levels relative to those measured in 
vehicle-treated lymphoma cells. 
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7.4.2 Isolation of UNC19999 resistant λ-MYC subclones  
To identify the genetic basis underlying acquired resistance of λ-MYC lymphomas to 
pharmacological inhibition of PRC2, we established through limiting dilution assays, a 
representative number of subclones from pools of UNC1999 chronically treated type-1 and 
type-2 lymphomas (Figure 64). Flow cytometric quantification of H3K27me3 in 
representative UNC1999-resistant subclones (expanded in the absence of the inhibitor), 
revealed levels of the histone mark fairly similar to Ezh2 proficient untreated lymphomas 
(Figure 65). These results indicate that UNC1999 resistant tumor cells retain a PRC2 
complex with intact methyltransferase activity. Future experiments based on the sequencing 
of the coding sequences of Ezh1 and Ezh2 in individual UNC1999-resistant clones will 
determine whether lymphoma cells selected mutations in the Polycomb proteins that prevent 
the binding to the inhibitor. 
 
 
Figure 64: Isolation of λ-MYC; Ezh2fl/fl clonal variants acquiring resistance to 
UNC1999 treatment 
Cartoon depicting the strategy to isolate λ-MYC; Ezh2fl/fl subclones acquiring resistance to 
Ezh1/2 inhibition. Briefly, representative type-1 (#73664) and type-2 (#160887) 
lymphomas were treated for 22 days with a low dose (0.6 µM) of UNC1999. Tumor cells 
were then cloned by limiting dilution in the absence of UNC1999. Clones were isolated 3 
weeks later and further expanded. 
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Figure 65: UNC1999 resistant clones display similar H3K27me3 levels to parental 
tumors 
Quantification of H3K27me3 levels by intracellular FACS analysis in representative 
UNC1999-resistant subclones (black line), established from type-1 (#73664) and type-2 
(#160887) λ-MYC; Ezh2fl/fl lymphomas. FACS measurements were made with lymphoma 
cells grown in the absence of UNC1999. H3K27me3 levels were compared to those present 
in the parental tumor (grey filled line).  
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8 Discussion 
The PRC2 catalytic subunit Ezh2 is highly expressed in proliferating B cell compartments, 
namely progenitors and GC B cells (Caganova et al., 2013). Elevated Ezh2 levels are also 
detected in high-grade B cell lymphomas, including BL (Dukers et al., 2004; Sander et al., 
2008; van Kemenade et al., 2001). These observations, coupled to genome mutation analysis 
indicating recurrent hyper-activation of EZH2 function in GC-derived DLBCL and FL, have 
identified the Polycomb protein as a novel marker gene of B cell lymphomas (Morin et al., 
2011; Lohr et al., PNAS 2012). The contribution of Ezh2 to the malignant nature of B cell 
lymphomas may fall in line of its essential role in the control of cell proliferation, survival 
and differentiation (Margueron and Reinberg, 2011). In addition, the function played by 
PRC2 to sustain the pluripotency network in embryonic, adult and induced pluripotent stem 
cells may represent a further strategy hijacked by malignant cells to maintain their immortal 
nature (Laugesen and Helin, 2014). 
High Ezh2 levels are contributed by the activation of the transcription factor E2F1 (Bracken 
et al., 2003). In proliferating cells, including B lymphocytes, Ezh2 plays a major role in the 
active regulation of cell cycle progression. In particular, Ezh2 acts within the PRC2 to 
regulate the G1-to-S transition through the active repression of genes encoding for the CDK 
inhibitors Cdkn2a, Cdkn1a/p21WAF, Cdkn1b/p27Kip1 and Cdkn1c/p57Kip2 (Fan et al., 2011; 
Fasano et al., 2007; Guo et al., 2011; Itahana et al., 2003; Yang et al., 2009). The failure to 
repress such genes represents a major cause of the proliferative defects observed in primary 
cells of mutant animals lacking expression of Ezh2 or other core components of the PRC2 
complex (Chen et al., 2009; Dhawan et al., 2009; Jacobs et al., 1999; Miyazaki et al., 2008). 
The contribution of Ezh2 and Polycomb proteins to cell cycle progression is not limited to 
the regulation of the G1-to-S transition. Indeed, recent lines of evidence have unveiled an 
active role for PRC1 and PRC2 in the control of DNA replication during S phase (Piunti et 
al., 2014). 
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Ezh2 also imposes a strict control over cell survival. This is achieved through the negative 
regulation of the tumor suppressor p19ARF, encoded by the Cdkn2a locus (Sherr, 2012). 
Cells undergoing inactivation of Ezh2, as well as other Polycomb components of PRC2 and 
PRC1, commonly activate p19ARF, which triggers p53-driven programmed cell death, in 
response to apoptotic stimuli (Kim and Sharpless, 2006; Sherr, 2012). In line with these 
observations, Polycomb mutant cells display increased sensitivity to genotoxic damage 
induced by oxidative stress, DNA damaging agents and/or endogenous mutagenic processes. 
For example, Ezh2 protects GC B cells from genotoxic stress, induced by AID during Ig 
SHM and isotype switching (Caganova et al., 2013). The ability of Polycomb proteins to 
protect cells from genotoxic damage may also be mediated by mechanisms other than 
p19ARF repression. In support of this, recent evidence has suggested that Polycomb proteins 
are directly involved in the early stages of the DNA damage response (Campbell et al., 
2013; Ginjala et al., 2011; Ismail et al., 2010; Wu et al., 2011) 
Ezh2, as well as other members of PRC1 and PRC2, exerts a fine temporal control over the 
expression of TFs that guide step-wise somatic cell differentiation, including B 
lymphopoiesis. Indeed, conditional gene inactivation studies have highlighted the essential 
role played by Ezh2 during early B cell differentiation and in mature B cells, recruited in the 
GC response (Beguelin et al., 2013; Caganova et al., 2013). In particular, Ezh2 inactivation 
in GC B cells caused a premature induction of the tumor suppressor and master regulator of 
terminal B cell differentiation, Blimp1, thereby limiting the persistence of B cells within the 
GC (Beguelin et al., 2013; Caganova et al., 2013). Conversely, constitutive activity and/or 
expression of Ezh2 may cause an enforced repression of developmental regulators under its 
control, stalling differentiation, thereby facilitating malignant transformation (Lund et al., 
2014). These results unveil the relevance of a strict control over Ezh2 expression/function to 
guarantee the normal transition of B cells, as well as other cellular lineages, through 
subsequent maturation stages. In embryonic, adult and induced pluripotent stem cells, Ezh2 
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sustains the activity of the pluripotency network through epigenetic silencing of cell fate 
determinants and by supporting stem cell self-renewal (Margueron and Reinberg, 2011). 
These properties render Ezh2 a likely determinant of the acquired self-renewal properties of 
malignant cells, in particular of those transformed by the c-MYC oncogene (Wee et al., 
2014).  
 
B cell lymphomas represent a heterogeneous group of diseases, predominantly originating 
from mature B cells recruited into the GC reaction (Basso and Dalla-Favera, 2015). The 
high Ezh2 expression levels detected in GC B cells, coupled to its critical role in protecting 
the cells from DNA damage-induced apoptosis, in restraining terminal differentiation and in 
facilitating cell proliferation, render the Polycomb protein a possible determinant of GC-
derived B cell lymphomas (Beguelin et al., 2013; Caganova et al., 2013). In support of this, 
whole exome/genome sequencing data have identified a substantial proportion (over 20 %) 
of DLBCL and FL, displaying heterozygous EZH2 g.o.f. mutations (Lohr et al., 2012; 
Morin et al., 2011; Yap et al., 2011). Two further sets of data support the relevance of Ezh2 
as a GC B cell oncogene. First, transgenic mice expressing mutant forms of EZH2 identified 
in DLBCL and FL, display GC B cell hyperplasia, which precedes malignant transformation 
if expression of the mutant Polycomb protein is combined with a BCL2 transgene (Beguelin 
et al., 2013). Importantly, Ezh2 mutations are more frequently observed in patients with 
DLBCL displaying BCL2 translocations. Second, g.o.f. mutations of the EZH2 gene are 
already observed in the early indolent stages of FL, pointing to a role of the Polycomb 
protein as a driver of malignant GC B cell transformation (Bodor et al., 2013; Pasqualucci et 
al., 2014).  
Another highly aggressive B cell lymphoma arising from GC B cells is BL. In BL, balanced 
chromosomal translocations juxtaposing the MYC oncogene to Ig heavy or light chain 
regulatory regions lead to constitutive expression of the proto-oncogene. Acquisition of 
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additional genetic alterations in BL precursor cells represents a strict requirement for pre-
tumoral cells to counteract the potent pro-apoptotic response, triggered by deregulated c-
MYC. Analyses of MYC-driven B cell lymphoma mouse models, including the λ-MYC 
model, have revealed a substantial increase in Ezh2 expression at the transition between the 
pre-tumoral and tumoral stage (van Kemenade et al., 2001). High Ezh2 levels, observed in 
murine MYC-driven lymphomas, BL primary tumors and BL cell lines, may be selected by 
malignant B cells to sustain their high rate of cell proliferation, further preventing 
differentiation (Dukers et al., 2004; Sander et al., 2008; van Kemenade et al., 2001). 
Alternatively, high Ezh2 levels may correspond to the levels of expression of the Polycomb 
protein in GC B centroblasts, the BL precursor cells (Calado et al., 2012; Dominguez-Sola 
et al., 2012; Victora et al., 2012). 
Regardless of the mechanism responsible for the high EZH2 expression in BL cells, it 
remains unknown whether the Polycomb protein contributes to their aggressiveness, as well 
as that of other malignant cancer types (Volkel et al., 2015). This question has remarkable 
clinical relevance, as small molecule inhibitors targeting the EZH2 protein in a highly 
selective manner have been recently developed. Moreover, tumors that may benefit from 
such drugs are currently being identified in phase-1 and -2 clinical trials 
(http://clinicaltrials.gov/ct2/show/NCT01897571)(http://clinicaltrials.gov/ct2/show/NCT02082977).  
Studies based on the Eµ-MYC lymphoma model have assigned opposing roles to the 
Polycomb protein in B cell lymphomagenesis. Whereas in Lee et al., the inactivation of 
Ezh2 favored the development of B cell lymphomas (Lee et al., 2013), recent work based on 
transgenic B cell-specific g.o.f. EZH2 mutants revealed cooperation between deregulated 
EZH2 and c-MYC in B cell tumorigenesis (Berg et al., 2014). Remarkably, while 
progenitors B cells represented the main target of transformation in the study by Lee et al., 
tumors described in the study by Berg and colleagues originated from immature/transitional 
B cells (Berg et al., 2014). These results suggest that the cell context plays an important role 
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in defining the specific contribution of Ezh2 to tumorigenesis. Hence, whereas in mature B 
cells recruited into the GC Ezh2 activity promotes tumorigenesis, it acts as a tumor 
suppressor in progenitor B cells. A tumor suppressor role for Ezh2 has also been proposed in 
myeloid and T-cell malignancies, which showed recurrent inactivating mutations also in 
other PRC2 components as well (Nikoloski et al., 2010; Ntziachristos et al., 2012; Simon et 
al., 2012).  
The studies based on the Eµ-MYC lymphoma model have started to uncover possible 
functions of Ezh2 during the onset of MYC-driven B cell lymphomas. However, the nature 
of the experiments (e.g. concomitant inactivation/activation of Ezh2 and c-MYC) renders 
them of limited help to define the importance of Ezh2 function in tumor maintenance and/or 
progression. Answering the latter question represented the main goal of this study. In 
particular, we were interested to establish whether high expression of Ezh2 (rather than its 
constitutive activation) is needed to sustain the malignant phenotype of aggressive B cell 
lymphomas. In order to achieve this goal, the tumor model had to fulfill the following 
criteria: 1) expression of Ezh2 increases in the transition from the pre-tumoral to the tumoral 
stage; 2) the tumor model should resemble a human lymphoma in terms of histological 
appearance, mode of dissemination and genetics and 3) the tumor model should allow time-
controlled inactivation of Ezh2 catalytic function. We succeeded to establish such model, 
combining the λ-MYC transgene to a conditional knockout allele for Ezh2 (Su et al., 2003). 
In λ-MYC; Ezh2fl/fl compound mice, IgM+ B cell lymphomas developed at high penetrance. 
Histologically, tumors resembled BL with typical “starry-sky” histological appearance. 
Tumors displayed a high mitotic index and could be easily transplanted into 
immunoproficient syngenic mice, pointing to an aggressive nature of the lymphomas. The 
establishment of primary cell lines from lymphomas isolated ex vivo from diseased animals 
was instrumental to conditionally inactivate Ezh2 in the malignant B cells. Transient 
delivery of Cre protein to tumor cells, using a transduction approach limiting the exposure to 
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the enzyme to malignant B cells, avoids the risk to observe toxic effects associated with 
prolonged Cre-mediated recombination (Peitz et al., 2002). TAT-Cre transduction allowed a 
good degree of recombination without interfering with the potential of tumor cells to grow 
in vitro and/or expand in vivo upon transplantation into immunoproficient syngenic animals.  
 
To determine the effects of acute inactivation of the Ezh2 methyltransferase activity on the 
growth of highly aggressive MYC-driven B cell lymphomas, we chose to monitor the 
capacity of single tumor cells to overcome anoikis and give rise to a clonal population of 
tumor cells. This stringent test revealed the existence of two major types of MYC-
transformed lymphomas. Specifically, whereas, type-1 lymphomas gave rise to a small 
fraction of Ezh2 mutant subclones following TAT-Cre transduction, type-2 lymphomas 
mostly generated Polycomb mutant subclones after treatment with the recombinant protein. 
This striking difference in the yield of Polycomb mutant clones starting from single cells 
was not caused by differences in the efficiency of TAT-Cre transduction, but rather reflected 
differences in the dependence of the two types of tumors on Ezh2 methyltransferase activity. 
This result has important implications for the biology of MYC-driven transformation. 
Indeed, our results suggest the existence of two major paths leading a MYC-overexpressing 
B cell to evolve into a malignant lymphoma. In type-1 lymphomas, epigenome rewiring in 
malignant B cells as a consequence of constitutive MYC expression strictly relies on 
continuous Ezh2 methyltransferase activity. Acute loss of such activity renders the majority 
of lymphoma B cells incapable to grow and/or survive as single cells. In contrast, type-2 
lymphomas evolved selecting transcriptional/epigenetic networks and/or pathways, which 
were less dependent on Ezh2 activity, allowing a better adaptation to its loss when grown 
starting from single cells. The opposite response to Ezh2 inhibition observed for type-1 and 
type-2 lymphomas was not due to differences in the degree of H3K27me3 loss, as the 
residual levels of the mark in Polycomb mutant subclones established from the two types of 
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tumors was comparable. Remarkably, all tested Ezh2 mutant subclones displayed over 95 % 
loss of global H3K27me3 levels. This result indicates that MYC-lymphomas can support a 
close-to-complete genome wide loss of H3K27me3 without suffering from major limitations 
in both in vitro and in vivo growth.  
In an effort to understand the molecular basis for the different requirement of type-1 and -2 
lymphomas for Ezh2, we performed whole transcriptome analysis. This approach also 
harbors the potential to identify possible biomarker(s) that could be used in the clinics to 
select lymphoma patients that may benefit from anti-EZH2 therapies. The comparison of the 
transcriptional profiles of type-1 and -2 primary tumors revealed a core subset of around 160 
genes that consistently discriminated the two types of MYC-driven lymphomas. Among the 
genes that were expressed at higher levels in type-2 lymphomas, we identified Cyclin D2 
and components of the DNA replication machinery (Mcm2, Mcm4 and Prim2). Higher 
levels of these genes may facilitate proliferation of MYC-expressing tumor cells starting 
from single cells. We also found that type-2 lymphomas expressed higher levels of the anti-
apoptotic protein Bcl2, which may represent a strategy for tumor cells to overcome anoikis, 
as previously described (Galante et al., 2009; Hausmann et al., 2011; Martin and Vuori, 
2004). 
The importance of Ezh2 in the negative regulation of the tumor suppressor Cdkn2a led us to 
hypothesize that type-1 and -2 MYC-driven lymphomas may differ in the functional status 
of Cdkn2a and thereby in the response to Ezh2 inhibition. According to this hypothesis, 
whereas type-1 lymphomas would retain a functional Cdkn2a gene, and therefore require 
Ezh2 to ensure its repression and guarantee cell cycle progression, type-2 tumors would lose 
Cdkn2a function to overcome negative regulation of G1-to-S transition. Upon Ezh2 
inactivation, type-1 lymphomas will suffer from de-repressed Cdkn2a expression, whereas 
Cdkn2a defective type-2 lymphoma will continue to grow. In support of our model, we 
observed that two out of three type-2 primary MYC lymphomas lost the integrity and/or the 
 143 
expression of Cdkn2a locus. Instead, all type-1 tumors retained Cdkn2a locus and were able 
to up-regulate its expression upon Ezh2 inactivation. Another line of evidence supporting 
the importance of Cdkn2a regulation in the response of tumors to Ezh2 inactivation comes 
from the genetic analysis of the Cdkn2a locus in Ezh2 mutant clones established from 
Cdkn2a proficient type-1 lymphomas. Indeed, in one instance, we found that the 
establishment of an Ezh2 mutant clone was associated with bi-allelic loss of the Cdkn2a 
locus. The confirmation that the loss of the tumor suppressor locus Cdkn2a confers tumor 
resistance to Ezh2 inhibition on a larger series of MYC-driven lymphomas (including BL 
cell lines), will provide a clear rationale to screen lymphoma patients for the loss/silencing 
of the Cdkn2a locus, before enrolling them in clinical trials and/or treatment regimens based 
on anti-Ezh2 inhibitors.  
The inactivation of Ezh2 in type-1 lymphomas led to the infrequent isolation of Ezh2 mutant 
subclones. We predicted that rare cells in the latter primary tumors had succeeded to 
overcome the acute loss of Ezh2 through the activation of compensatory mechanisms. The 
observation that Ezh2 mutant subclones, derived from type-1 lymphomas, had residual 
H3K27me3 levels led us to hypothesize that an alternative, non-canonical PRC2 complex 
consisting of Ezh1 replaced, at least partially, Ezh2 function in Ezh2 mutant cells, thereby 
facilitating clonal outgrowth starting from a single cell. To support this hypothesis, Ezh1 
transcripts were measured in λ-MYC lymphomas and found to be slightly up-regulated in 
Ezh2 mutant clones, suggesting a possible compensatory effect. We took advantage of a 
recently described Ezh1/2 double inhibitor, UNC1999 (Konze et al., 2013), to verify 
whether Ezh2 mutant lymphomas were dependent on Ezh1 for continuous growth. Indeed, 
significant in vitro growth impairment was observed in cultures of UNC1999-treated Ezh2 
mutant lymphoma cells when compared to vehicle-treated cells. The evidence that 
UNC1999 acted via inhibition of residual H3K27 methyltransferase activity (possibly 
provided by Ezh1) came from the observation that low H3K27me3 levels detected in Ezh2 
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mutant subclones were further reduced after treatment with the inhibitor. These results, 
combined with the observation that the vast majority of the genome remained devoid of 
H3K27me3 in Ezh2 mutant subclones, are compatible with a model whereby an alternative 
Ezh1/PRC2 gets preferentially recruited onto a small subset of Ezh2/PRC2 target genes to 
ensure their repression in order to sustain tumor growth. Ezh1 functional redundancy has 
been previously proposed to explain experimental observations in induced pluripotent stem 
cells, hair follicle stem cells, and hematopoietic progenitors undergoing acute Ezh2 
inactivation (Ezhkova et al., 2011; Fragola et al., 2013; Hidalgo et al., 2012) 
However, the intersection of transcriptome data with H3K27me3 genome wide distribution 
results from both Ezh2 proficient and mutant clones revealed a more complex scenario. The 
repertoire of H3K27me3 marked genes in Ezh2 proficient tumors was significantly enriched 
for bona fide Polycomb targets. The vast majority of the latter genes lost H3K27me3 in 
Ezh2 mutant subclones, in line with previous studies showing up-regulation of such genes in 
Polycomb mutant cells (Leeb et al., 2010). Together, these results suggested that Ezh2 
negatively regulates genes marked by H3K27me3 in lymphoma cells. Surprisingly, 
however, expression of the genes marked by H3K27me3 in Ezh2 proficient tumors 
remained largely unaffected after inactivation of the methyltransferase in type-1 
lymphomas. These results suggest that the few Ezh2 mutant subclones established from 
type-1 lymphomas had set in place H3K27me3-independent (compensatory) mechanisms to 
ensure normal expression of Ezh2 targets. Gene ontology classification of the latter genes 
identified functional categories related to stem cell pluripotency. In particular, genes marked 
by H3K27me3 and unaffected in type-1 lymphomas were enriched for modulators of the 
Wnt/β−catening signaling.  
Instead, inactivation of Ezh2 altered the expression of the majority of target genes in type-2 
lymphomas. The fairly weak correlation in the expression profile of H3K27me3 targets in 
Ezh2 mutant compared to Ezh2 proficient subclones, established from type-2 lymphomas, 
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reinforce the view that repression of H3K27me3 targets in this set of tumors is not strictly 
required to sustain the growth of lymphoma cells. 
Another unexpected observation came from the combined analysis of transcriptome and 
H3K27me3 distribution data obtained from type-1 Ezh2 mutant lymphoma cells. 
Specifically, bioinformatics analysis revealed that genes marked by H3K27me3 in Ezh2 
mutant tumor cells were not previously identified as Polycomb targets. Instead, they were 
classified as genes usually decorated by histone marks (H3K4me3 and H3K4me1) indicative 
of active transcription. In support of this, we failed to observe any enrichment for 
H3K27me3 at the promoter of these genes in Ezh2 proficient tumors. These results indicate 
that a non-canonical PRC2, likely composed of Ezh1, gets relocated onto new target genes 
in Ezh2 mutant lymphomas and contributes to their H3K27 trimethylation (Mousavi et al., 
2012). Pairwise comparison of the expression of the latter genes between Ezh2 proficient 
and mutant lymphomas revealed a poor correlation between the two experimental samples, 
pointing to a modulation of gene expression in Ezh2 mutant cells as a result of de novo 
H3K27me3 deposition by an alternative PRC2 complex.  
All together the data support a model whereby the acute inactivation of Ezh2 is compensated 
by transcriptional and/or epigenetic (DNA methylation) mechanisms that ensure normal 
regulation of Ezh2 targets genes in a subset of MYC-transformed B cells. At the same time, 
the lack of Ezh2, facilitates/ensures the formation of an alternative PRC2 complex 
consisting of Ezh1, which is recruited to novel, mostly transcriptionally competent, target 
genes and modulates their expression. Regulation of the latter genes appears to be crucial for 
tumor growth, as the treatment of type-1 Ezh2 mutant subclones with the Ezh1/2 inhibitor 
UNC1999 impaired lymphoma expansion in vitro. The ability of Ezh1 to be recruited into a 
non-canonical PRC2 complex in Ezh2 mutant cells, where it contributes to the expression of 
H3K4me3-marked genes was recently reported in a study addressing the role of Ezh2 in 
erythroid lineage differentiation (Xu et al., 2015b). Given the limited number of samples so 
 146 
far analyzed, the epigenomic and transcriptome analysis of a larger series of type-1 Ezh2 
mutant lymphomas will be needed to support our conclusions.   
The studies on type-1 lymphomas have unveiled the ability of MYC-transformed B cells to 
circumvent Ezh2 inactivation through the activity of Ezh1. These results have important 
clinical implications.  Treatment of lymphomas and possibly other cancers with Ezh2 
inhibitors may indeed unleash the growth of resistant cells that have compensated for the 
loss of Ezh2 methyltransferase activity through the action of Ezh1. In this context, the 
ability of the Ezh1/2 inhibitor UNC1999 to interfere with the growth of Ezh2 mutant 
lymphomas identifies inhibitors of PRC2 function (including UNC1999) as better options 
for the treatment of GC-derived lymphomas and possibly other cancer types. 
Recent evidence showing that lymphomas chronically exposed to low doses of Ezh2 
inhibitors lead to the selection of clonal variants acquiring resistance to the treatment 
(Gibaja et al., 2015), prompted us to investigate whether a similar phenomenon could occur 
in MYC-transformed B cells subjected to UNC1999 treatment. Chronic exposure of λ-MYC 
type-1 lymphomas to low doses of UNC1999 resulted in the selection of a pool of resistant 
cells. The acquired resistance to UNC1999 correlated with the restoration of H3K27me3 
activity by resistant tumor B cells. This result is in line with the strict dependence of type-1 
lymphomas on PRC2 catalytic activity provided by Ezh2. Future experiments on a 
representative number of independent clonal variants will indicate whether the reacquired 
capacity of resistant lymphoma cells to catalyze H3K27me3 results from acquired mutations 
within the Ezh2 coding sequence, which prevent the binding to UNC1999 (Gibaja et al., 
2015). Conversely, in full agreement with our previous findings, type-2 lymphomas resisted 
to pharmacological PRC2 inhibition without the need to select mechanisms ensuring 
restoration of H3K27me3. These results identify λ-MYC type-2 lymphomas as a group of 
highly aggressive (e.g. they grow in vivo significantly faster than type-1 lymphomas) tumors 
that selected genetic mutations allowing tumor cells to grow independently of the PRC2 
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function. The reconstruction, through whole exome sequencing, of a comprehensive map of 
genetic mutations selectively found in type-2 lymphomas will contribute to decipher the 
molecular and genetic bases for primary and acquired resistance of lymphoma cells to the 
PRC2 inhibition. 
 
8.1 Future plans 
8.1.1 Can we employ the molecular signature discriminating λ-MYC type-1 from type-2 
lymphomas to stratify B cell NHL?  
To address this question, we will initially investigate whether the transcriptional signature 
identified in λ-MYC lymphomas can help stratify BL cell lines into two separate classes of 
tumors. Should this be observed, we will test the effects of UNC1999 on representative 
cases of tumor lines falling in the two categories (responders vs. non responders). A similar 
approach will be also followed for DLBCL cell lines, including the ones carrying EZH2 
g.o.f. mutations. The comparison of the transcriptome profiles of BL (and DLBCL) lines 
differing in the response to UNC1999 treatment will represent a complementary strategy to 
ultimately identify a possible molecular signature that can predict the response of highly 
aggressive B cell tumors to PRC2 inhibition. 
 
8.1.2 Can Cdkn2a status predict the response of B cell lymphomas to PRC2 inhibition? 
The preferential inactivation/silencing of Cdkn2a in type-2 lymphomas suggests a possible 
contribution of this genetic alteration to the failure of lymphomas to response to Ezh2/PRC2 
inhibition. To validate these findings, we will follow two strategies: 
a) We will test the sensitivity to UNC1999 of Ezh2 mutant subclones derived from 
Cdkn2a proficient lymphomas that had subsequently lost Cdkn2a as a result of 
the cloning procedure. If Cdkn2a inactivation confers resistance to PRC2 
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inhibition, we expect to see a clear difference in the response to UNC1999 in 
Ezh2 mutant subclones that are respectively proficient and deficient for Cdkn2a; 
b) To establish whether Cdkn2a inactivation, alone, is sufficient to render MYC-
transformed B cells resistant to PRC2 inhibition, we will disrupt the Cdkn2a 
locus by Crispr/Cas9 technology in type-1 lymphomas followed by the treatment 
of mutant cells with UNC1999. The ability to specifically inhibit p16INK4a, 
p19ARF or both genes targeting alternative Cdkn2a exons, will allow us to 
distinguish which gene encoded by the Cdkn2a locus is required to confer 
response of tumor cells to PRC2 inhibition. 
 
8.1.3 The role of Ezh1 in the resistance of MYC lymphomas to Ezh2 inhibition 
The data collected so far point to a primary role played by Ezh1 in sustaining the growth of 
type-1 lymphomas, following Ezh2 inactivation. To corroborate these results, we will 
employ a genetic approach to inactivate both Ezh1 and Ezh2 in λ-MYC lymphomas of both 
type-1 and -2 lymphomas. This will be achieved taking advantage of Crispr/Cas9 
technology to disrupt the Ezh1 gene in λ-MYC; Ezh2fl/fl tumor cells, followed by TAT-Cre 
transduction in order to inactivate Ezh2. The goal of these studies is to confirm the different 
requirement of type-1 and -2 lymphomas for combined inactivation of Ezh proteins. Should 
these results confirm our current findings, we will validate the results inhibiting PRC2 
function through sequential disruption of the Ezh1 and Ezh2 genes in BL cell lines.  
Concerning the mechanism of action of Ezh1, we will consolidate our findings on the 
genome wide distribution of residual H3K27me3 in Ezh2 mutant subclones, analyzing a 
larger number of them. We will confirm the existence of H3K27me3 marked genes in Ezh2 
mutant subclones by performing by ChIP-qPCR on candidate genes. More importantly, we 
will test the acute effects of UNC1999 treatment on their expression, to establish which 
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genes are modulated by H3K27me3. The latter set of genes is expected to include important 
determinants of lymphoma resistance to Ezh2 inactivation.  
 
8.1.4 Genetics of resistance to PRC2 inhibition  
The λ-MYC lymphoma model has provided us with an invaluable source of tumors that 
display primary resistance to Ezh2 inactivation. This offers the opportunity to reconstruct 
the genetic map of resistance to Ezh2 inactivation. To this end, we will initially perform 
whole exome sequencing on three independent type-2 lymphomas, in order to define the 
spectrum of mutations selected in these tumors. The status of candidate genes will be 
assessed in type-1 lymphomas to exclude those that are shared between the two types of 
tumors and hence are likely not responsible for conferring resistance/sensitivity to Ezh2 
inhibition. 
 
8.1.5 Can UNC1999 treatment become an effective treatment to cure type-1 MYC-driven 
B cell lymphomas? 
In order to translate into the clinical setting our findings on the efficacy of UNC1999 to 
inhibit the growth of type-1 lymphomas, we will perform transplantation studies using type-
1 lymphomas, followed by the treatment of recipient animals with UNC1999. Goal of these 
studies is to reveal whether pharmacological Ezh1/2 inhibition in immunoproficient animals 
delays/impairs in vivo growth of λ-MYC type-1 lymphomas.  
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